Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Vaccines

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 2584 articles:
HTML format



Single Articles


    July 2024
  1. JIMENEZ-SEPULVEDA N, Gras-Valenti P, Chico-Sanchez P, Castro-Garcia JM, et al
    Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain.
    Vaccine. 2024;42:4011-4021.
    PubMed     Abstract available


  2. DANELIAN G, Burton L, Bayley T, Sanchez-Marroquin A, et al
    The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
    Vaccine. 2024;42:3838-3850.
    PubMed     Abstract available


  3. AGARWAL S, Harsukhbhai Chandpa H, Naskar S, Lal Meena C, et al
    Dominant B cell-T cell epitopes instigated robust immune response in-silico against Scrub Typhus.
    Vaccine. 2024;42:3899-3915.
    PubMed     Abstract available


  4. BUCHHORN DE FREITAS S, Clair Pinto Seixas Neto A, Aparecido Panagio L, Pereira Soares M, et al
    Hypothetical adhesin CAM87009.1 formulated in alum or biogenic silver nanoparticles protects mice from lethal infection by multidrug-resistant Acinetobacter baumannii.
    Vaccine. 2024;42:3802-3810.
    PubMed     Abstract available


  5. LI J, Gong L, Li J, Gong Z, et al
    Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster.
    Vaccine. 2024;42:3751-3755.
    PubMed     Abstract available


  6. SARTORI AL, Buffarini R, Machado da Silva A, Amaral de Andrade Leao O, et al
    Child COVID-19 vaccine uptake among participants of the 2015 Pelotas (Brazil) Birth Cohort Study.
    Vaccine. 2024 Jul 11:S0264-410X(24)00746-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  7. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Corrigendum to "Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024" [Vaccine 42(15) (2024) 3379-3383].
    Vaccine. 2024 Jul 11:S0264-410X(24)00743-6. doi: 10.1016/j.vaccine.2024.
    PubMed    


  8. GHARPURE R, Longley AT, Takamiya M, Hidle A, et al
    Typhoid conjugate vaccine perceptions and coverage among children and adults: Findings from a post-campaign coverage survey - Harare, Zimbabwe, 2019.
    Vaccine. 2024 Jul 10:S0264-410X(24)00727-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  9. WEITZMAN ER, Pierce SE, Blakemore LM, Murdock A, et al
    Need for strategic communications and stakeholder engagement to advance acceptability of an overdose preventing vaccine targeting fentanyl.
    Vaccine. 2024 Jul 10:S0264-410X(24)00722-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  10. ZOU M, Lei C, Huang D, Liu L, et al
    Application of plant-derived products as adjuvants for immune activation and vaccine development.
    Vaccine. 2024 Jul 9:S0264-410X(24)00756-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  11. SANCHEZ-GONZALEZ G, Luna-Casas G, Mascarenas C, Macina D, et al
    Corrigendum to "Pertussis in Mexico from 2000 to 2019: A real-world study of incidence, vaccination coverage, and vaccine effectiveness" [Vaccine 41(41) (2023) 6105-6111].
    Vaccine. 2024 Jul 8:S0264-410X(24)00726-6. doi: 10.1016/j.vaccine.2024.
    PubMed    


  12. JITENDER, Vikram Kumar B, Singh S, Verma G, et al
    Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster.
    Vaccine. 2024 Jul 8:S0264-410X(24)00740-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  13. BANG JY, Kim YJ, Seo YJ, Hong SH, et al
    Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination.
    Vaccine. 2024 Jul 8:S0264-410X(24)00757-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  14. KORCHINSKI I, Marquez C, McClymont E, Av-Gay G, et al
    Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in pregnancy: A prospective cohort study.
    Vaccine. 2024 Jul 8:S0264-410X(24)00785-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  15. WACHINGER J, Renosa MDC, Endoma V, Landicho-Guevarra J, et al
    Routines, disruptions, revised decisions: A biographical analysis of vaccination trajectories among Filipino caregivers.
    Vaccine. 2024 Jul 6:S0264-410X(24)00736-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  16. ARAUJO-CHAVERON L, Olivier C, Pellissier G, Bouvet E, et al
    Analyzing the 7C psychological antecedents of vaccine acceptance throughout the COVID-19 pandemic among healthcare sector workers in France: A repeated cross-sectional study (CappVac-Cov).
    Vaccine. 2024 Jul 6:S0264-410X(24)00744-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  17. LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al
    Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)].
    Vaccine. 2024 Jul 5:S0264-410X(24)00730-8. doi: 10.1016/j.vaccine.2024.
    PubMed    


  18. NOWALK MP, Smith KJ, Raviotta JM, Wateska A, et al
    Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age.
    Vaccine. 2024 Jul 5:S0264-410X(24)00748-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  19. MESHRAM R, Kolte B, Gacche R
    Reverse vaccinology approach for identification of epitopes from E1 protein as peptide vaccine against HCV: A proof of concept.
    Vaccine. 2024 Jul 5:S0264-410X(24)00747-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  20. KOUTSOUMPLI G, Stasiukonyte N, Hoogeboom BN, Daemen T, et al
    An in vitro CD8 T-cell priming assay enables epitope selection for hepatitis C virus vaccines.
    Vaccine. 2024 Jul 3:S0264-410X(24)00659-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  21. KAFADAR AH, Sabatini S, Jones KA, Dening T, et al
    Categorising interventions to enhance vaccine uptake or reduce vaccine hesitancy in the United Kingdom: A systematic review and meta-analysis.
    Vaccine. 2024 Jul 2:S0264-410X(24)00733-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  22. ZHANG D, Jiang Y, Wang M, Zhao J, et al
    A novel costimulatory molecule gene-modified leukemia cell-derived exosome enhances the anti-leukemia efficacy of DC vaccine in mouse models.
    Vaccine. 2024 Jul 2:S0264-410X(24)00738-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  23. HOULE SKD, Waite NM, Vernon-Wilson E, Dolovich L, et al
    Uptake and outcomes of VaxCheck, an adult life-course vaccination service: A study among community pharmacists.
    Vaccine. 2024 Jul 1:S0264-410X(24)00737-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    June 2024
  24. GAO H, Zhang S, Chang H, Guo Y, et al
    Generation of a novel attenuated IBDV vaccine strain by mutation of critical amino acids in IBDV VP5.
    Vaccine. 2024 Jun 28:S0264-410X(24)00723-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  25. ROOZEN GVT, Granger A, van Binnendijk RS, den Hartog G, et al
    Intradermal fractional dose vaccination as a method to vaccinate individuals with suspected allergy to mRNA COVID-19 vaccines.
    Vaccine. 2024 Jun 28:S0264-410X(24)00734-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  26. BHELLA S, Wilkin AM, Hueniken K, Vijenthira A, et al
    COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies.
    Vaccine. 2024 Jun 28:S0264-410X(24)00715-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  27. PLEY C, Kampmann B
    Opportunities and challenges to the development and deployment of vaccines for pregnant women in Germany.
    Vaccine. 2024 Jun 28:S0264-410X(24)00735-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  28. KELLY JA, Walsh JL, Quinn K, Amirkhanian YA, et al
    Factors predicting primary and booster COVID-19 vaccination in a community sample of African American men and women in the United States Midwest.
    Vaccine. 2024 Jun 27:S0264-410X(24)00729-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  29. JIN F, Zhu L, Wang Y, Qin G, et al
    Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic.
    Vaccine. 2024 Jun 26:S0264-410X(24)00700-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  30. GUTIERREZ MP, Huckaby AB, Yang E, Weaver KL, et al
    Antibody-mediated immunological memory correlates with long-term Lyme veterinary vaccine protection in mice.
    Vaccine. 2024 Jun 26:S0264-410X(24)00725-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  31. COULIBALY D, Douba A, N'Guessan K, N'Gattia AK, et al
    Intent to receive flu vaccine and influenza vaccination coverage among health professionals during 2019, 2020 and 2021 campaigns in Cote d'Ivoire.
    Vaccine. 2024 Jun 25:S0264-410X(24)00717-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  32. YOO YM, Katz MA, Greenberg D, Marcenac P, et al
    Knowledge, attitudes, and practices associated with influenza vaccine uptake among healthcare personnel in Israel during three influenza seasons, 2016-2019.
    Vaccine. 2024 Jun 25:S0264-410X(24)00705-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  33. HUSSEIN I, Mohamud H, Hussein A, Luomala O, et al
    "If the nurse tells me this is a good thing, I trust her completely" - Exploring health system enablers of MMR vaccine uptake in the Finnish Somali community: A mixed method study.
    Vaccine. 2024 Jun 25:S0264-410X(24)00728-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  34. VIANNA CM, Noronha TG, Camacho LAB, Andrade RC, et al
    Duration of post-vaccination immunity to yellow fever in volunteers ten years after a dose-response study - A complementary study.
    Vaccine. 2024 Jun 25:S0264-410X(24)00724-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  35. CHATZILENA A, Hyams C, Challen R, Marlow R, et al
    Winter 2022-23 influenza vaccine effectiveness against influenza-related hospitalised aLRTD: A test-negative, case-control study.
    Vaccine. 2024 Jun 24:S0264-410X(24)00713-8. doi: 10.1016/j.vaccine.2024.
    PubMed    


  36. LE GARS M, Sadoff J, Cardenas V, Heerwegh D, et al
    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.
    Vaccine. 2024 Jun 24:S0264-410X(24)00401-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  37. LIN M, Deng JZ, Scapin G, Yuan Y, et al
    Quantitation and characterization of serotype 6A activation for pneumococcal conjugate vaccine by cryo-EM and SEC methods.
    Vaccine. 2024 Jun 24:S0264-410X(24)00709-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  38. HELARY A, Botelho-Nevers E, Bonneton M, Khennouf L, et al
    Factors, motivations and barriers associated with eagerness to volunteer in COVID-19 vaccine clinical trials in France: A mixed-method study.
    Vaccine. 2024 Jun 22:S0264-410X(24)00662-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  39. FITZPATRICK T, Yamoah P, Lacuesta G, Sadarangani M, et al
    Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study.
    Vaccine. 2024 Jun 22:S0264-410X(24)00719-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  40. RIMAL RN, Ganjoo R, Jamison A, Parida M, et al
    Social norms, vaccine confidence, and interpersonal communication as predictors of vaccination intentions: Findings from slum areas in Varanasi, India.
    Vaccine. 2024 Jun 21:S0264-410X(24)00666-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  41. POVEDA-URKIXO I, Mena-Bueno S, Ramirez GA, Zabalza-Barangua A, et al
    Brucella melitensis Rev1Deltawzm: Placental pathogenesis studies and safety in pregnant ewes.
    Vaccine. 2024;42:3710-3720.
    PubMed     Abstract available


  42. MCDERMID P, Abdi I, Mustafa K, Blazek K, et al
    Examining the influence of community leaders and other community actors on immunisation practices in Australia: A national cross-sectional study.
    Vaccine. 2024;42:3647-3654.
    PubMed     Abstract available


  43. PISCHEL L, Martini BA, Yu N, Cacesse D, et al
    Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis.
    Vaccine. 2024 Jun 20:S0264-410X(24)00694-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  44. CHU X, Ge S, Zuo Y, Cui J, et al
    Thoughts on the research of African swine fever live-attenuated vaccines.
    Vaccine. 2024 Jun 20:S0264-410X(24)00693-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  45. ZHANG X, Monnat SM
    Watchful, skeptics, and system distrusters: Characteristics associated with different types of COVID-19 vaccine hesitancy among U.S. working-age adults.
    Vaccine. 2024 Jun 19:S0264-410X(24)00721-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  46. CARLSON CJ, Garnier R, Tiu A, Luby SP, et al
    Strategic vaccine stockpiles for regional epidemics of emerging viruses: A geospatial modeling framework.
    Vaccine. 2024 Jun 19:S0264-410X(24)00690-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  47. CARLOS GUILLERMO B, Tomas Alberto O, Julio I
    First vaccine confidence and access index in Argentina: Comparison of results from 2019 to 2022.
    Vaccine. 2024 Jun 19:S0264-410X(24)00711-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  48. AHMED T, Tauheed I, Hoque S, Sarower Bhuyan G, et al
    A phase 3 non-inferiority trial of locally manufactured Meningococcal ACWY vaccine 'Ingovax ACWY' among Bangladeshi adults.
    Vaccine. 2024 Jun 18:S0264-410X(24)00704-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  49. CHICHILI GR, Smulders R, Santos V, Cywin B, et al
    Corrigendum to "Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years" [Vaccine 40 (2002) 4190-4198].
    Vaccine. 2024 Jun 18:S0264-410X(24)00650-9. doi: 10.1016/j.vaccine.2024.
    PubMed    


  50. HOPKINS KL, Lihemo G, Underwood T, Sommers T, et al
    The second annual Vaccination Acceptance Research Network Conference (VARN2023): Shifting the immunization narrative to center equity and community expertise.
    Vaccine. 2024 Jun 18:S0264-410X(24)00655-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  51. CHENG TM, Chen YS, Wei KC, Chang YC, et al
    Assessment of the herpes zoster risk among renal transplant recipients administered the influenza vaccine.
    Vaccine. 2024 Jun 18:S0264-410X(24)00716-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  52. LAEMMLE-RUFF I, Morgan HJ, Harris A, Abruzzo V, et al
    Guillain-Barre syndrome temporally associated with COVID-19 vaccines - Progress over time.
    Vaccine. 2024 Jun 17:S0264-410X(24)00714-X. doi: 10.1016/j.vaccine.2024.
    PubMed    


  53. YAZDAN PANAH M, Vaheb S, Mokary Y, Afshari-Safavi A, et al
    Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders.
    Vaccine. 2024 Jun 16:S0264-410X(24)00702-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  54. FERM J, Jaworski DC, Stoll I, Kleinhenz MD, et al
    Genetically modified live vaccine offers protective immunity against wild-type Anaplasma marginale tick-transmission challenge.
    Vaccine. 2024 Jun 15:S0264-410X(24)00710-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  55. DESLAURIERS F, Hoq M, Kaufman J, Enticott J, et al
    Comparison of parent-reported motivators of non-vaccination for children 5-11 years old in Australia and Canada: Results of the iCARE study.
    Vaccine. 2024 Jun 15:S0264-410X(24)00698-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  56. WALTENBURG MA, Kainulainen MH, Whitesell A, Nyakarahuka L, et al
    Knowledge, attitudes, and practices and long-term immune response after rVSVDeltaG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda.
    Vaccine. 2024 Jun 15:S0264-410X(24)00658-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  57. GUL C, Gul A, Karakavuk T, Erkunt Alak S, et al
    A novel DNA vaccine encoding the SRS13 protein administered by electroporation confers protection against chronic toxoplasmosis.
    Vaccine. 2024 Jun 15:S0264-410X(24)00706-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  58. JIANG X, Wang J, Li C, Yeoh EK, et al
    Relationship between parental acceptance of the COVID-19 vaccine and attitudes towards measles vaccination for children: A cross-sectional study.
    Vaccine. 2024 Jun 15:S0264-410X(24)00708-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  59. REY-ARES L, Ta A, Freigofaite D, Warren S, et al
    Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
    Vaccine. 2024 Jun 14:S0264-410X(24)00670-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  60. TING DK, Rosychuk RJ, Hau JP, Righolt CH, et al
    Leveraging a clinical emergency department dataset to estimate two-dose COVID-19 vaccine effectiveness and duration of protection in Canada.
    Vaccine. 2024 Jun 14:S0264-410X(24)00699-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  61. SONG T, Cao F, Huang X, Wu S, et al
    Augmenting vaccine efficacy: Tailored immune strategy with alum-stabilized Pickering emulsion.
    Vaccine. 2024 Jun 13:S0264-410X(24)00649-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  62. WHITE MC, Osazuwa-Peters OL, Abouelella DK, Barnes JM, et al
    Trends and factors associated with receipt of human papillomavirus (HPV) vaccine in private, public, and alternative settings in the United States.
    Vaccine. 2024 Jun 13:S0264-410X(24)00663-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  63. DAVEY SA, Hampson C, Christodoulaki ME, Gaffiero D, et al
    Investigating the predictors of COVID-19 vaccine decision-making among parents of children aged 5-11 in the UK.
    Vaccine. 2024 Jun 13:S0264-410X(24)00646-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  64. HASSO-AGOPSOWICZ M, Sparrow E, Cameron AM, Sati H, et al
    The role of vaccines in reducing antimicrobial resistance: A review of potential impact of vaccines on AMR and insights across 16 vaccines and pathogens.
    Vaccine. 2024 Jun 13:S0264-410X(24)00676-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  65. CARDOSO N, Eschbaumer M, Capozzo AV
    An IgG1 single-dilution avidity ELISA predicts cross-protection against heterologous foot-and-mouth disease virus challenge after vaccination.
    Vaccine. 2024 Jun 13:S0264-410X(24)00707-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  66. EMILIE HARTVIG RASMUSSEN C, Odgaard Vedel J, Moller Jensen A, Da Silva Borges I, et al
    Implementation of the vaccination program in Guinea-Bissau: Coverage and missed opportunities for BCG at birth.
    Vaccine. 2024 Jun 12:S0264-410X(24)00697-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  67. QUIROGA R, Gastellu S, Fernandez B, Ottaviani R, et al
    The impact of COVID-19 childhood and adolescent vaccination on mortality in Argentina.
    Vaccine. 2024 Jun 12:S0264-410X(24)00665-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  68. CARDENAS V, Le Gars M, Truyers C, Ruiz-Guinazu J, et al
    Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
    Vaccine. 2024;42:3536-3546.
    PubMed     Abstract available


  69. SHERMAN AC, van Haren SD, Borberg E, Swank Z, et al
    Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series.
    Vaccine. 2024 Jun 10:S0264-410X(24)00695-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  70. MANANDHAR P, Katz J, Lama TP, Khatry SK, et al
    COVID-19 vaccine hesitancy, trust, and communication in Sarlahi District, Nepal.
    Vaccine. 2024 Jun 10:S0264-410X(24)00661-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  71. HOFFMAN E, Kahan T, Auerbach E, Brody H, et al
    Peer education as a strategy to promote vaccine acceptance: A randomized controlled trial within New York community healthcare practices.
    Vaccine. 2024 Jun 10:S0264-410X(24)00654-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  72. OTSUKI T, Akada S, Anami A, Kosaka K, et al
    Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
    Vaccine. 2024 Jun 8:S0264-410X(24)00668-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  73. BRADY K, Lee A, Bassler J, Young Pierce J, et al
    Human papillomavirus vaccine beliefs and intentions Post-COVID-19 vaccine release among mothers in Alabama.
    Vaccine. 2024 Jun 8:S0264-410X(24)00673-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  74. BADLIS S, Yu H, Klusaritz H, S L Tan A, et al
    Engaging Trusted Messengers to Increase COVID-19 Pediatric Vaccine Uptake in Philadelphia: Lessons from the VaxUpPhillyFamilies program.
    Vaccine. 2024 Jun 8:S0264-410X(24)00664-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  75. SRITIPSUKHO P, Sinlapamongkolkul P, Satdhabudha A, Chaiyakulsil C, et al
    Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received.
    Vaccine. 2024 Jun 7:S0264-410X(24)00652-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  76. R MUGALI R, Ip H, Zikusooka A, Vong L, et al
    Striving for equitable vaccination coverage: Leveraging rapid coverage and community assessments during the COVID-19 pandemic to reach missed populations in Cambodia.
    Vaccine. 2024 Jun 7:S0264-410X(24)00642-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  77. JAYAWARDANA S, Esquivel M, Oreskovic T, Mossialos E, et al
    Gender differences in COVID-19 preventative measures and vaccination rates in the United States: A longitudinal survey analysis.
    Vaccine. 2024 Jun 7:S0264-410X(24)00671-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  78. DE POUVOURVILLE G, Guyot E, Farge G, Belhassen M, et al
    Human Papillomavirus (HPV) vaccination coverage among French adolescents: A claims data study.
    Vaccine. 2024 Jun 7:S0264-410X(24)00667-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  79. VILLENA R, Izquierdo G, Wilhelm J, Garcia C, et al
    Dynamics of multisystem inflammatory syndrome in children associated to COVID-19 in Chile: Epidemiologic trends during pandemic, before and after children vaccination.
    Vaccine. 2024 Jun 7:S0264-410X(24)00640-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  80. YOUNES S, Nicolai E, Younes N, Pieri M, et al
    Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting.
    Vaccine. 2024 Jun 5:S0264-410X(24)00669-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  81. KANG DW, June Choe Y, Lee JY, Suk IA, et al
    Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea.
    Vaccine. 2024 Jun 5:S0264-410X(24)00616-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  82. LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al
    Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
    Vaccine. 2024 Jun 4:S0264-410X(24)00644-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  83. KAWASUJI H, Morinaga Y, Tani H, Yamada H, et al
    Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4-5 vaccine and practical application of dried blood spots.
    Vaccine. 2024 Jun 4:S0264-410X(24)00656-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  84. GOBIN S, Sahakyan G, Kusi Appiah M, Manukyan A, et al
    Costs of in- and outpatient respiratory disease and the seasonal influenza vaccination program in Armenia - 2020-2021.
    Vaccine. 2024 Jun 4:S0264-410X(24)00623-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  85. FENG J, Du Y, Chen L, Su W, et al
    A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models.
    Vaccine. 2024 Jun 3:S0264-410X(24)00624-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  86. FABIANI M, Mateo-Urdiales A, Sacco C, Fotakis EA, et al
    Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged >/=60 years: Estimates over calendar time and by time since administration during prevalent circulation of different O
    Vaccine. 2024 Jun 3:S0264-410X(24)00653-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  87. BEJKO D, Ernst C, Vergison A, Stranges S, et al
    High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis.
    Vaccine. 2024 Jun 1:S0264-410X(24)00636-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    May 2024
  88. KUPEK E
    Avoidable COVID-19-related deaths and hospitalizations in Brazil, 2020-2023.
    Vaccine. 2024;42:3437-3444.
    PubMed     Abstract available


  89. WOLFSCHMIDT-FIETKAU A, Goertz RS, Goertzen S, Schmid K, et al
    Immunity against vaccine-preventable diseases among pregnant employees in Germany. A situation analysis before the introduction of the Measles Protection Act.
    Vaccine. 2024 May 31:S0264-410X(24)00604-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  90. HE Q, Chen Y, Li Y, Cheng X, et al
    Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus.
    Vaccine. 2024 May 31:S0264-410X(24)00583-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  91. EDOKA I, Silal S, Jamieson L, Meyer-Rath G, et al
    A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme.
    Vaccine. 2024 May 31:S0264-410X(24)00595-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  92. COMER D, Warner NZ, Noone C
    Human PapillomaVirus vaccination in gay and bi men: Predictors, dynamic norms, and connectedness to the LGBT+ community.
    Vaccine. 2024 May 31:S0264-410X(24)00639-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  93. MANSFIELD LN, Kahn BZ, Kokitkar S, Kritikos KI, et al
    HPV vaccine standing orders and communication in primary care: A qualitative study.
    Vaccine. 2024 May 29:S0264-410X(24)00554-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  94. NAKASE T, Brownwright T, Okunromade O, Egwuenu A, et al
    The impact of sub-national heterogeneities in demography and epidemiology on the introduction of rubella vaccination programs in Nigeria.
    Vaccine. 2024 May 28:S0264-410X(24)00589-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  95. LUO H, Ma Y, Bi J, Li Z, et al
    Experimental and molecular dynamics simulation studies on the physical properties of three HBc-VLP derivatives as nanoparticle protein vaccine candidates.
    Vaccine. 2024 May 28:S0264-410X(24)00599-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  96. BATOOL R, Yousafzai MT, Mir F, Muhammad S, et al
    Longevity of serologic responses following a single dose of typhoid conjugate vaccine among children living with HIV in Pakistan: A prospective cohort study.
    Vaccine. 2024 May 28:S0264-410X(24)00625-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  97. BEGUM T, Efstathiou N, Bailey C, Guo P, et al
    Cultural and social attitudes towards COVID-19 vaccination and factors associated with vaccine acceptance in adults across the globe: A systematic review.
    Vaccine. 2024 May 27:S0264-410X(24)00600-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  98. EOM J, Kim Y, Kim D, Lee E, et al
    Cost-benefit analysis of human adenovirus vaccine development in a Korean military setting.
    Vaccine. 2024 May 27:S0264-410X(24)00622-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  99. MENA-BUENO S, Garrido V, Romero F, Zabalza-Barangua A, et al
    Rev1Deltawzm vaccine candidate is safe in young and adult sheep and protects against Brucella ovis infection in rams.
    Vaccine. 2024 May 27:S0264-410X(24)00605-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  100. LUSTIG Y, Barda N, Weiss-Ottolenghi Y, Indenbaum V, et al
    Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
    Vaccine. 2024 May 27:S0264-410X(24)00635-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  101. VASHIST K, Yankey D, Elam-Evans LD, Mu Y, et al
    Changes in vaccine hesitancy among parents of children aged 6 months - 17 Years, National Immunization Surveys, 2019-2022.
    Vaccine. 2024 May 27:S0264-410X(24)00596-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  102. RENDUCHINTALA K, Arevalo M, Fonseca G, Haver MK, et al
    Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping review.
    Vaccine. 2024 May 27:S0264-410X(24)00602-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  103. TREHARNE A, Patel Murthy B, Zell ER, Jones-Jack N, et al
    Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S. jurisdictions.
    Vaccine. 2024 May 25:S0264-410X(24)00603-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  104. DOHERTY K, Bonnett L, Agbla SC, Beveridge NER, et al
    The effectiveness of revaccination with pneumococcal polysaccharide vaccine for preventing pneumococcal disease in older adults in England: A population-based cohort study.
    Vaccine. 2024 May 24:S0264-410X(24)00618-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  105. OKOLI GN, Neilson CJ, Grossman Moon A, Kimmel Supron H, et al
    Exploration of individual socioeconomic and health-related characteristics associated with human papillomavirus vaccination initiation and vaccination series completion among adult females: A comprehensive systematic evidence review with meta-analysis
    Vaccine. 2024 May 24:S0264-410X(24)00601-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  106. LYNETTE EJEZIE C, Cuccaro P, Savas LS, Shegog R, et al
    Regional differences in provider recommendation of HPV vaccines among 13-to-17 year old adolescents from 2019 to 2021.
    Vaccine. 2024 May 24:S0264-410X(24)00581-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  107. WU JY, Zhang W, Pu J, Liu Y, et al
    A randomized, double-blind, placebo-controlled phase I clinical trial of rotavirus inactivated vaccine (Vero cell) in a healthy adult population aged 18-49 years to assess safety and preliminary observation of immunogenicity.
    Vaccine. 2024 May 24:S0264-410X(24)00559-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  108. BAK J, Hasan Q, Kissa J, Mere MO, et al
    Deployment of COVID-19 vaccine in the WHO Eastern Mediterranean Region 2021-23: How do we switch to a life course approach?
    Vaccine. 2024 May 24:S0264-410X(24)00560-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  109. MARANTOS T, Kyriazopoulou E, Angelakis E, Kitsos D, et al
    Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: A single-center prospective study.
    Vaccine. 2024 May 24:S0264-410X(24)00617-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  110. TSAMPALIEROS A, Zemek R, Barrowman N, Langlois MA, et al
    Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years.
    Vaccine. 2024 May 23:S0264-410X(24)00588-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  111. BENEDICT KPOZEHOUEN E, Raina Macintyre C, Tan TC
    Coverage of influenza, pneumococcal and zoster vaccination and determinants of influenza and pneumococcal vaccination among adults with cardiovascular diseases in community.
    Vaccine. 2024 May 23:S0264-410X(24)00619-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  112. EIBERG MF, Rezahosseini O, Bukan KB, Charlotte Arp B, et al
    Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis.
    Vaccine. 2024 May 23:S0264-410X(24)00566-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  113. KANDASAMY R, Gurung M, Shrestha S, Gautam MC, et al
    Decline in pneumococcal vaccine serotype carriage, multiple-serotype carriage, and carriage density in Nepalese children after PCV10 introduction: A pre-post comparison study.
    Vaccine. 2024 May 23:S0264-410X(24)00564-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  114. YEGANEH N, Yin S, Moir O, Danza P, et al
    Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in Los Angeles County, August 29, 2022 to January 1, 2023.
    Vaccine. 2024 May 23:S0264-410X(24)00594-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  115. CARNALLA M, Stern D, Arantxa Colchero M, Rangel-Moreno K, et al
    Who is getting COVID-19 boosters? A latent class analysis in a nationally representative sample of Mexican adults 60 years and over.
    Vaccine. 2024;42:3273-3276.
    PubMed     Abstract available


  116. RAMOS-DUARTE VA, Orlowski A, Jaquenod de Giusti C, Corigliano MG, et al
    Safe plant Hsp90 adjuvants elicit an effective immune response against SARS-CoV2-derived RBD antigen.
    Vaccine. 2024;42:3355-3364.
    PubMed     Abstract available


  117. PROSPER P, Rodriguez Puertas R, Guerin DMA, Branda MM, et al
    Computational method for designing vaccines applied to virus-like particles (VLPs) as epitope carriers.
    Vaccine. 2024 May 22:S0264-410X(24)00584-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  118. ZHOU H, Zhao W, Ma R, Zheng Y, et al
    Mixed methods examination of risk perception on vaccination intentions: The perspective of doctor-patient communication.
    Vaccine. 2024 May 22:S0264-410X(24)00565-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  119. ZHANG WX, Zhang Y, Du J, Shi W, et al
    Effectiveness of momentary intervention on influenza vaccination among the elderly in China: From willingness to action.
    Vaccine. 2024 May 22:S0264-410X(24)00591-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  120. PAN X, Guo X, Shi J
    Design of a novel multiepitope vaccine with CTLA-4 extracellular domain against Mycoplasma pneumoniae: A vaccine-immunoinformatics approach.
    Vaccine. 2024 May 21:S0264-410X(24)00568-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  121. CHIHANA R, Jin Kee J, Moodie Z, Huang Y, et al
    Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.
    Vaccine. 2024 May 21:S0264-410X(24)00598-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  122. VAN DER PLAS JL, Haijema BJ, Leenhouts K, Paul Zoeteweij J, et al
    Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): A randomized, double-blind, controlled, ascending dose study in healthy adults and elderly.
    Vaccine. 2024 May 20:S0264-410X(24)00370-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  123. MACHIDA M, Fukushima S, Saitoh A, Inoue S, et al
    Uptake among four indicated vaccines by adults aged 65 years and older in Japan, 2023.
    Vaccine. 2024 May 20:S0264-410X(24)00592-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  124. KARIMI-SHAHRBABAK E, Di Chiara C, Farrar DS, Abu Fadaleh SM, et al
    COVID-19 vaccine acceptance and uptake among caregivers of children aged 5-11?years in Ontario, Canada: A cross-sectional survey.
    Vaccine. 2024 May 20:S0264-410X(24)00553-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  125. GARG R, Liu Q, Van Kessel J, Asavajaru A, et al
    Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern.
    Vaccine. 2024 May 19:S0264-410X(24)00586-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  126. TSUJII A, Takahashi K, Harada H, Kawashima S, et al
    Evaluation of the protective effect of the intranasal vaccines adjuvanted with bacterium-like particles against intestinal infection.
    Vaccine. 2024 May 18:S0264-410X(24)00582-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  127. ANN COSTA CLEMENS S, Weckx L, Milan EP, Smolenov I, et al
    Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.
    Vaccine. 2024 May 17:S0264-410X(24)00555-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  128. YANG T, Tong F, Tang L, Li P, et al
    Repeated vaccination does not appear to significantly weaken the protective effect of influenza vaccine in the elderly: A test-negative case-control study in China.
    Vaccine. 2024 May 17:S0264-410X(24)00593-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  129. KIM S, Choi JK, Suh J, Park SH, et al
    The epidemiologic and economic impact of varicella and herpes zoster vaccination in South Korea: A mathematical modelling study.
    Vaccine. 2024 May 17:S0264-410X(24)00562-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  130. GRIFFIN I, Berry I, Navarra T, Priyamvada L, et al
    Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.).
    Vaccine. 2024 May 17:S0264-410X(24)00563-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  131. GARCIA-VICENTE EJ, Rey-Casero I, Martin M, Perez A, et al
    Oral supplementation with postbiotics modulates the immune response produced by myxomatosis vaccination in wild rabbits.
    Vaccine. 2024 May 16:S0264-410X(24)00585-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  132. URAGUCHI K, Matsumoto N, Mitsuhashi T, Takao S, et al
    Pediatric otitis media in Japan: A nationwide longitudinal study of the pre- and post-pneumococcal conjugate vaccine eras born in 2001 and 2010.
    Vaccine. 2024 May 16:S0264-410X(24)00567-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  133. NG'OMBE H, Bosomprah S, Phiri B, Muchimba M, et al
    Comparative analysis of cholera serum vibriocidal antibodies from Convalescent and vaccinated adults in Zambia.
    Vaccine. 2024 May 16:S0264-410X(24)00587-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  134. URQUIDI C, Sepulveda-Penaloza A, Valenzuela MT, Ponce A, et al
    Vaccine effectiveness in reducing COVID-19-related hospitalization after a risk-age-based mass vaccination program in a Chilean municipality: A comparison of observational study designs.
    Vaccine. 2024 May 14:S0264-410X(24)00538-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  135. MIRANDA-LOPEZ A, Gonzalez-Ortega O, Govea-Alonso DO, Betancourt-Mendiola L, et al
    Rational design and production of a chimeric antigen targeting Zika virus that induces neutralizing antibodies in mice.
    Vaccine. 2024 May 14:S0264-410X(24)00518-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  136. MUANGNOICHAROEN S, Wiangcharoen R, Lawpoolsri S, Nanthapisal S, et al
    Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
    Vaccine. 2024 May 13:S0264-410X(24)00556-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  137. KARIM S, Rehana Siddiqui A, Karim N, Pradhan NA, et al
    Role of rotavirus vaccine in reducing diarrheal episodes in infants visiting private primary health care clinics in Karachi, Pakistan: A mixed-methods study.
    Vaccine. 2024 May 13:S0264-410X(24)00558-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  138. EJNAR HANSEN M, David Pickering S
    The role of religion and COVID-19 vaccine uptake in England.
    Vaccine. 2024;42:3215-3219.
    PubMed     Abstract available


  139. MUTTUCUMARU R, Lau CL, Leeb A, Mills DJ, et al
    Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia.
    Vaccine. 2024;42:3166-3171.
    PubMed     Abstract available


  140. LIU F, Li Z, Wang H, Cao Y, et al
    Effectiveness of the varicella vaccine in the real world, a matched case-control study.
    Vaccine. 2024 May 10:S0264-410X(24)00552-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  141. DINH THIEM V, Van Anh PT, Van Men C, Hung DT, et al
    A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.
    Vaccine. 2024 May 10:S0264-410X(24)00523-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  142. MALTEZOU HC, Gamaletsou MN, Giannouchos TV, Koukou DM, et al
    Effectiveness of COVID-19 booster vaccination, morbidity and absenteeism among healthcare personnel during the 2022-2023 season dominated by Omicron BA.5 and BA.2 subvariants.
    Vaccine. 2024 May 9:S0264-410X(24)00522-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  143. SHANI M, Hermesh I, Feldhamer I, Reges O, et al
    The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities.
    Vaccine. 2024 May 9:S0264-410X(24)00536-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  144. LEE KY, Song KH, Lee KH, Baek JY, et al
    Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection.
    Vaccine. 2024 May 9:S0264-410X(24)00539-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  145. KIM DH, Lee SH, Kim J, Lee J, et al
    Efficacy of live and inactivated recombinant Newcastle disease virus vaccines expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian influenza in SPF chickens, Broilers, and domestic ducks.
    Vaccine. 2024 May 8:S0264-410X(24)00527-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  146. LAURA SORIANO PEREZ M, Montironi I, Alejandro Funes J, Margineda C, et al
    Nanogel-Mediated antigen delivery: Biocompatibility, immunogenicity, and potential for tailored vaccine design across species.
    Vaccine. 2024 May 7:S0264-410X(24)00525-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  147. BASKOL ELIK D, Yildirim C, Akyol Seyhan D, Aytac Erdem H, et al
    Evaluation of antibody responses in healthcare workers before & after meningococcal vaccine and determination of meningococcal carriage rates.
    Vaccine. 2024 May 7:S0264-410X(24)00540-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  148. TIPPINS A, Acevedo JC, Palomeque FS, Coy KC, et al
    Strategies to strengthen COVID-19 vaccine uptake and improve vaccine equity in U.S. Territories and Freely Associated States during the first six months of vaccine rollout.
    Vaccine. 2024 May 7:S0264-410X(24)00541-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  149. DIONNE M, Etienne D, Witteman HO, Sauvageau C, et al
    Impact of interventions to improve HPV vaccination acceptance and uptake in school-based programs: Findings of a pilot project in Quebec.
    Vaccine. 2024 May 6:S0264-410X(24)00528-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  150. CAO A, Ueta M, Uchibori M, Murakami M, et al
    Trust in governments, public health institutions, and other information sources as determinants of COVID-19 vaccine uptake behavior in Japan.
    Vaccine. 2024 May 6:S0264-410X(24)00520-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  151. SONG H, Waheed Abdullah S, Yin S, Dong H, et al
    Virus-like particle-based multipathogen vaccine of FMD and SVA elicits balanced and broad protective efficacy in mice and pigs.
    Vaccine. 2024 May 6:S0264-410X(24)00530-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  152. SOE P, Wong H, Naus M, Muller MP, et al
    mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network.
    Vaccine. 2024 May 6:S0264-410X(24)00535-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  153. JEARANAIWITAYAKUL T, Sunintaboon P, Kittiayuwat A, Limthongkul J, et al
    Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development.
    Vaccine. 2024 May 6:S0264-410X(24)00519-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  154. KOLAKOWSKA A, Marshall E, Krastinova E, Cros A, et al
    Insufficient vaccine coverage and vaccine hesitancy in people living with HIV: A prospective study in outpatient clinics in the Paris region.
    Vaccine. 2024 May 6:S0264-410X(24)00516-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  155. KIM J, Chang J
    Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2.
    Vaccine. 2024 May 6:S0264-410X(24)00481-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  156. LI H, Li Q, Hao Z, Zhang L, et al
    A recombinant IL-1beta vaccine attenuates bleomycin-induced pulmonary fibrosis in mice.
    Vaccine. 2024 May 6:S0264-410X(24)00531-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  157. CROWE CL, Dreyfus J, Lanes S, Chung H, et al
    Variation in incidence rates of outcomes relevant to vaccine safety monitoring in a US commercially insured population by case identification algorithm.
    Vaccine. 2024 May 6:S0264-410X(24)00534-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  158. MAJE BELLO A, Chaimongkolnukul K, Poomputsa K, Mekvichitsaeng P, et al
    Immunogenicity and immunodominant linear B-cell epitopes of a new DNA-based tetravalent vaccine against four major enteroviruses causing hand, foot, and mouth disease.
    Vaccine. 2024 May 4:S0264-410X(24)00526-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  159. ANDREJKO KL, Gierke R, Rowlands JV, Rosen JB, et al
    Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
    Vaccine. 2024 May 3:S0264-410X(24)00499-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  160. ADINUGROHO I, Stafford T, Bentall RP
    The correlation between conspiracy mentality and vaccine intentions is moderated by social events: Evidence from longitudinal data during COVID-19 pandemic in the UK.
    Vaccine. 2024 May 3:S0264-410X(24)00510-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  161. CHRISTOU-ERGOS M, Bleicher K, Leask J
    Factors associated with vaccination intention and uptake over time in a sample of older Australians.
    Vaccine. 2024 May 3:S0264-410X(24)00508-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  162. ESPARZA J
    Introduction of the smallpox vaccine in Napoleonic France, as recorded in contemporary medals.
    Vaccine. 2024 May 3:S0264-410X(24)00503-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  163. SHI XC, Gruber JF, Ondari M, Lloyd PC, et al
    Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older.
    Vaccine. 2024 May 3:S0264-410X(24)00478-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  164. MAUREL M, Mazagatos C, Goerlitz L, Oroszi B, et al
    Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.
    Vaccine. 2024 May 3:S0264-410X(24)00497-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  165. SEFAT KMSR, Kumar M, Kehl S, Kulkarni R, et al
    An intranasal nanoparticle vaccine elicits protective immunity against Mycobacterium tuberculosis.
    Vaccine. 2024 May 3:S0264-410X(24)00482-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  166. BENEDICT KPOZEHOUEN E, Macintyre CR, Tan TC
    Determinants of uptake of influenza, zoster and pneumococcal vaccines in patients with cardiovascular diseases.
    Vaccine. 2024 May 3:S0264-410X(24)00445-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  167. BAGLIVO F, De Angelis L, Magri M, De Nicola I, et al
    The impact of COVID-19 vaccination campaign on pediatric vaccine uptake based on parents' attitudes towards mandatory and recommended vaccination in Southern Italy.
    Vaccine. 2024 May 3:S0264-410X(24)00513-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  168. MERTENS JE, Rigby CA, Bardelli M, Quinkert D, et al
    Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
    Vaccine. 2024 May 3:S0264-410X(24)00514-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  169. MARINTHE G, Brown G, Cristea M, Kutlaca M, et al
    Predicting vaccination hesitancy: The role of basic needs satisfaction and institutional trust.
    Vaccine. 2024 May 3:S0264-410X(24)00507-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  170. HU H, Ma F, Gong L, Wang Y, et al
    Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults.
    Vaccine. 2024 May 3:S0264-410X(24)00495-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  171. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024.
    Vaccine. 2024 May 3:S0264-410X(24)00494-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  172. ANGAITKAR P, Ram Janghel R, Prasad Sahu T
    An MCDM approach for Reverse vaccinology model to predict bacterial protective antigens.
    Vaccine. 2024 May 3:S0264-410X(24)00517-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  173. DHALARIA P, Kumar P, Verma A, Priyadarshini P, et al
    Exploring landscape of measles vaccination coverage: A step towards measles elimination goal in India.
    Vaccine. 2024 May 3:S0264-410X(24)00511-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  174. EHRLICH KB, Lyle SM, Corallo KL, Lavner JA, et al
    Changes in depressive symptoms and antibody production following influenza vaccination in adolescents and adults.
    Vaccine. 2024 May 2:S0264-410X(24)00505-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  175. MASTROLEO I
    Use of experimental vaccines is ethically permissible during public health emergencies.
    Vaccine. 2024 May 1:S0264-410X(24)00504-8. doi: 10.1016/j.vaccine.2024.
    PubMed    


    April 2024
  176. LV M, Du J, Xie MZ, Zhou Y, et al
    Protective effect of PCV13 against all-cause hospitalized pneumonia in children in Beijing, China: real-world evidence.
    Vaccine. 2024;42:3091-3098.
    PubMed     Abstract available


  177. WANG Z, Wang M, Wang F, Luo Y, et al
    Dendritic cell targeting peptide plus Salmonella FliCd flagellin fused outer membrane protein H (OmpH) demonstrated increased efficacy against infections caused by different Pasteurella multocida serogroups in mouse models.
    Vaccine. 2024;42:3075-3083.
    PubMed     Abstract available


  178. MAGALI P, Sophie M, Arnaud B, Pol L, et al
    Retrospective study on the health and economic burden of hospitalized patients due to pneumonia and invasive pneumococcal infections in Belgium settings.
    Vaccine. 2024;42:3018-3023.
    PubMed     Abstract available


  179. GRANT LR, Hanquet G, Sepulveda-Pachon IT, Theilacker C, et al
    Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance.
    Vaccine. 2024;42:2983-2993.
    PubMed     Abstract available


  180. JI W, Zhou H, Li J, Britto CD, et al
    Distributions of candidate vaccine Targets, virulence Factors, and resistance features of invasive group B Streptococcus using Whole-Genome Sequencing: A Multicenter, population-based surveillance study.
    Vaccine. 2024 Apr 30:S0264-410X(24)00498-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  181. FLEARY SA, Shahn Z, Teasdale CA
    Effects of parental childhood cultural health environment on children's influenza and COVID-19 vaccination status.
    Vaccine. 2024 Apr 29:S0264-410X(24)00515-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  182. NIESSEN FA, Bruijning-Verhagen PCJL, Bonten MJM, Knol MJ, et al
    Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands by medical risk condition: A test-negative case-control study.
    Vaccine. 2024 Apr 29:S0264-410X(24)00432-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  183. GUDOORU K, Nguyen K, Le K, Sarabu V, et al
    Collective good and individual choice: Perceptions on COVID-19 vaccine mandate among COVID-19 vaccinated individuals.
    Vaccine. 2024 Apr 27:S0264-410X(24)00479-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  184. DORJEE K, Namdon T, Topgyal S, Gyatso U, et al
    Association between Covishield vaccine and menstrual disturbance. Findings from a cross-sectional study among participants of Zero TB cohort in India.
    Vaccine. 2024 Apr 27:S0264-410X(24)00500-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  185. PIASECKI AM, Hall DM, Zajac J, Miller SA, et al
    A programmatic update on COVID-19 vaccination in rural communities in the United States.
    Vaccine. 2024 Apr 25:S0264-410X(24)00469-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  186. LUO G, Zeng Y, Sheng R, Zhang Z, et al
    Wa-VP4* as a candidate rotavirus vaccine induced homologous and heterologous virus neutralizing antibody responses in mice, pigs, and cynomolgus monkeys.
    Vaccine. 2024 Apr 25:S0264-410X(24)00483-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  187. XIE Z, Stallings-Smith S, Patel S, Case S, et al
    COVID-19 booster vaccine uptake and reduced risks for long-COVID: A cross-sectional study of a U.S. adult population.
    Vaccine. 2024 Apr 25:S0264-410X(24)00509-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  188. LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
    Authors' reply: Excess mortality in Cyprus during the COVID-19 vaccination campaign.
    Vaccine. 2024 Apr 25:S0264-410X(24)00506-1. doi: 10.1016/j.vaccine.2024.
    PubMed    


  189. FUJITA DM, da Silva Nali LH, da Costa RR, de Andrade Junior HF, et al
    Low vaccine coverage and varicella outbreaks in Brazil - 2019-2022.
    Vaccine. 2024 Apr 24:S0264-410X(24)00435-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  190. SELLIES AJ, Knol MJ, de Melker HE, Bruijning-Verhagen PCJL, et al
    Non-specific effects of the inactivated influenza vaccine. A test-negative study: The inactivated influenza vaccine and SARS-CoV-2 infections.
    Vaccine. 2024 Apr 23:S0264-410X(24)00468-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  191. SWITALSKI J, Miazga W, Wnuk K, Tatara T, et al
    Analyzing the dynamics of meningococcal vaccinations initiatives by local government units in Poland (2017-2021) - Scope, challenges and recommendations.
    Vaccine. 2024 Apr 22:S0264-410X(24)00472-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  192. SONG S, Madewell ZJ, Liu M, Miao Y, et al
    A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants.
    Vaccine. 2024 Apr 22:S0264-410X(24)00476-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  193. MUSA S, Merdrignac L, Skocibusic S, Nedic R, et al
    BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study.
    Vaccine. 2024 Apr 20:S0264-410X(24)00471-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  194. WANG Y, Xu F, Yuan C, Zhang Y, et al
    Comparison of immune effects of porcine circovirus type 2d (PCV2d) capsid protein expressed by Escherichia coli and baculovirus-insect cells.
    Vaccine. 2024;42:2848-2857.
    PubMed     Abstract available


  195. MOHANTY S, Done N, Liu Q, Song Y, et al
    Incidence of pneumococcal disease in children
    Vaccine. 2024;42:2758-2769.
    PubMed     Abstract available


  196. LIEVRE G, Sicsic J, Galmiche S, Charmet T, et al
    Are the 7C psychological antecedents associated with COVID-19 vaccine behaviours beyond intentions? A cross-sectional study on at-least-one-dose and up-to-date vaccination status, and uptake speed among adults in France.
    Vaccine. 2024 Apr 19:S0264-410X(24)00438-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  197. INGRAO F, Ngabirano E, Rauw F, Dauphin G, et al
    Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken.
    Vaccine. 2024 Apr 18:S0264-410X(24)00452-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  198. WON H, Kim JA, Jeong NY, Choi NK, et al
    Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly.
    Vaccine. 2024 Apr 18:S0264-410X(24)00400-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  199. RICKE IJ, Spaulding AB, Rajtar NN, Benton EM, et al
    Predictors of willingness to receive updated 2023-2024 COVID-19 booster vaccines among a convenience sample in Minnesota.
    Vaccine. 2024 Apr 18:S0264-410X(24)00480-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  200. ORANGZEB S, Desalegn A, Trinh NTH, Zhao J, et al
    COVID-19 vaccine uptake among children and adolescents in Norway: A comprehensive registry-based cohort study of over 800,000 individuals.
    Vaccine. 2024 Apr 18:S0264-410X(24)00464-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  201. GAJEWSKA M, Lewtak K, Gorynski P, Piotrowicz M, et al
    Effect of the PCV 10 vaccination on community-acquired pneumonia hospitalisations after four years of its introduction into the Polish National Immunisation Programme: Follow-up study.
    Vaccine. 2024 Apr 18:S0264-410X(24)00433-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  202. TRINITE B, Durr E, Pons-Grifols A, O'Donnell G, et al
    VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
    Vaccine. 2024 Apr 18:S0264-410X(24)00473-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  203. BEITARI S, Yi S, Sharma S, Yung R, et al
    Exploring COVID-19 vaccine uptake and hesitancy among vulnerable populations in inner city Vancouver, Canada: Insights into characteristics and clinical outcomes.
    Vaccine. 2024 Apr 17:S0264-410X(24)00477-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  204. MUTSAERTS EAML, van Cranenbroek B, Madhi SA, Simonetti E, et al
    Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones.
    Vaccine. 2024 Apr 17:S0264-410X(24)00448-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  205. MATUR RV, Thuluva S, Gunneri S, Yerroju V, et al
    Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
    Vaccine. 2024 Apr 17:S0264-410X(24)00362-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  206. VAN DER POL S, Zeevat F, Postma MJ, Boersma C, et al
    Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations.
    Vaccine. 2024 Apr 17:S0264-410X(24)00465-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  207. JI Y, Sui X, Miao W, Wang C, et al
    Erratum to "Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model" [Vaccine 42(6) (2024) 1292-1299].
    Vaccine. 2024 Apr 16:S0264-410X(24)00386-4. doi: 10.1016/j.vaccine.2024.
    PubMed    


  208. PEREIRA ET, Iasulaitis S, Greco BC
    Analysis of causal relations between vaccine hesitancy for COVID-19 vaccines and ideological orientations in Brazil.
    Vaccine. 2024 Apr 16:S0264-410X(24)00436-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  209. GEE J, Shimabukuro TT, Su JR, Shay D, et al
    Overview of U.S. COVID-19 vaccine safety surveillance systems.
    Vaccine. 2024 Apr 16:S0264-410X(24)00224-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  210. LEE N, Hong Y, Kirkpatrick CE, Hu S, et al
    COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants.
    Vaccine. 2024 Apr 16:S0264-410X(24)00402-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  211. DEAL A, Crawshaw AF, Salloum M, Hayward SE, et al
    Understanding the views of adult migrants around catch-up vaccination for missed routine immunisations to define strategies to improve coverage: A UK in-depth interview study.
    Vaccine. 2024 Apr 16:S0264-410X(24)00406-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  212. SHEFFER R, Bucris E, Amitai Z, Indenbaum V, et al
    Measles outbreak associated with a preschool setting among partially vaccinated children in the Tel Aviv District, Israel, October 2023.
    Vaccine. 2024 Apr 15:S0264-410X(24)00427-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  213. MELNIKOW J, Padovani A, Zhang J, Miller M, et al
    Patient concerns and physician strategies for addressing COVID-19 vaccine hesitancy.
    Vaccine. 2024 Apr 15:S0264-410X(24)00437-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  214. WONG IOL, Wong C, Mak N, Dai A, et al
    Assessment of the impact of the vaccine pass policy on COVID-19 vaccine hesitancy and uptake among Chinese adults in Hong Kong.
    Vaccine. 2024 Apr 15:S0264-410X(24)00449-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  215. DAVIS BM, Blake I, Panicker G, Meites E, et al
    Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9-14 years at 5 years after vaccination.
    Vaccine. 2024 Apr 15:S0264-410X(24)00447-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  216. YAGI A, Ueda Y, Kimura T
    HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine and to provide effective evaluation of the problem through social-medical and behavioral-economic perspectives.
    Vaccine. 2024 Apr 13:S0264-410X(24)00407-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  217. SUKIK L, Chemaitelly H, Ayoub HH, Coyle P, et al
    Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient.
    Vaccine. 2024 Apr 13:S0264-410X(24)00440-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  218. BAKER J, Aliabadi N, Munjal I, Jiang Q, et al
    Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
    Vaccine. 2024 Apr 13:S0264-410X(24)00387-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  219. NASKAR S, Harsukhbhai Chandpa H, Agarwal S, Meena J, et al
    Super epitope dengue vaccine instigated serotype independent immune protection in-silico.
    Vaccine. 2024 Apr 13:S0264-410X(24)00423-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  220. YONEKAWA M, Watanabe T, Kogawara O, Yoshii C, et al
    Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and older.
    Vaccine. 2024 Apr 12:S0264-410X(24)00388-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  221. LEE JS, Choi H, Shin SH, Hwang MJ, et al
    Characterization of Brighton Collaboration criteria for myocarditis and pericarditis following COVID-19 vaccine in Korean adolescents.
    Vaccine. 2024 Apr 11:S0264-410X(24)00446-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  222. NOLAN MB, Chrenka E, Walker P, Steiner A, et al
    COVID-19 vaccine uptake among non-US-born populations in the United States, 2020-2022.
    Vaccine. 2024 Apr 11:S0264-410X(24)00443-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  223. KAINTH MK, Sembajwe GN, Ahn H, Qian M, et al
    Despite mandated primary series, health care personnel still hesitant about COVID-19 vaccine and immunizing children.
    Vaccine. 2024 Apr 11:S0264-410X(24)00442-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  224. AHERN S, Browne J, Murphy A, Teljeur C, et al
    An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
    Vaccine. 2024 Apr 11:S0264-410X(24)00441-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  225. OWUSU-EDUSEI K, Favre-Bulle A, Tsoumani E, Mutschler T, et al
    Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
    Vaccine. 2024 Apr 11:S0264-410X(24)00431-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  226. PITTS PJ, Poland GA
    Addressing vaccine hesitancy: Learning from the successes and failures of the COVID-19 pandemic.
    Vaccine. 2024 Apr 10:S0264-410X(24)00396-7. doi: 10.1016/j.vaccine.2024.
    PubMed    


  227. HUSETH-ZOSEL AL, Fuller H, Hicks A, Carson PJ, et al
    Reliance on sources of immunization information and vaccine uptake among older adults in a rural state: The mediating role of trust.
    Vaccine. 2024 Apr 10:S0264-410X(24)00444-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  228. BLAKE JM, Thompson J, HogenEsch H, Ekenstedt KJ, et al
    Heritability and genome-wide association study of vaccine-induced immune response in Beagles: A pilot study.
    Vaccine. 2024 Apr 10:S0264-410X(24)00398-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  229. THAI H, Audet EC, Koestner R
    Motivation for COVID-19 Vaccination: Applying a Self-Determination Theory Perspective to a Global Health Crisis.
    Vaccine. 2024 Apr 9:S0264-410X(24)00439-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  230. AKMATOVA R, Ebama MS, Temirbekov S, Alymkulova V, et al
    A comparative analysis of knowledge, attitude, and practice (KAP) towards influenza and influenza vaccination among healthcare workers in Kyrgyzstan prior to and during the COVID-19 pandemic.
    Vaccine. 2024 Apr 9:S0264-410X(24)00420-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  231. EL BUSHRA HE, Haroun AAA, Dauod Altaf M, Gardiwal H, et al
    Early use of oral cholera vaccines as a prime control measure during outbreaks: Necessary but not sufficient.
    Vaccine. 2024 Apr 8:S0264-410X(24)00332-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  232. KONERU A, Wells K, Amanda Carnes C, Drumhiller K, et al
    A survey of state and local practices encouraging pediatric COVID-19 vaccination of children ages 6 months through 11 years.
    Vaccine. 2024 Apr 8:S0264-410X(24)00369-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  233. ARCHER H, McCoy SI, Sears D, Kwan A, et al
    Indirect vaccine effectiveness in an outbreak of Alpha B.1.1.7 variant in a California state Prison, May 2021.
    Vaccine. 2024 Apr 6:S0264-410X(24)00368-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  234. CUMMINGS JF, Polhemus ME, Kester KE, Ockenhouse CF, et al
    A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naive adults.
    Vaccine. 2024 Apr 6:S0264-410X(24)00389-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  235. CHONG CY, Kam KQ, Zhang J, Bertoletti A, et al
    Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination.
    Vaccine. 2024 Apr 6:S0264-410X(24)00425-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  236. BINTE HOSSAIN F, Muscatello D, Jayasinghe S, Jonnagaddala J, et al
    Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13.
    Vaccine. 2024 Apr 6:S0264-410X(24)00426-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  237. CHARD AN, Machingaidze C, Loayza S, Gharpure R, et al
    Estimating averted illnesses from influenza vaccination for children and pregnant women - El Salvador, Panama, and Peru, 2011-2018.
    Vaccine. 2024 Apr 6:S0264-410X(24)00419-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  238. SCHULTZE A, Martin I, Messina D, Bots S, et al
    A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases.
    Vaccine. 2024 Apr 5:S0264-410X(24)00330-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  239. STEFANIZZI P, Moscara L, Palmieri C, Martinelli A, et al
    Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
    Vaccine. 2024 Apr 5:S0264-410X(24)00311-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  240. NYBRU GLEDITSCH R, Skogset Ofitserova T, Aubrey White R, Karoline Raberg Kjollesdal M, et al
    Vaccine coverage among children born to immigrant parents in Norway, 2000-2020.
    Vaccine. 2024 Apr 5:S0264-410X(24)00395-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  241. NAKANO T, Hasegawa M, Endo M, Matsuda K, et al
    Immunogenicity and safety of adsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)-Haemophilus type b conjugate combined vaccine (DPT-IPV-Hib) in healthy Japanese Infants >/= 2 and < 43 months of Age: A phase III, multicenter
    Vaccine. 2024 Apr 5:S0264-410X(24)00394-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  242. BAUM HE, Thirard R, Halliday A, Baos S, et al
    Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial.
    Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  243. ALTAWALBEH SM, Wateska AR, Nowalk MP, Lin CJ, et al
    Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older.
    Vaccine. 2024 Apr 4:S0264-410X(24)00404-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  244. HEISLER-MACKINNON JA, Queen T, Yi Kong W, Kennedy KL, et al
    Identifying effective vaccine champions: Findings from a national survey of primary care professionals.
    Vaccine. 2024 Apr 3:S0264-410X(24)00403-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  245. NURDIN A, Movieta Nency Y, Maddeppungeng M, Sekartini R, et al
    Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial.
    Vaccine. 2024 Apr 3:S0264-410X(24)00399-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  246. TEMBO G, Mayuni M, Kamng'ona R, Chimgoneko L, et al
    Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation.
    Vaccine. 2024 Apr 2:S0264-410X(24)00360-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  247. WU CY, Kao SE, Tseng YC, Hou JT, et al
    Pilot-scale production of a highly efficacious and stable monoglycosylated influenza split virus vaccine.
    Vaccine. 2024;42:2220-2228.
    PubMed     Abstract available


  248. LIU J, Qi Q, Liu Y, Ni P, et al
    A paired measles-rubella catch-up campaign in Sichuan China to stop an outbreak and strengthen local immunization programs.
    Vaccine. 2024;42:2155-2160.
    PubMed     Abstract available


  249. SU L, Zhou X, Peng W, Luo J, et al
    Investigation on the correlation factors of positive Streptococcus pneumoniae antibody and IgG antibody level of Streptococcus pneumoniae in the elderly over 60 years old in Shenzhen.
    Vaccine. 2024;42:2448-2454.
    PubMed     Abstract available


  250. HUBER A, Kovacs E, Horvath A, Sahin-Toth J, et al
    Prevalence, serogroup distribution and risk factors of Neisseria meningitidis carriage in high school and university students in Hungary.
    Vaccine. 2024;42:2271-2277.
    PubMed     Abstract available


  251. KIMBUGWE G, Vatrinet R, Mwanga JA, Kakuru R, et al
    Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda.
    Vaccine. 2024 Apr 1:S0264-410X(24)00358-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    March 2024
  252. GONG JD, Barnboym E, O'Mara M, Gurevich N, et al
    Self-reported determinants of COVID-19 vaccine acceptance among persons with and without autoimmune disease.
    Vaccine. 2024 Mar 30:S0264-410X(24)00373-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  253. MALTEZOU HC, Kontogianni S, Michailidou E, Vergadi E, et al
    Effectiveness of COVID-19 vaccination against school absenteeism in children and adolescents hospitalized with COVID-19.
    Vaccine. 2024 Mar 30:S0264-410X(24)00397-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  254. PADENIYA TN, Hui BB, Wood JG, Regan DG, et al
    Review of mathematical models of Neisseria gonorrhoeae vaccine impact: Implications for vaccine development.
    Vaccine. 2024 Mar 30:S0264-410X(24)00380-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  255. HUF SW, Grailey K, Crespo RF, Woldmann L, et al
    Testing the impact of differing behavioural science informed text message content in COVID-19 vaccination invitations on vaccine uptake: A randomised clinical trial.
    Vaccine. 2024 Mar 28:S0264-410X(24)00365-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  256. FUKUDA Y, Suzuki T, Iwata KI, Haruta K, et al
    Nanopore sequencing in distinguishing between wild-type and vaccine strains of Varicella-Zoster virus.
    Vaccine. 2024 Mar 27:S0264-410X(24)00333-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  257. BRUUN N, Laursen MF, Carmelo R, Christensen E, et al
    Novel nucleotide-packaging vaccine delivers antigen and poly(I:C) to dendritic cells and generate a potent antibody response in vivo.
    Vaccine. 2024 Mar 26:S0264-410X(24)00364-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  258. PARISI A, Nunez O, Lopez-Perea N, Masa-Calles J, et al
    Reduced pertussis disease severity in infants following the introduction of pertussis vaccination of pregnant women in Spain, 2015-2019.
    Vaccine. 2024 Mar 25:S0264-410X(24)00315-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  259. WEYANT C, Hooda Y, Munira SJ, Lo NC, et al
    Cost-effectiveness and public health impact of typhoid conjugate vaccine introduction strategies in Bangladesh.
    Vaccine. 2024 Mar 25:S0264-410X(24)00322-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  260. DALEY MF, Reifler LM, Shoup JA, Glanz JM, et al
    Influenza vaccination accuracy among adults: Self-report compared with electronic health record data.
    Vaccine. 2024 Mar 25:S0264-410X(24)00339-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  261. BIEGUS J, Szenborn L, Zymlinski R, Zakliczynski M, et al
    The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure.
    Vaccine. 2024 Mar 25:S0264-410X(24)00366-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  262. VOLKMANN AM, Goldin S, McMurren B, Gapare C, et al
    Leveraging seasonal influenza health worker vaccination programmes for COVID-19 vaccine Introduction: A global qualitative analysis.
    Vaccine. 2024 Mar 25:S0264-410X(23)01490-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  263. DAHL BA, Tritter B, Butryn D, Dahlke M, et al
    Global VAX: A U.S. contribution to global COVID-19 vaccination efforts, 2021-2023.
    Vaccine. 2024 Mar 23:S0264-410X(24)00359-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  264. PONNE S, Kumar R, Vanmathi SM, Brilhante RSN, et al
    Reverse engineering protection: A comprehensive survey of reverse vaccinology-based vaccines targeting viral pathogens.
    Vaccine. 2024 Mar 23:S0264-410X(24)00265-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  265. MORGAN G, Casalino S, Chowdhary S, Frangione E, et al
    COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00317-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  266. STUREBORG R, Nichols J, Dhingra B, Yang J, et al
    Development and validation of VaxConcerns: A taxonomy of vaccine concerns and misinformation with Crowdsource-Viability.
    Vaccine. 2024 Mar 22:S0264-410X(24)00255-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  267. CONDIE J, Northstone K, Major-Smith D, Halstead I, et al
    Exploring associations between the Big Five personality traits and cognitive ability with COVID-19 vaccination hesitancy and uptake among mothers and offspring in a UK prospective cohort study.
    Vaccine. 2024 Mar 22:S0264-410X(24)00305-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  268. COMES JDG, Doets K, Zegers T, Kessler M, et al
    Evaluation of bird-adapted self-amplifying mRNA vaccine formulations in chickens.
    Vaccine. 2024 Mar 22:S0264-410X(24)00319-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  269. PRICE O, Dietze P, Maher L, Dore GJ, et al
    High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs.
    Vaccine. 2024 Mar 21:S0264-410X(24)00337-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  270. HIRTH J, Ostovar-Kermani T, Gutierrez JA, Thompson EL, et al
    Effect of age at initiation of the human papillomavirus vaccine on the association between race/ethnicity and completion of the vaccine series.
    Vaccine. 2024 Mar 21:S0264-410X(24)00336-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  271. ZHANG Y, Wang Y, Li G, Zhao X, et al
    A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and older.
    Vaccine. 2024 Mar 21:S0264-410X(24)00331-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  272. KLUWER B, Gleditsch R, Rydland KM, Mamelund SE, et al
    Higher educational attainment associated with higher confidence in influenza vaccination in Norway.
    Vaccine. 2024 Mar 21:S0264-410X(24)00338-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  273. ZHAO Z, Meng Q, Sun TZ, Zhu B, et al
    Mannose modified targeted immersion vaccine delivery system improves protective immunity against Infectious spleen and kidney necrosis virus in mandarin fish (Siniperca chuatsi).
    Vaccine. 2024 Mar 21:S0264-410X(24)00335-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  274. MOFFETT KW, Seserman K, Margolis KA, Kranzler EC, et al
    Differences in social media use by COVID-19 vaccination status.
    Vaccine. 2024 Mar 20:S0264-410X(24)00318-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  275. SASI A, Dandotiya J, Kaushal J, Ganguly S, et al
    Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study.
    Vaccine. 2024 Mar 20:S0264-410X(24)00329-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  276. BROOKS SP, Sidhu K, Cooper E, Michelle Driedger S, et al
    The influence of health service interactions and local policies on vaccination decision-making in immigrant women: A multi-site Canadian qualitative study.
    Vaccine. 2024 Mar 20:S0264-410X(24)00299-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  277. CRISTINA MARTINI RODRIGUES C, Caroline Ribeiro Sales A, Marli Christovam Sartori A, de Souza Azevedo A, et al
    Yellow fever neutralizing antibody seroprevalence proportion and titers in previously vaccinated adults with chronic kidney disease.
    Vaccine. 2024 Mar 20:S0264-410X(24)00316-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  278. ARTIGAS-JERONIMO S, Villar M, Estrada-Pena A, Alberdi P, et al
    Subolesin knockdown in tick cells provides insights into vaccine protective mechanisms.
    Vaccine. 2024 Mar 19:S0264-410X(24)00278-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  279. CHENG Y, Shen R, Liu F, Li Y, et al
    Humoral and cellular immune responses induced by serogroup W135 meningococcal conjugate and polysaccharide vaccines.
    Vaccine. 2024 Mar 19:S0264-410X(24)00326-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  280. KRASILNIKOV I, Isaev A, Djonovic M, Ivanov A, et al
    Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity.
    Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  281. GEHRT L, Englund H, Laake I, Nieminen H, et al
    Is vaccination against measles, mumps, and rubella associated with reduced rates of antibiotic treatments among children below the age of 2 years? Nationwide register-based study from Denmark, Finland, Norway, and Sweden.
    Vaccine. 2024 Mar 19:S0264-410X(24)00313-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  282. ANWARI P, Burnett E, Chavers TP, Samsor A, et al
    Post-marketing surveillance of intussusception after Rotarix administration in Afghanistan, 2018-2022.
    Vaccine. 2024;42:2059-2064.
    PubMed     Abstract available


  283. LLOYD PC, Lufkin B, Moll K, Ogilvie RP, et al
    Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020.
    Vaccine. 2024;42:2004-2010.
    PubMed     Abstract available


  284. SOVIK WLM, Madsen AMR, Aaby P, Nielsen S, et al
    The association between BCG scars and self-reported chronic diseases: A cross-sectional observational study within an RCT of Danish health care workers.
    Vaccine. 2024;42:1966-1972.
    PubMed     Abstract available


  285. KWON KW, Choi HG, Choi HH, Choi E, et al
    Immunogenicity and protective efficacy of RipA, a peptidoglycan hydrolase, against Mycobacterium tuberculosis Beijing outbreak strains.
    Vaccine. 2024;42:1941-1952.
    PubMed     Abstract available


  286. HILL-BATORSKI L, Bowen R, Bielefeldt-Ohmann H, Moser MJ, et al
    Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.
    Vaccine. 2024 Mar 19:S0264-410X(24)00327-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  287. SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y, et al
    CHO cells for virus-like particle and subunit vaccine manufacturing.
    Vaccine. 2024 Mar 18:S0264-410X(24)00321-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  288. WU J, Jiang L, Shao Q, Liu J, et al
    Comparison of the safety and efficacy of the wild-type and lpxL/lpxM mutant inactivated vaccine against the avian pathogenic Escherichia coli O1, O2, and O78 challenge.
    Vaccine. 2024 Mar 18:S0264-410X(24)00325-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  289. MEDENI V, Altiner OT, Medeni I
    Measles vaccination coverage and immunization status of nurses: An interventional study in Turkiye.
    Vaccine. 2024 Mar 18:S0264-410X(24)00324-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  290. DANGOR Z, Benson N, Berkley JA, Bielicki J, et al
    Vaccine value profile for Klebsiella pneumoniae.
    Vaccine. 2024 Mar 18:S0264-410X(24)00248-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  291. OPMEER L, Gazzoli I, Ballmann M, Willemsen M, et al
    High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains.
    Vaccine. 2024 Mar 18:S0264-410X(24)00130-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  292. CAMPAGNA R, Dominelli F, Zingaropoli MA, Ciurluini F, et al
    COVID-19 vaccination in cancer patients: Immune responses one year after the third dose.
    Vaccine. 2024 Mar 17:S0264-410X(24)00304-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  293. FIERRO C, Weidenthaler H, Vidojkovic S, Schmidt D, et al
    Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial.
    Vaccine. 2024 Mar 16:S0264-410X(24)00296-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  294. HARTMEIER PR, Ostrowski SM, Busch EE, Empey KM, et al
    Lymphatic distribution considerations for subunit vaccine design and development.
    Vaccine. 2024 Mar 16:S0264-410X(24)00320-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  295. FIX J, Christopher Mast T, Smith K, Baker N, et al
    Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
    Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  296. COTTON SA, Subramanian A, Hughes TD, Huang Y, et al
    The effect of SARS-COV-2 variant on non-respiratory features and mortality among vaccinated and non-fully vaccinated patients.
    Vaccine. 2024 Mar 14:S0264-410X(24)00195-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  297. JUNEAU C, Fall E, Bros J, Le Duc-Banaszuk AS, et al
    Do boys have the same intentions to get the HPV vaccine as girls? Knowledge, attitudes, and intentions in France.
    Vaccine. 2024 Mar 14:S0264-410X(24)00256-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  298. CAMERON DB, Grage L, Van Wyck R, Edwards A, et al
    Identifying trusted local sources and predicting behavior change pathways according to COVID-19 vaccination status: Results of a 2022 statewide survey of Alaskan adults.
    Vaccine. 2024 Mar 14:S0264-410X(24)00314-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  299. MACKENZIE GA, Hossain I, Salaudeen R, Badji H, et al
    Impact of pneumococcal conjugate vaccination on pneumococcal nasopharyngeal carriage in the Gambia: Population-based cross-sectional surveys.
    Vaccine. 2024 Mar 14:S0264-410X(24)00225-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  300. EL SALIBI N, Abdulrahim S, El Haddad M, Abi Zeid B, et al
    Predicting intention to vaccinate against COVID-19 in older Syrian refugees in Lebanon: Findings from a multi-wave study.
    Vaccine. 2024 Mar 13:S0264-410X(24)00213-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  301. MCCOSKER LK, Ware RS, Seale H, Hooshmand D, et al
    The effect of a financial incentive on COVID-19 vaccination uptake, and predictors of uptake, in people experiencing homelessness: A randomized controlled trial.
    Vaccine. 2024 Mar 13:S0264-410X(24)00307-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  302. SAKAUE T, Sugawara T, Mukasa K, Nohara M, et al
    Varicella outbreak at nursery school under routine immunization in Japan in 2017 and 2018 and vaccine effectiveness.
    Vaccine. 2024 Mar 12:S0264-410X(24)00250-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  303. CHEUNG DH, Chen S, Fang Y, Sun F, et al
    Influences of mpox disease perceptions, sources and contents of information exposure on mpox vaccine uptake among gay, bisexual, and other men who have sex with men in Hong Kong, China.
    Vaccine. 2024 Mar 12:S0264-410X(24)00259-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  304. SHERMAN SM, Allerton-Price C, Lingley-Heath N, Lai J, et al
    UK healthcare professionals' attitudes towards the introduction of varicella vaccine into the routine childhood vaccination schedule and their preferences for administration.
    Vaccine. 2024 Mar 12:S0264-410X(24)00274-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  305. RUSS S, Myers C, Licherdell E, Bowden A, et al
    Sociodemographic and Occupational Characteristics Associated with Early and Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY.
    Vaccine. 2024 Mar 12:S0264-410X(24)00306-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  306. MERDRIGNAC L, Ait El Belghiti F, Pandolfi E, Acosta L, et al
    Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 201
    Vaccine. 2024 Mar 11:S0264-410X(24)00272-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  307. SHIJIA YAN A, Jay Sehgal N
    Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among Parents/Guardians and vaccine uptake among children in the U.S.
    Vaccine. 2024 Mar 11:S0264-410X(24)00309-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  308. SENPUKU K, Kataoka-Nakamura C, Kunishima Y, Hirai T, et al
    An inactivated whole-virion vaccine for Enterovirus D68 adjuvanted with CpG ODN or AddaVax elicits potent protective immunity in mice.
    Vaccine. 2024 Mar 11:S0264-410X(24)00303-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  309. MORO PL, Carlock G, Fifadara N, Habenicht T, et al
    Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
    Vaccine. 2024 Mar 9:S0264-410X(24)00262-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  310. HARRELL JE, Roy CJ, Gunn JS, McLachlan JB, et al
    Current vaccine strategies and novel approaches to combatting Francisella infection.
    Vaccine. 2024 Mar 8:S0264-410X(24)00264-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  311. SU YW, Qiu YZ, Wang YH, Xu Y, et al
    Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
    Vaccine. 2024 Mar 8:S0264-410X(24)00277-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  312. LUISI M, Geana MV, Pei J
    Pandemic antecedents - Exploring predictivity and relationships between COVID-19 vaccine uptake and influenza, shingles, and HPV vaccination.
    Vaccine. 2024 Mar 8:S0264-410X(24)00275-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  313. BROUSSEAU N, Angers-Goulet ME, Bastien R, Ye L, et al
    Vaccination during pregnancy and modulation of IgG response to pertussis vaccines in infants: The impact of different vaccine formulations.
    Vaccine. 2024 Mar 8:S0264-410X(24)00300-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  314. ST-LOUIS P, Martin C, Khatri V, Bourgault S, et al
    Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli filaments and the highly conserved M2e epitope confers protection against influenza a virus in mice.
    Vaccine. 2024 Mar 8:S0264-410X(24)00222-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  315. GHASEMIFAR S, Chabak O, Piri-Gharaghie T, Doosti A, et al
    PIRES2-EGFP/CTB-UreI vaccination activated a mixed Th1/Th2/Th17 immune system defense towards Helicobacter pylori infection in the BALB/c mice model.
    Vaccine. 2024 Mar 7:S0264-410X(24)00209-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available



  316. Expression of Concern: "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine [33/1], 1 January 2015, Pages 108-116].
    Vaccine. 2024;42:1851.
    PubMed    



  317. Expression of Concern: "Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses" [Vaccine Volume 38, Issue 4, 22 January 2020, Pages 830-839].
    Vaccine. 2024;42:1850.
    PubMed    


  318. DE WAELE A, Hendrickx G, Valckx S, Dominguez A, et al
    The Vaccine Training Barometer: Assessing healthcare providers' confidence to answer vaccine-related questions and their training needs.
    Vaccine. 2024 Mar 7:S0264-410X(24)00254-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  319. SIREK G, Ulysse S, Jacques Toussaint M, Nosamiefan C, et al
    A community-engaged approach to translate a Vaccine Hesitancy Scale into Haitian Creole.
    Vaccine. 2024 Mar 7:S0264-410X(24)00257-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  320. GILBERT PB, Fong Y, Hejazi NS, Kenny A, et al
    Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial.
    Vaccine. 2024 Mar 7:S0264-410X(24)00247-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  321. MALDONADO I, Rodriguez Nino N, Valencia CF, Ortiz D, et al
    Evaluation of the safety profile of the quadrivalent vaccine against human papillomavirus in the risk of developing autoimmune, neurological, and hematological diseases in adolescent women in Colombia.
    Vaccine. 2024 Mar 7:S0264-410X(24)00263-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  322. ZIBOLENOVA J, Malobicka E, Ulbrichtova R, Novak M, et al
    Probability of exposure to the wild measles virus in adult population - Estimation from seroepidemiology and historical data.
    Vaccine. 2024;42:1648-1655.
    PubMed     Abstract available


  323. HYAMS C, Lahuerta M, Theilacker C, King J, et al
    Surveillance of pneumococcal serotypes in adults hospitalised with acute lower respiratory tract infection in Bristol, UK.
    Vaccine. 2024;42:1599-1607.
    PubMed     Abstract available


  324. MENG L, Harris L, Shaw L, Lymon H, et al
    Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged >/= 12 years, United States, August 2021-October 2
    Vaccine. 2024 Mar 6:S0264-410X(24)00271-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  325. KARRAS J, Harrison M, Steffens M, Abdi I, et al
    "COVID is a huge jigsaw puzzle that I am trying to make sense of myself": Exploring the perceptions towards the COVID-19 vaccine communication strategy in Australia amongst unvaccinated Australian adults.
    Vaccine. 2024 Mar 6:S0264-410X(24)00276-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  326. WONG WHS, Leung DL, Yip KM, So HK, et al
    Effectiveness of inactivated COVID-19 vaccine CoronaVac in children aged less than 3 years old during Omicron wave in Hong Kong.
    Vaccine. 2024 Mar 6:S0264-410X(24)00226-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  327. RAETHKE M, van Hunsel F, Luxi N, Lieber T, et al
    Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.
    Vaccine. 2024 Mar 6:S0264-410X(24)00273-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  328. CHEN D, Cowling BJ, Ainslie KEC, Lin Y, et al
    Association of COVID-19 vaccination with duration of hospitalization in older adults in Hong Kong.
    Vaccine. 2024 Mar 5:S0264-410X(24)00252-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  329. MARQUES RF, Gimenez AM, Caballero O, Simpson A, et al
    Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol(R)) as adjuvant.
    Vaccine. 2024 Mar 5:S0264-410X(24)00229-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  330. BEAVIS AC, Dienger-Stambaugh K, Briggs K, Chen Z, et al
    A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice.
    Vaccine. 2024 Mar 4:S0264-410X(24)00227-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  331. DUAN X, Zhang L, Ding L, Zhang C, et al
    Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection.
    Vaccine. 2024 Mar 2:S0264-410X(24)00172-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  332. ZAMAN K, Schuind AE, Adjei S, Antony K, et al
    Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: Interim analysis from a phase 3 clinical trial.
    Vaccine. 2024 Mar 1:S0264-410X(24)00251-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  333. YASHAR-GERSHMAN SG, Rosenberg AT, Sawhney M, Fernanda Machicao M, et al
    Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy at point of care.
    Vaccine. 2024 Mar 1:S0264-410X(24)00228-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    February 2024
  334. YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
    Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial.
    Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  335. KOHLI M, Maschio M, Lee A, Igarashi A, et al
    Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine.
    Vaccine. 2024 Feb 29:S0264-410X(24)00117-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  336. CHATHAM-STEPHENS K, Carter RJ, Duggar C, Woodworth KR, et al
    An overview of the COVID-19 pediatric vaccine program - The U.S. experience vaccinating children ages 6 months through 17 years.
    Vaccine. 2024 Feb 29:S0264-410X(24)00166-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  337. LEVIN MJ, Ginde AA, Schmid DS, Lang N, et al
    Effect of high dose vitamin D supplementation on subsequent immune responses to administration of the live herpes zoster vaccine to long-term care residents.
    Vaccine. 2024 Feb 28:S0264-410X(24)00214-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  338. MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
    Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake in Kwazulu-Natal, South Africa.
    Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  339. OMAR ALI S, Dessart C, Parikh R
    Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.
    Vaccine. 2024 Feb 28:S0264-410X(24)00194-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  340. GUO J, Chen X, Guo Y, Liu M, et al
    Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies.
    Vaccine. 2024 Feb 28:S0264-410X(24)00218-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  341. ZHOU W, Guo X, Lu J, Lu X, et al
    Parental willingness to accept and pay human papillomavirus vaccine for boys aged 9-14 in a metropolis area of China: Evidence for developing a vaccination strategy.
    Vaccine. 2024 Feb 28:S0264-410X(24)00253-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  342. JACKSON S, Kabir Z, Comiskey C
    Retrospective cohort study exploring the impact of universal Tuberculosis (TB) vaccination cessation on the epidemiology of paediatric TB in Ireland, 2011-2021.
    Vaccine. 2024 Feb 28:S0264-410X(24)00220-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  343. JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al
    Intensification of integrated immunization services to recover routine vaccination coverage and bring COVID-19 vaccine to the population of Iraq in 2022.
    Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  344. TANAKA M, Okubo R, Hoshi SL, Kondo M, et al
    Cost-effectiveness analysis of pertussis booster vaccination for adolescents in Japan.
    Vaccine. 2024 Feb 27:S0264-410X(24)00199-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  345. GIDENGIL C, Scherer AM, Parker AM, Gedlinske A, et al
    Lyme disease vaccine attitudes and intentions among parents of children aged 5-18 years in the United States.
    Vaccine. 2024 Feb 27:S0264-410X(24)00105-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  346. YANG XY, Liu T, Jiang SC, Zhang ZW, et al
    Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human muscle cells and neuroglial cells.
    Vaccine. 2024;42:1259-1267.
    PubMed     Abstract available


  347. MUNDO ORTIZ A, Nasri B
    Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring differences across the Health Region model.
    Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  348. KEGELE LIGNANI L, de Vasconcellos Carvalhaes de Oliveira R, Matos Dos Santos E, Antonio Bastos Camacho L, et al
    Neutralizing antibody titers against D8 genotype and persistence of measles humoral and cell-mediated immunity eight years after the first dose of measles, mumps, and rubella vaccine in Brazilian children.
    Vaccine. 2024 Feb 26:S0264-410X(24)00219-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  349. TOLENTINO JUNIOR DS, Vasconcelos Marques MS, de Oliveira RC
    Rabies vaccination of the Maxakali indigenous population.
    Vaccine. 2024 Feb 26:S0264-410X(23)01542-6. doi: 10.1016/j.vaccine.2023.
    PubMed    


  350. KRISTINSDOTTIR I, Haraldsson A, Thors V
    Influenza vaccination in pregnant women in Iceland 2010-2020 and the burden of influenza in pregnant women and their infants.
    Vaccine. 2024 Feb 26:S0264-410X(24)00205-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  351. NEWALL AT, Nazareno AL, Muscatello DJ, Boettiger D, et al
    The association between influenza vaccination uptake and influenza and pneumonia-associated deaths in the United States.
    Vaccine. 2024 Feb 24:S0264-410X(24)00113-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  352. BIJUKCHHE SM, Gurung M, Pokhrel B, Shakya M, et al
    Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.
    Vaccine. 2024 Feb 22:S0264-410X(24)00156-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  353. MURPHY C, Kwan MYW, Chan ELY, Wong JSC, et al
    Influenza vaccine effectiveness against hospitalizations associated with influenza A(H3N2) in Hong Kong children aged 9 months to 17 years, June-November 2023.
    Vaccine. 2024 Feb 22:S0264-410X(24)00215-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  354. SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al
    Audiovestibular adverse events following COVID-19 vaccinations.
    Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  355. XU S, Sy LS, Hong V, Farrington P, et al
    Mortality risk after COVID-19 vaccination: A self-controlled case series study.
    Vaccine. 2024 Feb 21:S0264-410X(24)00191-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  356. PLIESKATT J, Bang P, Wood GK, Naghizadeh M, et al
    Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP.
    Vaccine. 2024 Feb 21:S0264-410X(24)00202-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  357. BOTTCHER J, Bauer BU, Ambros C, Alex M, et al
    The immune response to a Coxiella burnetii vaccine in sheep varies according to their natural pre-exposure.
    Vaccine. 2024 Feb 21:S0264-410X(24)00207-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  358. YIN Q, Zheng Y, Ying Z, Li J, et al
    Immunogenicity and lot-to-lot consistency of booster shot with Sabin inactivated poliomyelitis vaccine in Chinese children aged 18-24 Months: A phase ? clinical trial.
    Vaccine. 2024 Feb 21:S0264-410X(24)00201-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  359. KABORE L, Pecenka C, Hausdorff WP
    Lassa fever vaccine use cases and demand: Perspectives from select West African experts.
    Vaccine. 2024 Feb 17:S0264-410X(24)00203-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  360. BRUEL S, Rakotomampionona Z, Gignon M, Agrinier N, et al
    The intentions of French health university students to recommend and to receive the HPV vaccine are mainly influenced by vaccine knowledge, confidence in vaccines and personal HPV vaccination.
    Vaccine. 2024 Feb 17:S0264-410X(24)00192-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  361. SHOUKAT A, Bawden CE, Rost G, LeBlanc JJ, et al
    Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2024 Feb 16:S0264-410X(24)00200-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  362. PIKE J, Lueken J, Zajac J, Tippins A, et al
    2022 Polio outbreak, Rockland County, NY: Cost evaluation of strategies to prevent future outbreaks of vaccine-preventable diseases.
    Vaccine. 2024 Feb 16:S0264-410X(24)00171-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  363. FABER BW, Yeoh LM, Kurtovic L, Mol WEM, et al
    A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies.
    Vaccine. 2024 Feb 16:S0264-410X(24)00175-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  364. KOCHHAR S, Assis DN, Mack C, Izurieta HS, et al
    Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Vaccine. 2024 Feb 16:S0264-410X(24)00021-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  365. POLAND GA, Raina MacIntyre C
    Celebrating vaccines: The 2023 Nobel prize in medicine or physiology.
    Vaccine. 2024 Feb 15:S0264-410X(23)01258-6. doi: 10.1016/j.vaccine.2023.
    PubMed    


  366. JIN F, Qiu Y, Wu Z, Wang YH, et al
    Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
    Vaccine. 2024 Feb 15:S0264-410X(24)00124-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  367. MZIOU E, Hchaichi A, Letaief H, Dhaouadi S, et al
    Vaccine effectiveness against COVID-19: A test negative case-control study in Tunisia, August 2021.
    Vaccine. 2024 Feb 15:S0264-410X(24)00174-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  368. TOBACK S, Marchese AM, Warren B, Ayman S, et al
    Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine.
    Vaccine. 2024 Feb 15:S0264-410X(24)00196-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  369. THIAUCOURT F, Exbrayat A, Loire E, Boissiere A, et al
    Deep sequencing and variant frequency analysis for the quality control of a live bacterial vaccine against contagious bovine pleuropneumonia, strain T1.
    Vaccine. 2024 Feb 15:S0264-410X(24)00177-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  370. ROCKSON ADJEI M, Longsignikuu A, Saeed Iddris I, Nang Suuri T, et al
    Trend of measles-rubella vaccination coverage and impact on measles epidemiology in the Savannah Region, Ghana; 2018-2022: A secondary data analysis.
    Vaccine. 2024 Feb 15:S0264-410X(24)00170-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  371. KIM HK, Park SK, Choe SA, Gwak ES, et al
    Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study.
    Vaccine. 2024 Feb 15:S0264-410X(24)00168-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  372. KUTER BJ, Brien K, Anderson S, Bass SB, et al
    COVID-19 vaccine perspectives and uptake among university students three years into the pandemic.
    Vaccine. 2024 Feb 15:S0264-410X(24)00162-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  373. DREYFUS J, Munnangi S, Bengtsson C, Correia B, et al
    Background incidence rates of health outcomes in populations at risk for Lyme disease using US administrative claims data.
    Vaccine. 2024;42:1094-1107.
    PubMed     Abstract available


  374. PREVOT-MONSACRE P, Hamaide-Defrocourt F, Guyonvarch O, Masse S, et al
    What is the relevancy of a surveillance of mumps without a systematic laboratory confirmation in highly immunized populations? Epidemiology of suspected and biologically confirmed mumps cases seen in general practice in France between 2014 and 2020.
    Vaccine. 2024;42:1065-1070.
    PubMed     Abstract available


  375. ROWLEY F, Cottrell S, Howard C, Meredith N, et al
    Use of invitations and reminders are associated with higher levels of Herpes zoster (shingles) vaccination uptake. A cross-sectional survey of general practices in Wales, and ecological analysis of uptake data, 2022.
    Vaccine. 2024 Feb 14:S0264-410X(24)00193-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  376. ACEVES-SANCHEZ MJ, Barrios-Payan JA, Segura-Cerda CA, Flores-Valdez MA, et al
    Erratum to "BCGDeltaBCG1419c and BCG differ in induction of autophagy, c-di-GMP content, proteome, and progression of lung pathology in Mycobacterium tuberculosis HN878-infected male BALB/c mice" [Vaccine 41(26) (2023) 3824-3835].
    Vaccine. 2024 Feb 14:S0264-410X(24)00176-2. doi: 10.1016/j.vaccine.2024.
    PubMed    


  377. DUGGAR C, Santoli JM, Noblit C, Moore LB, et al
    U.S. COVID-19 vaccine distribution strategies, systems, performance, and lessons learned, December 2020 - May 2023.
    Vaccine. 2024 Feb 14:S0264-410X(24)00167-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  378. BORYS D, Rupp R, Smulders R, Chichili GR, et al
    Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial.
    Vaccine. 2024 Feb 14:S0264-410X(24)00145-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  379. BATHEJA A, Balkrishnan R
    Rhode Island as a model for promoting flu vaccination in the United States.
    Vaccine. 2024 Feb 14:S0264-410X(24)00161-0. doi: 10.1016/j.vaccine.2024.
    PubMed    


  380. OKOLI GN, Righolt CH, Zhang G, Van Caeseele P, et al
    A population-based, province-wide, record-linkage interrupted time series analysis of impact of the universal seasonal influenza vaccination policy on seasonal influenza vaccine uptake among 5-64-year-olds in the province of Manitoba, Canada.
    Vaccine. 2024 Feb 14:S0264-410X(24)00104-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  381. KLASSEN AC, Lee G, Chiang S, Murray R, et al
    Did the COVID-19 experience change U.S. parents' attitudes towards HPV vaccination? Results from a national survey.
    Vaccine. 2024 Feb 14:S0264-410X(24)00142-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  382. DONATO F, Pilotto A, Foca E, Tresoldi M, et al
    The impact of time since SARS-Cov-2 vaccination, age, sex and comorbidities on COVID-19 outcome in hospitalized patients with SARS-CoV-2 infection.
    Vaccine. 2024 Feb 13:S0264-410X(24)00147-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  383. HEARN EB, Kehinde G, Sambamoorthi U
    Food insecurity and COVID-19 vaccine hesitancy among adults in the United States (US).
    Vaccine. 2024 Feb 13:S0264-410X(24)00102-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  384. MCDERMID P, Blazek K, Mougin N, Thomson A, et al
    Attitudes and behaviors of maternal Tdap vaccination in Panama, Peru, and Colombia: An international cross-sectional study.
    Vaccine. 2024 Feb 13:S0264-410X(24)00143-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  385. LI Y, Sun X, Fu Y, You X, et al
    Literature review to identify evidence of secondary transmission of pentavalent human-bovine reassortant rotavirus vaccine (RV5) strains to unvaccinated subjects.
    Vaccine. 2024 Feb 13:S0264-410X(24)00107-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  386. BHARUCHA T, Gangadharan B, Clarke R, Fernandez LG, et al
    Repurposing rapid diagnostic tests to detect falsified vaccines in supply chains.
    Vaccine. 2024 Feb 13:S0264-410X(24)00019-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  387. MORGAN HJ, Clothier HJ, Sepulveda Kattan G, Boyd JH, et al
    Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - A self-controlled case series analysis.
    Vaccine. 2024 Feb 12:S0264-410X(24)00126-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  388. MABALE MAA, Tejero LMS, Montes LA, Collante MTM, et al
    Implications of information heard about Dengvaxia on Filipinos' perception on vaccination.
    Vaccine. 2024 Feb 12:S0264-410X(24)00123-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  389. AMDISEN L, Pedersen L, Abildgaard N, Benn CS, et al
    The coverage of influenza vaccination and predictors of influenza non-vaccination in Danish cancer patients: A nationwide register-based cohort study.
    Vaccine. 2024 Feb 12:S0264-410X(24)00155-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  390. FAKSOVA K, Walsh D, Jiang Y, Griffin J, et al
    COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Vaccine. 2024 Feb 12:S0264-410X(24)00127-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  391. MANNING J, Manna S, Dunne EM, Bongcaron V, et al
    Immunization with a whole cell vaccine reduces pneumococcal nasopharyngeal density and shedding, and middle ear infection in mice.
    Vaccine. 2024 Feb 12:S0264-410X(24)00131-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  392. VALENTIN J, Ingrao F, Rauw F, Lambrecht B, et al
    Protection conferred by an H5 DNA vaccine against highly pathogenic avian influenza in chickens: The effect of vaccination schedules.
    Vaccine. 2024 Feb 12:S0264-410X(23)01422-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  393. DE WALS P, Desjardins M
    Minimal interval for the administration of a pneumococcal polysaccharide vaccine following the administration of a pneumococcal conjugate vaccine.
    Vaccine. 2024 Feb 12:S0264-410X(24)00163-4. doi: 10.1016/j.vaccine.2024.
    PubMed    


  394. LIJESKIC O, Bauman N, Markovic M, Srbljanovic J, et al
    SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Vaccine. 2024 Feb 10:S0264-410X(24)00110-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  395. WHITAKER HJ, Hassell K, Hoschler K, Power L, et al
    Influenza vaccination during the 2021/22 season: A data-linkage test-negative case-control study of effectiveness against influenza requiring emergency care in England and serological analysis of primary care patients.
    Vaccine. 2024 Feb 10:S0264-410X(24)00150-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  396. MARKOWITZ LE, Hopkins RH Jr, Broder KR, Lee GM, et al
    COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemic.
    Vaccine. 2024 Feb 9:S0264-410X(23)01505-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  397. WEI J, Tan TC, Moa AM, MacIntyre CR, et al
    Cost-benefit of influenza vaccination in preventing sudden cardiac arrest amongst Australian adults.
    Vaccine. 2024 Feb 9:S0264-410X(24)00154-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  398. NGUYEN KH, Chen S, Zhao R, Vasudevan L, et al
    Vaccination patterns and up-to-date status of children 19-35 months, 2011-2021.
    Vaccine. 2024 Feb 9:S0264-410X(24)00122-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  399. FORTUNATO F, Musco A, Iannelli G, Meola M, et al
    Effectiveness of the combined MMRV Priorix-Tetra vaccine against varicella in a large Italian region: A case-control study.
    Vaccine. 2024 Feb 9:S0264-410X(24)00146-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  400. BUEKENS P, Berrueta M, Ciapponi A, Bardach A, et al
    Safe in pregnancy: A global living systematic review and meta-analysis of COVID-19 vaccines in pregnancy.
    Vaccine. 2024 Feb 9:S0264-410X(24)00158-0. doi: 10.1016/j.vaccine.2024.
    PubMed    


  401. WADAPURKAR R, Singh S, Singh A
    Leveraging the immunoinformatics approach for designing the SARS-CoV-2 omicron-specific antigenic cassette of mRNA vaccine.
    Vaccine. 2024 Feb 8:S0264-410X(24)00111-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  402. SERRANO-MAYORGA CC, Ibanez-Prada ED, Restrepo-Martinez JM, Garcia-Gallo E, et al
    The potential impact of PCV-13, PCV-15 and PCV-20 vaccines in Colombia.
    Vaccine. 2024 Feb 8:S0264-410X(24)00109-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  403. AMINZADEH A, Hilgers L, Paul Platenburg P, Riou M, et al
    Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant.
    Vaccine. 2024 Feb 8:S0264-410X(24)00101-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  404. WELDEGEBRIEL GG, Okot C, Majingo N, Oumer NJ, et al
    Resurgent rotavirus diarrhoea outbreak five years after introduction of rotavirus vaccine in Botswana, 2018.
    Vaccine. 2024 Feb 7:S0264-410X(24)00108-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  405. CHEN M, Feng X, Liu J, Wang J, et al
    Prokaryote-derived phosphorylated Tau epitope vaccine is immunogenic and non-T-cell activated in the mice model.
    Vaccine. 2024 Feb 7:S0264-410X(23)01517-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  406. KOLANDAI K, Milne B, von Randow M, Bullen C, et al
    Public opinion on global COVID-19 vaccine procurement and distribution policies: A nationally representative survey in Aotearoa New Zealand 2022.
    Vaccine. 2024 Feb 6:S0264-410X(24)00115-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  407. LAMBACH P, Orenstein W, Silal S, Sbarra AN, et al
    Report from the World Health Organization's immunization and vaccines related implementation research advisory committee (IVIR-AC) meeting, Geneva, 11-13 September 2023.
    Vaccine. 2024 Feb 6:S0264-410X(24)00160-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  408. SOBLE A, Ko M, Gilchrist S, Malvolti S, et al
    A review of potential use cases for measles-rubella, measles-mumps-rubella, and typhoid-conjugate vaccines presented on microarray patches.
    Vaccine. 2024 Feb 6:S0264-410X(23)01493-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  409. KOHLI K, Jain B, Dee EC, Ho BL, et al
    Addressing cultural and political drivers of vaccine hesitancy: Considerations for the African and Asian contexts.
    Vaccine. 2024 Feb 6:S0264-410X(24)00159-2. doi: 10.1016/j.vaccine.2024.
    PubMed    


  410. SMITH TC, Gorski DH
    Infertility: A common target of antivaccine misinformation campaigns.
    Vaccine. 2024;42:924-929.
    PubMed     Abstract available


  411. PENG Y, Yan H, Zhang J, Peng R, et al
    Potent immune responses against thermostable Foot-and-Mouth disease virus VP1 nanovaccine adjuvanted with polymeric thermostable scaffold.
    Vaccine. 2024;42:732-737.
    PubMed     Abstract available


  412. MAEDA M, Murata F, Fukuda H
    The age-specific impact of COVID-19 vaccination on medical expenditures and hospitalization duration after breakthrough infection: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study.
    Vaccine. 2024 Feb 5:S0264-410X(24)00106-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  413. KIM NE, Kim MJ, Park BJ, Kwon JW, et al
    A DNA vaccine against GII.4 human norovirus VP1 induces blocking antibody production and T cell responses.
    Vaccine. 2024 Feb 5:S0264-410X(24)00114-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  414. HOUY N, Flaig J
    Value of information dynamics in Disease X vaccine clinical trials.
    Vaccine. 2024 Feb 3:S0264-410X(24)00075-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  415. RIVERS P, Porter C, LeClair LB, Jeddy Z, et al
    Longitudinal parental perception of COVID-19 vaccines for children in a multi-site, cohort study.
    Vaccine. 2024 Feb 2:S0264-410X(24)00010-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  416. HWANG YH, Byeon Y, Ahn SH, Kim MY, et al
    Live attenuated smallpox vaccine candidate (KVAC103) efficiently induces protective immune responses in mice.
    Vaccine. 2024 Feb 2:S0264-410X(24)00076-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  417. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial.
    Vaccine. 2024 Feb 2:S0264-410X(24)00068-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  418. LI D, Han M, Cao Y, Du J, et al
    Protective effect against toxoplasmosis in BALB/C mice vaccinated with recombinant Toxoplasma gondii CDPK3, GRA35, and ROP46 protein cocktail vaccine.
    Vaccine. 2024 Feb 2:S0264-410X(24)00062-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  419. WANG ZJ, Zhang RR, Wu M, Zhao H, et al
    Development of a live-attenuated chimeric vaccine against the emerging Usutu virus.
    Vaccine. 2024 Feb 2:S0264-410X(24)00098-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  420. MIYAMOTO S, Suzuki T
    Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
    Vaccine. 2024 Feb 2:S0264-410X(24)00112-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  421. SUMNER T, Clark RA, Mukandavire C, Portnoy A, et al
    Modelling the health and economic impacts ofM72/AS01(E) vaccination and BCG-revaccination: Estimates for South Africa.
    Vaccine. 2024 Feb 1:S0264-410X(24)00096-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  422. BENNETT JC, Luiten KG, O'Hanlon J, Han PD, et al
    Utilizing a university testing program to estimate relative effectiveness of monovalent COVID-19 mRNA booster vaccine versus two-dose primary series against symptomatic SARS-CoV-2 infection.
    Vaccine. 2024 Feb 1:S0264-410X(24)00103-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  423. DE DEUS N, Chissaque A, Bauhofer A, Barata A, et al
    Safety of incidental exposure to the novel oral poliovirus vaccine type 2 in pregnancy: A longitudinal observational study in Mozambique, 2022-2023.
    Vaccine. 2024 Feb 1:S0264-410X(24)00095-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  424. DATTA S, Vattiato G, Maclaren OJ, Hua N, et al
    The impact of Covid-19 vaccination in Aotearoa New Zealand: A modelling study.
    Vaccine. 2024 Feb 1:S0264-410X(24)00128-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    January 2024
  425. SCHONBORN L, Pavord S, Chen VMY, Pai M, et al
    Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Vaccine. 2024 Jan 31:S0264-410X(24)00057-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  426. SLAVKOVSKY R, Callen E, Pecenka C, Mvundura M, et al
    Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review.
    Vaccine. 2024 Jan 31:S0264-410X(24)00118-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  427. SOOD S, Matar MM, Kim J, Kinsella M, et al
    Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer.
    Vaccine. 2024 Jan 31:S0264-410X(24)00077-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  428. JI Y, Sui X, Miao W, Wang C, et al
    Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.
    Vaccine. 2024 Jan 30:S0264-410X(24)00097-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  429. KOFF WC, Anandkumar A, Poland GA
    AI and the future of vaccine development.
    Vaccine. 2024 Jan 30:S0264-410X(24)00071-9. doi: 10.1016/j.vaccine.2024.
    PubMed    


  430. POLAND GA, Black S
    Cryptic vaccine-associated adverse events: The critical need for a new vaccine safety surveillance paradigm to improve public trust in vaccines.
    Vaccine. 2024 Jan 30:S0264-410X(24)00070-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  431. BURNS KE, Dube E, Nascimento HG, Meyer SB, et al
    Erratum to "Examining vaccine hesitancy among a diverse sample of Canadian adults" [Vaccine 42(2) (2024) 129-135].
    Vaccine. 2024 Jan 30:S0264-410X(24)00061-6. doi: 10.1016/j.vaccine.2024.
    PubMed    


  432. HUANG Y, Shi H, Forgacs D, Ross TM, et al
    Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection.
    Vaccine. 2024 Jan 30:S0264-410X(23)01543-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  433. XIAOFEI L, Yudan LI, Qinghui C, Jiaming S, et al
    Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-serotype community acquired pneumococcal diseases among children in China: A test-negative case-control study.
    Vaccine. 2024 Jan 30:S0264-410X(24)00080-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  434. SHAPIRO BEN DAVID S, Baruch Gez S, Adler L, Kovatch R, et al
    Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey.
    Vaccine. 2024 Jan 27:S0264-410X(24)00067-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  435. BALSELLS E, Vicente M, Reyes S, Figueroa M, et al
    Impact of the 'Health on Wheels' (HoW) strategy on COVID-19 vaccination coverage in hard-to-reach communities in Alta Verapaz, Guatemala, 2022.
    Vaccine. 2024 Jan 27:S0264-410X(24)00033-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  436. VIDLUND J, Gelalcha BD, Gillespie BE, Agga GE, et al
    Efficacy of novel staphylococcal surface associated protein vaccines against Staphylococcus aureus and non-aureus staphylococcal mastitis in dairy cows.
    Vaccine. 2024 Jan 27:S0264-410X(24)00079-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  437. MURATA F, Maeda M, Ono R, Fukuda H, et al
    Association between regular physical activity and pneumonia-related hospitalization according to pneumococcal vaccination status: The VENUS study.
    Vaccine. 2024 Jan 27:S0264-410X(24)00072-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  438. OKPANI AI, Adu P, Paetkau T, Lockhart K, et al
    Are COVID-19 vaccination mandates for healthcare workers effective? A systematic review of the impact of mandates on increasing vaccination, alleviating staff shortages and decreasing staff illness.
    Vaccine. 2024 Jan 27:S0264-410X(24)00052-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  439. HALL E, Mahon BE, Peacock G
    The U.S. COVID-19 vaccination program: A look back and future directions.
    Vaccine. 2024 Jan 26:S0264-410X(24)00065-3. doi: 10.1016/j.vaccine.2024.
    PubMed    


  440. LEVIN A, Yeung KHT, Hutubessy R
    Systematic review of cost projections of new vaccine introduction.
    Vaccine. 2024 Jan 25:S0264-410X(24)00024-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  441. TAKALANI A, Robinson M, Jonas P, Bodenstein A, et al
    Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
    Vaccine. 2024 Jan 25:S0264-410X(24)00078-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  442. FILIPAS DK, Labban M, Beatrici E, Stone BV, et al
    Exploring preventive care practices among unvaccinated individuals in the United States during the COVID-19 pandemic.
    Vaccine. 2024;42:441-447.
    PubMed     Abstract available


  443. FERRERAS-COLINO E, Contreras M, Risalde MA, Sevilla IA, et al
    Heat-inactivated mycobacteria activate the toll-like receptor 2 and 4 pathways in the zebrafish model of tuberculosis.
    Vaccine. 2024;42:403-409.
    PubMed     Abstract available


  444. KHAN A, Hussain I, Rhoda DA, Umer M, et al
    Determinants of immunization in polio super high-risk union councils of Pakistan.
    Vaccine. 2024;42:583-590.
    PubMed     Abstract available


  445. RUSS S, Bennett N, van Wijngaarden E, Hill E, et al
    Influence of Community Determinants on Barriers and Facilitators to COVID-19 Vaccine Uptake: Regional Stakeholders' Perspectives.
    Vaccine. 2024 Jan 24:S0264-410X(24)00051-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  446. RATTAY K, Thierry JM, Yeargin-Allsopp M, Griffin-Blake S, et al
    Lessons learned: COVID-19 vaccinations and people with disabilities.
    Vaccine. 2024 Jan 23:S0264-410X(24)00028-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  447. WANG CP, Lin YT, Du YZ, Zhang T, et al
    Impact of innovative immunization strategy on PCV13 vaccination coverage among children under 5 years in Weifang city, China: A retrospective study.
    Vaccine. 2024 Jan 23:S0264-410X(24)00030-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  448. LIU R, Fan Y, Patel A, Liu H, et al
    The association between influenza vaccination, cardiovascular mortality and hospitalization: A living systematic review and prospective meta-analysis.
    Vaccine. 2024 Jan 23:S0264-410X(24)00053-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  449. HARANAKA M, Young Song J, Huang KC, de Solom R, et al
    A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults?>/=?60 years of age in Japan, South Korea, and Taiwan.
    Vaccine. 2024 Jan 23:S0264-410X(24)00008-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  450. ABAD N, Bonner KE, Kolis J, Brookmeyer KA, et al
    Strengthening COVID-19 vaccine confidence & demand during the US COVID-19 emergency response.
    Vaccine. 2024 Jan 23:S0264-410X(24)00029-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  451. HADLER SC, Shefer AM, Cavallaro KF, Ebama M, et al
    Supporting National Immunization Technical Advisory Groups (NITAGs) in development of evidence-based vaccine recommendations and NITAG assessments - New tools and approaches.
    Vaccine. 2024 Jan 23:S0264-410X(24)00035-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  452. CLOTHIER HJ, Shetty AN, Mesfin Y, Mackie M, et al
    What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safety.
    Vaccine. 2024 Jan 22:S0264-410X(24)00025-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  453. CAO H, Li H, Luan N, Zhang H, et al
    A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity.
    Vaccine. 2024 Jan 22:S0264-410X(24)00069-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  454. HAMAD SAIED M, van Straalen JW, de Roock S, Verduyn Lunel FM, et al
    Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study.
    Vaccine. 2024 Jan 22:S0264-410X(24)00059-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  455. PAL R, Ferrari MG, Honda-Okubo Y, Wattay L, et al
    Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
    Vaccine. 2024 Jan 22:S0264-410X(24)00034-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  456. CATALDI JR, Suresh K, Brewer SE, Perreira C, et al
    Boot Camp Translation using Community-Engaged messaging for adolescent Vaccination: A Cluster-Randomized trial.
    Vaccine. 2024 Jan 21:S0264-410X(24)00054-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  457. SANTORO PE, Paladini A, Borrelli I, Amantea C, et al
    Vaccine-preventable diseases: Immune response in a large population of healthcare students.
    Vaccine. 2024 Jan 20:S0264-410X(24)00049-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  458. HILL PL, Morstead T, Pfund GN, Burrow AL, et al
    Examining changes in sense of purpose before, during, and after COVID-19 vaccination.
    Vaccine. 2024 Jan 20:S0264-410X(24)00027-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  459. KUMWICHAR P, Chongsuvivatwong V, Vasoppakarn S, Atthakul N, et al
    Incidence rates of myocarditis and pericarditis within 30 days following homologous and heterologous BNT162b2 vaccinations in individuals 5-40 years of age.
    Vaccine. 2024 Jan 20:S0264-410X(24)00026-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  460. GEINITZ H, Silberberger E, Spiegl K, Feichtinger J, et al
    SARS-CoV-2 vaccination willingness and humoral vaccination response in radiation oncology patients.
    Vaccine. 2024 Jan 20:S0264-410X(24)00004-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  461. MITCHELL MM, Klott A, Scholtes J, Braden BB, et al
    Mixed-methods examination of attitudes and behaviors related to COVID-19 vaccines among parents of children with autism and autistic adults.
    Vaccine. 2024 Jan 19:S0264-410X(24)00013-6. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  462. MEMEDOVICH A, Orr T, Hollis A, Salmon C, et al
    Social network risk factors and COVID-19 vaccination: A cross-sectional survey study.
    Vaccine. 2024 Jan 18:S0264-410X(24)00005-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  463. MUNKWASE G
    Implications of vaccine non-specific effects on licensure of new vaccines.
    Vaccine. 2024 Jan 18:S0264-410X(24)00060-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  464. CHRISTOPH R, Giovanni A, Arne S, Sebastian V, et al
    Immunogenicity of tick-borne-encephalitis-virus-(TBEV)-vaccination and impact of age on humoral and cellular TBEV-specific immune responses in patients with rheumatoid arthritis.
    Vaccine. 2024 Jan 18:S0264-410X(24)00022-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  465. HICKEN A, Jones P, Menon A, Rozek LS, et al
    Can endorsement by religious leaders move the needle on vaccine hesitancy?
    Vaccine. 2024 Jan 18:S0264-410X(24)00006-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  466. FIEBELKORN AP, Adelsberg S, Anthony R, Ashenafi S, et al
    The role of funded partnerships in working towards decreasing COVID-19 vaccination disparities, United States, March 2021-December 2022.
    Vaccine. 2024 Jan 17:S0264-410X(23)01507-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  467. LEMMER Y, Chapman R, Abolnik C, Smith T, et al
    Protective efficacy of a plant-produced beta variant rSARS-CoV-2 VLP vaccine in golden Syrian hamsters.
    Vaccine. 2024 Jan 17:S0264-410X(24)00036-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  468. GRIMA AA, Kwong JC, Richard L, Reid J, et al
    The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data.
    Vaccine. 2024 Jan 17:S0264-410X(24)00023-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  469. FAN J, Song Y, Cong S, Millman AJ, et al
    Assessing interventions to encourage primary care health workers to recommend influenza vaccination and the impact on vaccination uptake for persons with Non-Communicable diseases in China.
    Vaccine. 2024 Jan 16:S0264-410X(24)00011-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  470. HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Warner ND, et al
    Restricted Omicron-specific cross-variant memory B-cell immunity after a 3rd dose/booster of monovalent Wuhan-Hu-1-containing COVID-19 mRNA vaccine.
    Vaccine. 2024 Jan 16:S0264-410X(24)00032-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  471. TIAN X, Wang J, Chen H, Ding M, et al
    In vivo functional immunoprotection correlates for vaccines against invasive bacteria.
    Vaccine. 2024 Jan 16:S0264-410X(24)00018-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  472. KING ML
    How manufacturing won or lost the COVID-19 vaccine race.
    Vaccine. 2024 Jan 15:S0264-410X(23)01477-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  473. KANG DW, Kim CR, Song JY, Park SK, et al
    Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
    Vaccine. 2024 Jan 14:S0264-410X(24)00031-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  474. MCADAM E, Hayashi K, Barker B, Reddon H, et al
    COVID-19 vaccination among young people who use drugs in Vancouver, Canada.
    Vaccine. 2024 Jan 14:S0264-410X(24)00009-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  475. BEARSON SMD, Monson MS, Bearson BL, Whelan SJ, et al
    Commercial vaccine provides cross-protection by reducing colonization of Salmonella enterica serovars Infantis and Hadar in turkeys.
    Vaccine. 2024 Jan 13:S0264-410X(23)01500-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  476. GUO W, Wang C, Song X, Xu H, et al
    Immunogenicity and protective efficacy of a trimeric full-length S protein subunit vaccine for porcine epidemic diarrhea virus.
    Vaccine. 2024 Jan 13:S0264-410X(24)00020-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  477. NAUTA J
    Estimand for non-inferiority influenza vaccine immunogenicity trials.
    Vaccine. 2024 Jan 13:S0264-410X(24)00014-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  478. RATISHVILI T, Quach HQ, Haralambieva IH, Suryawanshi YR, et al
    A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides.
    Vaccine. 2024;42:162-174.
    PubMed     Abstract available


  479. VAN ROEKEL C, Labuschagne L, Pijpers J, van Roon A, et al
    Factors associated with COVID-19 autumn 2022 booster uptake in the Netherlands among older adults aged >/= 60 years and younger adults with chronic conditions.
    Vaccine. 2024;42:146-155.
    PubMed     Abstract available


  480. KURATA T, Kaida Y, Kanbayashi D, Motomura K, et al
    Achieving measles elimination and emerging modified measles: Longitudinal measles epidemiology from 1982 to 2021 in Osaka Prefecture, Japan.
    Vaccine. 2024;42:271-286.
    PubMed     Abstract available


  481. SMITH CL, Richardson B, Rubsamen M, Cameron MJ, et al
    Adjuvant AS01 activates human monocytes for costimulation and systemic inflammation.
    Vaccine. 2024;42:229-238.
    PubMed     Abstract available


  482. THOMPSON KM, Kalkowska DA, Kidd SE, Burns CC, et al
    Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization.
    Vaccine. 2024 Jan 12:S0264-410X(23)01541-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  483. KNIJFF M, van Lier A, Boer M, de Vries M, et al
    Parental intention, attitudes, beliefs, trust and deliberation towards childhood vaccination in the Netherlands in 2022: Indications of change compared to 2013.
    Vaccine. 2024 Jan 11:S0264-410X(23)01539-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  484. GOLDIN S, Moen A, Moss WJ, Nuzzo J, et al
    Assessing the relationship between existing childhood, adolescent and adult immunization programmes and national COVID-19 vaccination capacities in 2021.
    Vaccine. 2024 Jan 11:S0264-410X(23)01484-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  485. JOACHIM GE, Wagner AL, Naseem M, Boulton ML, et al
    Trends in childhood vaccination in Pakistan and associated factors; 2006-2018.
    Vaccine. 2024 Jan 10:S0264-410X(24)00015-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  486. SHARP M, Lozano P, Southworth A, Peters A, et al
    Mixed methods approach to understanding COVID-19 vaccine hesitancy among immigrants in the Chicago.
    Vaccine. 2024 Jan 9:S0264-410X(23)01508-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  487. LIN HH, Wu YS, Chang MT, Shyur LF, et al
    Plant-derived galactolipids enhance specific antibody production and induce class-switch as vaccine adjuvant.
    Vaccine. 2024 Jan 9:S0264-410X(24)00002-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  488. HINSON-ENSLIN AM, Espinoza LE
    The mental health symptoms of individuals with sensory disabilities and the reasons that lead to COVID-19 vaccine refusal and hesitancy.
    Vaccine. 2024 Jan 9:S0264-410X(24)00012-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  489. MULLER MP, Navarro C, Wilson SE, Shulha HP, et al
    Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study.
    Vaccine. 2024 Jan 9:S0264-410X(23)01514-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  490. OKUMOTO A, Nomura Y, Okuda S, Shikano M, et al
    Issues with infectious disease vaccine introduction into routine vaccination in Japan, and considerations for accelerating the process.
    Vaccine. 2024 Jan 9:S0264-410X(23)01504-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  491. QURESHI NS, Miller LG, Judge SP, Tran NDT, et al
    Characterizing predictors of COVID-19 vaccine refusal in an urban southern California jail population.
    Vaccine. 2024 Jan 9:S0264-410X(24)00017-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  492. CARROLL JC, Herbert SMC, Nguyen TQ, Schork CJ, et al
    Vaccination equity and the role of community pharmacy in the United States: A qualitative study.
    Vaccine. 2024 Jan 8:S0264-410X(23)01509-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  493. ROZENBAUM MH, Huang L, Perdrizet J, Cane A, et al
    Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants.
    Vaccine. 2024 Jan 7:S0264-410X(23)01503-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  494. COSTA M, Mansilla F, Manuel Sala J, Saravia A, et al
    Fasciola hepatica infection modifies IgG1 specific immune response to foot-and-mouse disease virus induced by vaccination.
    Vaccine. 2024 Jan 6:S0264-410X(23)01513-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  495. STELETOU E, Giannouchos T, Dimitriou G, Karatza A, et al
    Parental concerns and vaccine hesitancy against COVID-19 vaccination for children in Greece: A cross-sectional survey.
    Vaccine. 2024 Jan 6:S0264-410X(24)00003-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  496. DOBROVOLSKIENE N, Balevicius R, Mlynska A, Zilionyte K, et al
    Immunomodulatory properties of bacteriophage derived dsRNA of different size and their use as anticancer vaccine adjuvants.
    Vaccine. 2024 Jan 5:S0264-410X(23)01518-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  497. STONE ND, Parker Fiebelkorn A, Guo A, Mothershed E, et al
    Challenges and opportunities during the COVID-19 vaccination efforts in long-term care.
    Vaccine. 2024 Jan 5:S0264-410X(23)01510-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  498. REIS JN, Azevedo J, de Oliveira AML, Menezes APO, et al
    Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil.
    Vaccine. 2024 Jan 5:S0264-410X(23)01501-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  499. ENYINNAYA JC, Anderson AA, Kelp NC, Long M, et al
    The Social Ecology of Health Beliefs and Misinformation Framework: Examining the impact of misinformation on vaccine uptake through individual and sociological factors.
    Vaccine. 2024 Jan 5:S0264-410X(24)00001-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  500. KRANZLER EC, Ihongbe TO, Marshall MC, Denison B, et al
    Racial and ethnic differences in COVID-19 vaccine readiness among adults in the United States, January 2021-April 2023.
    Vaccine. 2024 Jan 4:S0264-410X(23)01537-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  501. BUHL C, Jacobsen R, Almarsdottir AB, Abtahi S, et al
    Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states.
    Vaccine. 2024 Jan 4:S0264-410X(23)01511-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  502. ALVAREZ CA, Hall RG 2nd, Lin S, Perkins AR, et al
    Compliance with recommended pneumococcal vaccination schedule in patients treated for rheumatoid arthritis: A retrospective cohort study in the Veterans Affairs population.
    Vaccine. 2024 Jan 3:S0264-410X(23)01532-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  503. CHARPIGNON ML, Gupta S, Shahnaz Majumder M
    Massachusetts companion program bolsters COVID-19 vaccine rates among seniors.
    Vaccine. 2024 Jan 3:S0264-410X(23)01494-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  504. DAVIDSON AM, Burns S, White LA, Perlman M, et al
    "I shall not poison my child with your human experiment": Investigating predictors of parents' hesitancy about vaccinating younger children (<12) in Canada.
    Vaccine. 2024 Jan 2:S0264-410X(23)01519-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  505. YAEGASHI M, Matsui H, Yoshida A, Ban H, et al
    A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
    Vaccine. 2024 Jan 2:S0264-410X(23)01540-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  506. HUSSEIN I, Vanska S, Sivela J, Leino T, et al
    Factors associated with parental Human Papillomavirus (HPV) vaccination intention of daughter: A national survey in Finland.
    Vaccine. 2024 Jan 2:S0264-410X(23)01473-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  507. AGASSE E, Rodriguez GF, Vilarino V, Galli JH, et al
    Social determinants of health and vaccine uptake in pregnancy: Disparities in a diverse, predominately foreign-born population.
    Vaccine. 2024 Jan 2:S0264-410X(23)01515-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  508. DE PINHO RB, Barbosa TN, Dall'Agno L, da Rocha Fonseca B, et al
    Mycobacterium bovis BCG expressing the proteins CP40 or CP09720 of Corynebacterium pseudotuberculosis promotes protection in mice after challenge.
    Vaccine. 2024;42:33-39.
    PubMed     Abstract available


  509. VASHI MD, Watkins M
    Missed opportunities: Reducing zero dose children amongthe urban poor after COVID, Mumbai India, 2022.
    Vaccine. 2024;42:59-63.
    PubMed     Abstract available


    December 2023
  510. ZOLA MATUVANGA T, Lariviere Y, Lemey G, Isekah Osang'ir B, et al
    Longitudinal assessment of an Ebola vaccine trial understanding among healthcare providers in the Democratic Republic of the Congo.
    Vaccine. 2023 Dec 31:S0264-410X(23)01530-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  511. ROMANO IG, Core SB, Lee NR, Mowry C, et al
    A bacteriophage virus-like particle vaccine against oxycodone elicits high-titer and long-lasting antibodies that sequester drug in the blood.
    Vaccine. 2023 Dec 29:S0264-410X(23)01533-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  512. TO A, Wong TAS, Ball AH, Lieberman MM, et al
    Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection.
    Vaccine. 2023 Dec 28:S0264-410X(23)01499-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  513. BARZEN G, Rieber F, Stangl K, Hahn K, et al
    mRNA vaccines for COVID-19 are safe and clinically effective in patients with cardiac amyloidosis.
    Vaccine. 2023 Dec 28:S0264-410X(23)01487-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  514. RUBIO-CASILLAS A, Rodriguez-Quintero CM, Redwan EM, Gupta MN, et al
    Do vaccines increase or decrease susceptibility to diseases other than those they protect against?
    Vaccine. 2023 Dec 28:S0264-410X(23)01506-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  515. OLIVER SE, Wallace M, Twentyman E, Moulia DL, et al
    Development of COVID-19 vaccine policy - United States, 2020-2023.
    Vaccine. 2023 Dec 28:S0264-410X(23)01466-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  516. SURTEES TC, Granade CJ, Wells C, Banks M, et al
    CDC COVID-19 vaccination program: Healthcare provider compliance with COVID-19 vaccine requirements and recommendations.
    Vaccine. 2023 Dec 27:S0264-410X(23)01467-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  517. GHARPURE R, Akumu AO, Dawa J, Gobin S, et al
    Costs of seasonal influenza vaccine delivery in a pediatric demonstration project for children aged 6-23 months - Nakuru and Mombasa Counties, Kenya, 2019-2021.
    Vaccine. 2023 Dec 27:S0264-410X(23)01475-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  518. SHENTON P, Schrader S, Smith J, Alafaci A, et al
    Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study.
    Vaccine. 2023 Dec 27:S0264-410X(23)01516-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  519. FONSECA HAR, Zimerman A, Monfardini F, Guimaraes HP, et al
    In-Hospital influenza vaccination to prevent cardiorespiratory events in the first 45 days after acute coronary syndrome: A prespecified analysis of the VIP-ACS trial.
    Vaccine. 2023 Dec 27:S0264-410X(23)01531-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  520. MIRANDA MCR, Nunes CM, Santos LF, da Silva LB, et al
    Ordered mesoporous silicas for potential applications in solid vaccine formulations.
    Vaccine. 2023 Dec 24:S0264-410X(23)01478-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  521. SEESKIN ZH, Ganesh N, Maitra P, Herman P, et al
    Estimating county-level vaccination coverage using small area estimation with the National Immunization Survey-Child.
    Vaccine. 2023 Dec 23:S0264-410X(23)01492-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  522. NGUYEN KH, Coy KC, Black CL, Scanlon P, et al
    Comparison of adult hesitancy towards COVID-19 vaccines and vaccines in general in the USA.
    Vaccine. 2023 Dec 23:S0264-410X(23)01488-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  523. MAHMOOD S, Skinner P, Warren CJ, Mayers J, et al
    In vivo challenge studies on vaccinated chickens indicate a virus genotype mismatched vaccine still offers significant protection against NDV.
    Vaccine. 2023 Dec 23:S0264-410X(23)01483-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  524. KACHKO A, Selvaraj P, Liu S, Kim J, et al
    Vaccine-associated respiratory pathology correlates with viral clearance and protective immunity after immunization with self-amplifying RNA expressing the spike (S) protein of SARS-CoV-2 in mouse models.
    Vaccine. 2023 Dec 22:S0264-410X(23)01498-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  525. SEPPALA E, Dahl J, Veneti L, Rydland KM, et al
    Covid-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: A population-based cohort study, 3 October 2022 to 20 June 2023.
    Vaccine. 2023 Dec 22:S0264-410X(23)01496-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  526. LANGLEY JM, Gantt S, Halperin SA, Ward B, et al
    An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: A first-in-humans Canadian Immunization Research Network (CIRN) study.
    Vaccine. 2023 Dec 22:S0264-410X(23)01452-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  527. LO E, Brousseau N, Defay F, Fortin E, et al
    Neighborhood-level vaccine impact on COVID-19 infection and hospital admission in Quebec, Canada, during the Delta and early Omicron periods.
    Vaccine. 2023 Dec 22:S0264-410X(23)01489-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  528. LEVITAN B, Hadler SC, Hurst W, Izurieta HS, et al
    The Brighton collaboration standardized module for vaccine benefit-risk assessment.
    Vaccine. 2023 Dec 21:S0264-410X(23)01109-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  529. JORDAN Z, Rowland E
    Parental perceptions of chickenpox and the varicella vaccine: A qualitative systematic review.
    Vaccine. 2023 Dec 20:S0264-410X(23)01491-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  530. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
    Vaccine. 2023 Dec 20:S0264-410X(23)01482-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  531. LINK-GELLES R, Britton A, Fleming-Dutra KE
    Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions.
    Vaccine. 2023 Dec 20:S0264-410X(23)01435-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  532. WOLFF M, Charpentier P, Canals A, Vial C, et al
    Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
    Vaccine. 2023 Dec 19:S0264-410X(23)01481-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  533. STUMPF J, Anders L, Siepmann T, Schwobel J, et al
    9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients.
    Vaccine. 2023 Dec 18:S0264-410X(23)01479-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  534. ARASHIRO T, Miwa M, Nakagawa H, Takamatsu J, et al
    COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study).
    Vaccine. 2023 Dec 18:S0264-410X(23)01480-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  535. PILIOU S, Farman TA, Marini A, Manoharan S, et al
    Commensal Neisseria cinerea outer membrane vesicles as a platform for the delivery of meningococcal and gonococcal antigens to the immune system.
    Vaccine. 2023;41:7671-7681.
    PubMed     Abstract available


  536. DAWA J, Jalang'o R, Mirieri H, Kalani R, et al
    Comparing performance of year-round and campaign-mode influenza vaccination strategies among children aged 6-23 months in Kenya: 2019-2021.
    Vaccine. 2023 Dec 16:S0264-410X(23)01380-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  537. PICHON S, Moureau A, Petit C, Kirstein JL, et al
    Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax(R) Rabies) administered in a simulated rabies post-exposure regimen in healthy adults.
    Vaccine. 2023 Dec 16:S0264-410X(23)01398-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  538. JACKSON LA, Stapleton JT, Walter EB, Chen WH, et al
    Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.
    Vaccine. 2023 Dec 16:S0264-410X(23)01434-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  539. ZHAN XY, Chen Y, Zhang X, Shi Q, et al
    Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination.
    Vaccine. 2023 Dec 15:S0264-410X(23)01465-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  540. BAJRACHARYA D, Jansen RJ
    Observations of COVID-19 vaccine coverage and vaccine hesitancy on COVID-19 outbreak: An American ecological study.
    Vaccine. 2023 Dec 15:S0264-410X(23)01441-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  541. JIANG W, Lu C, Yan X, Tucker JD, et al
    Vaccine confidence mediates the association between a pro-social pay-it-forward intervention and improved influenza vaccine uptake in China: A mediation analysis.
    Vaccine. 2023 Dec 15:S0264-410X(23)01392-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  542. BURNS KE, Dube E, Godinho Nascimento H, Meyer SB, et al
    Examining vaccine hesitancy among a diverse sample of Canadian adults.
    Vaccine. 2023 Dec 15:S0264-410X(23)01476-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  543. DONG C, Ma Y, Zhu W, Wang Y, et al
    Influenza immune imprinting synergizes PEI-HA/CpG nanoparticle vaccine protection against heterosubtypic infection in mice.
    Vaccine. 2023 Dec 14:S0264-410X(23)01485-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  544. FERRONI E, Gennaro N, Maifredi G, Leoni O, et al
    Access to SARS-CoV-2 vaccination in immigrants in Italy, by geographical area of origin.
    Vaccine. 2023 Dec 13:S0264-410X(23)01387-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  545. CAO Z, Yu R, Yuan Q, Ji W, et al
    Impact of the COVID-19 pandemic on routine vaccination coverage under varying prevalence Conditions: A cohort study in Beijing, China.
    Vaccine. 2023 Dec 13:S0264-410X(23)01447-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  546. SCHARF LG, Adeniyi K, Augustini E, Boyd D, et al
    Monitoring and reporting the US COVID-19 vaccination effort.
    Vaccine. 2023 Dec 13:S0264-410X(23)01438-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  547. LYU Y, Choong A, Chow EPF, Seib KL, et al
    Vaccine value profile for Neisseria gonorrhoeae.
    Vaccine. 2023 Dec 13:S0264-410X(23)00086-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  548. O'NEIL SS, Pendl-Robinson EL, Carosella EA, Sullivan BD, et al
    The importance of community-specific survey data in understanding behavioral and social drivers of COVID-19 vaccination: Lessons learned from urban neighborhoods in four United States cities.
    Vaccine. 2023 Dec 12:S0264-410X(23)01450-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  549. OPRIESSNIG T, Gauger PC, Filippsen Favaro P, Rawal G, et al
    An experimental universal swine influenza a virus (IAV) vaccine candidate based on the M2 ectodomain (M2e) peptide does not provide protection against H1N1 IAV challenge in pigs.
    Vaccine. 2023 Dec 11:S0264-410X(23)01445-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  550. YAMADA N, Nakatsuka K, Tezuka M, Murata F, et al
    Pneumococcal vaccination coverage and vaccination-related factors among older adults in Japan: LIFE Study.
    Vaccine. 2023 Dec 11:S0264-410X(23)01442-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  551. YANG X, Shi N, Liu C, Zhang J, et al
    Relationship between vaccine hesitancy and vaccination behaviors: Systematic review and meta-analysis of observational studies.
    Vaccine. 2023 Dec 11:S0264-410X(23)01397-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  552. LYTRAS T, Di Gregorio AAA, Apostolopoulos D, Naziris D, et al
    Effectiveness of COVID-19 vaccine mandates in raising vaccination rates among the elderly and general population in Europe: Controlled interrupted time series analysis.
    Vaccine. 2023 Dec 11:S0264-410X(23)01472-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  553. LO VECCHIO A, Scarano SM, Palladino R, Del Bene M, et al
    Co-administration with Men-B vaccine increases Rotavirus vaccination coverage: A 5-year regionwide retrospective cohort study (STORM study).
    Vaccine. 2023 Dec 9:S0264-410X(23)01436-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  554. SKIRROW H, Foley K, Bedford H, Lewis C, et al
    Impact of pregnancy vaccine uptake and socio-demographic determinants on subsequent childhood Measles, Mumps and Rubella vaccine uptake: A UK birth cohort study.
    Vaccine. 2023 Dec 9:S0264-410X(23)01431-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  555. MESIDOR M, Liu Y, Talbot D, Skowronski DM, et al
    Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review.
    Vaccine. 2023 Dec 9:S0264-410X(23)01446-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  556. AKMATOVA R, Dzhangaziev B, Ebama MS, Otorbaeva D, et al
    Knowledge, attitudes, and practices (KAP) towards seasonal influenza and influenza vaccine among pregnant women in Kyrgyzstan: A cross-sectional study.
    Vaccine. 2023 Dec 9:S0264-410X(23)01453-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  557. BJERKHAUG AU, Ramalingham S, Mboizi R, Le Doare K, et al
    The immunogenicity and safety of Group B Streptococcal maternal vaccines: A systematic review.
    Vaccine. 2023 Dec 9:S0264-410X(23)01420-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  558. JONGEN VW, Groot Bruinderink ML, Boyd A, Koole JCD, et al
    What determines mpox vaccination uptake? Assessing the effect of intent-to-vaccinate versus other determinants among men who have sex with men.
    Vaccine. 2023 Dec 9:S0264-410X(23)01449-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  559. SUI Y, Andersen H, Li J, Hoang T, et al
    SARS-CoV-2 mucosal vaccine protects against clinical disease with sex bias in efficacy.
    Vaccine. 2023 Dec 8:S0264-410X(23)01426-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  560. DI CHIARA C, Cantarutti A, Raffaella Petrara M, Bonfante F, et al
    Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5-11 years old children with prior COVID-19.
    Vaccine. 2023 Dec 8:S0264-410X(23)01439-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  561. MALAKER R, Hasanuzzaman M, Hooda Y, Rahman H, et al
    Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: A prospective population-based study in rural Bangladesh.
    Vaccine. 2023 Dec 8:S0264-410X(23)01440-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  562. LI J, Ding J, Chen K, Xu X, et al
    Protective effects of a novel chimeric virus-like particle vaccine against virulent NDV and IBDV challenge.
    Vaccine. 2023 Dec 8:S0264-410X(23)01430-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  563. CHENG DR, Reimer H, Le D, Crawford NW, et al
    Analyzing an immunization resource website: User browsing trends.
    Vaccine. 2023;41:7498-7502.
    PubMed     Abstract available


  564. REEF SE, Icenogle JP, Plotkin SA
    The path to eradication of rubella.
    Vaccine. 2023;41:7525-7531.
    PubMed     Abstract available


  565. LESCOP J, Pennes B, Epaulard O
    Mind the gap: Concordance between perceptions regarding vaccination as declared by patients and their evaluation by their general practitioner.
    Vaccine. 2023 Dec 7:S0264-410X(23)01433-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  566. YU Y, Zhang X, Lau MMC, Lau JTF, et al
    The intention to get COVID-19 booster vaccination and its association with cognitive and emotional factors: A survey of Chinese COVID-19 infected people in Hong Kong.
    Vaccine. 2023 Dec 7:S0264-410X(23)01448-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  567. GRAMACHO W, Turgeon M, Santos Mundim P, Pereira I, et al
    Why did Brazil fail to vaccinate children against COVID-19 during the pandemic? An assessment of attitudinal and behavioral determinants.
    Vaccine. 2023 Dec 6:S0264-410X(23)01432-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  568. CHOKEPHAIBULKIT K, Puthanakit T, Chaithongwongwatthana S, Bhat N, et al
    Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines.
    Vaccine. 2023 Dec 6:S0264-410X(23)01386-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  569. HUANG L, Chen Z, Song Y, Tan J, et al
    Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13 years and older: A randomized, double-blind, controlled study.
    Vaccine. 2023 Dec 5:S0264-410X(23)01212-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  570. MADNI SA, Sharma AJ, Zauche LH, Waters AV, et al
    CDC COVID-19 Vaccine Pregnancy Registry: Design, data collection, response rates, and cohort description.
    Vaccine. 2023 Dec 5:S0264-410X(23)01423-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  571. ENUL H, Uzar S, Satir E, Sarac F, et al
    Humoral immune response profile of a cattle herd vaccinated with 5- and 10-times Bakirkoy strain sheep pox vaccine under field conditions.
    Vaccine. 2023 Dec 5:S0264-410X(23)01388-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  572. CANEVARI JT, Cheng AC, Wu L, Rowe SL, et al
    The relative effectiveness of three and four doses of COVID-19 vaccine in Victoria, Australia: A data linkage study.
    Vaccine. 2023 Dec 5:S0264-410X(23)01393-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  573. DIONNE M, Sauvageau C, Kiely M, Dahhou M, et al
    School-based vaccination program against HPV and Hepatitis B: A longitudinal analysis of vaccine coverage between 2015 and 2021 in Quebec.
    Vaccine. 2023 Dec 2:S0264-410X(23)01419-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  574. SATO S, Katsuta T, Kawazoe Y, Takahashi M, et al
    Immune thrombocytopenic purpura and Guillain-Barre syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study.
    Vaccine. 2023 Dec 2:S0264-410X(23)01399-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  575. PRASERT K, Praphasiri P, Lerdsamran H, Nakphook S, et al
    Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial.
    Vaccine. 2023 Dec 1:S0264-410X(23)01396-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  576. JENNINGS MC, Sauer M, Manchester C, Soeters HM, et al
    Supporting evidence-based rotavirus vaccine introduction decision-making and implementation: Lessons from 8 Gavi-eligible countries.
    Vaccine. 2023 Dec 1:S0264-410X(23)01379-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    November 2023
  577. BAQAR S, Bonavia A, Louis Bourgeois A, Campo JJ, et al
    The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops.
    Vaccine. 2023 Nov 29:S0264-410X(23)01391-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  578. BANERJEE S, Barry EM, Baqar S, Louis Bourgeois A, et al
    The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of abstract-based presentations.
    Vaccine. 2023 Nov 28:S0264-410X(23)01364-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  579. WANG Y, Hu Y, Ma Y, Li P, et al
    RBD class 1 and 2 antibody epitopes elicit around 70% neutralizing capacity against SARS-CoV-2 virus following boosting with inactivated virus vaccine.
    Vaccine. 2023 Nov 27:S0264-410X(23)01381-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  580. NISHIYAMA T, Miyamatsu Y, Park H, Nakamura N, et al
    Modeling COVID-19 vaccine booster-elicited antibody response and impact of infection history.
    Vaccine. 2023 Nov 25:S0264-410X(23)01384-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  581. TANAKA T, Kakiuchi S, Tashiro M, Fujita A, et al
    Adherence to recommended vaccination policies for pre- and post-solid organ transplantation patients: A national questionnaire survey in Japan.
    Vaccine. 2023 Nov 24:S0264-410X(23)01377-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  582. MOITA D, Nunes-Cabaco H, Rola C, Franke-Fayard B, et al
    Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines.
    Vaccine. 2023 Nov 24:S0264-410X(23)01335-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  583. DUCASA N, Benencio P, Mauro E, Anders M, et al
    Evaluation of the humoral response to the third dose of SARS-COV-2 vaccines in liver transplant recipients.
    Vaccine. 2023 Nov 24:S0264-410X(23)01383-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  584. PAYNE AB, Ciesla AA, Rowley EAK, Weber ZA, et al
    Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design.
    Vaccine. 2023 Nov 23:S0264-410X(23)01337-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  585. SOWE A, Namatovu F, Cham B, Gustafsson PE, et al
    Missed opportunities for vaccination at point of care and their impact on coverage and urban-rural coverage inequity in the Gambia.
    Vaccine. 2023 Nov 22:S0264-410X(23)01385-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  586. WANG B, McDonough J, Chen G, Ong JJ, et al
    Sociodemographic factors and attitudes associated with Australian parental acceptance of paediatric COVID-19 vaccination.
    Vaccine. 2023 Nov 22:S0264-410X(23)01336-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  587. NEELY SR, Hao F
    Breakthrough COVID-19 infections and perceived vaccine effectiveness.
    Vaccine. 2023 Nov 22:S0264-410X(23)01365-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  588. ECONOMIDOU EC, Soteriades ES
    Excess mortality in Cyprus during the COVID-19 vaccination campaign.
    Vaccine. 2023 Nov 22:S0264-410X(23)01361-0. doi: 10.1016/j.vaccine.2023.
    PubMed    


  589. KAUR R, Gonzalez E, Pham M, Pichichero M, et al
    Naturally-induced serum antibody levels in children to pneumococcal polysaccharide 15B that correlate with protection from nasopharyngeal colonization but anti-serotype 15B antibody has low functional cross-reactivity with serotype 15C.
    Vaccine. 2023;41:7265-7273.
    PubMed     Abstract available


  590. NEUHANN JM, Stemler J, Carcas AJ, Frias-Iniesta J, et al
    Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults >/=75 years (EU-COVAT-1).
    Vaccine. 2023;41:7166-7175.
    PubMed     Abstract available


  591. ZURCHER SJ, Signorell A, Lechot-Huser A, Aebi C, et al
    Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
    Vaccine. 2023;41:7226-7233.
    PubMed     Abstract available


  592. LARIVIERE Y, Matuvanga TZ, Lemey G, Osang'ir BI, et al
    Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned.
    Vaccine. 2023 Nov 21:S0264-410X(23)01363-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  593. LAW AW, Judy J, Atwell JE, Willis S, et al
    Maternal Tdap and influenza vaccination uptake 2017-2021 in the United States: Implications for maternal RSV vaccine uptake in the future.
    Vaccine. 2023 Nov 21:S0264-410X(23)01307-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  594. NAUGLE D, Tibbels N, Dosso A, Benie W, et al
    "I'd do it for my baby": Lessons learned from qualitative research on COVID-19 vaccination among pregnant women in Cote d'Ivoire.
    Vaccine. 2023 Nov 19:S0264-410X(23)01333-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  595. MAN-LIK CHOI E, Abu-Baker Mustapher G, Omosa-Manyonyi G, Foster J, et al
    Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in
    Vaccine. 2023 Nov 17:S0264-410X(23)01257-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  596. SHRESTHA AC, Field E, Rajmokan M, Lambert SB, et al
    Assessing the impact of chickenpox and shingles vaccination using intermittent enhanced surveillance in Queensland, Australia.
    Vaccine. 2023 Nov 16:S0264-410X(23)01327-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  597. CHANDPA HH, Panda AK, Meena CL, Meena J, et al
    Beyond the polysaccharide and glycoconjugate vaccines for Streptococcus pneumoniae: Does protein/peptide nanovaccines hold promises?
    Vaccine. 2023 Nov 16:S0264-410X(23)01332-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  598. YU Z, Keskinocak P, Orenstein WA, Toktay LB, et al
    A mixed integer programming model for vaccine pricing within a group purchasing organization.
    Vaccine. 2023 Nov 15:S0264-410X(23)01223-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  599. ANRAAD C, van Empelen P, Ruiter RAC, van Keulen H, et al
    Effects of an online tailored decision aid to promote informed decision making about maternal pertussis vaccination in the Netherlands: A randomized controlled trial.
    Vaccine. 2023 Nov 15:S0264-410X(23)01281-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  600. CHRISTENSEN S, Bouguermouh S, Ilangovan K, Pride MW, et al
    A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age.
    Vaccine. 2023 Nov 15:S0264-410X(23)01296-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  601. HAEDER SF
    Assessing parental intention to vaccinate against COVID-19, influenza, and RSV in the United States in late 2023.
    Vaccine. 2023 Nov 15:S0264-410X(23)01303-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  602. CHOI Y, Park S, Lee J, Kim Y, et al
    Who gets COVID-19 booster vaccination? Trust in public health institutions and promotion strategies post-pandemic in the Republic of Korea.
    Vaccine. 2023 Nov 15:S0264-410X(23)01294-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  603. AMITAI N, Wertheimer R, Prais D, Wertheimer KO, et al
    Influenza vaccination in children with pulmonary disease during the COVID-19 pandemic.
    Vaccine. 2023 Nov 15:S0264-410X(23)01338-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  604. PLUMB ID, Briggs Hagen M, Wiegand R, Dumyati G, et al
    Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
    Vaccine. 2023 Nov 14:S0264-410X(23)01287-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  605. CHOE S, Park GN, Kim KS, Shin J, et al
    Efficacy of an orally administered classical swine fever live marker vaccine (Flc-LOM-BE(rns) strain) in pigs.
    Vaccine. 2023 Nov 14:S0264-410X(23)01286-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  606. SARAFIAN JT, Eucker SA, Gillman M, DeLaroche AM, et al
    Impact of a hypothetical COVID-19 vaccine mandate on parental likelihood to vaccinate children: Exploring school-related concerns and vaccination decision-making.
    Vaccine. 2023 Nov 14:S0264-410X(23)01334-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  607. GUBERNOT D, Menis M, Whitaker B
    Background rates for severe cutaneous reactions in the US: Contextual support for safety assessment of COVID-19 vaccines and novel biologics.
    Vaccine. 2023;41:6922-6929.
    PubMed     Abstract available


  608. CUBIZOLLES C, Barjat T, Chauleur C, Bruel S, et al
    Evaluation of intentions to get vaccinated against influenza, COVID 19, pertussis and to get a future vaccine against respiratory syncytial virus in pregnant women.
    Vaccine. 2023 Nov 12:S0264-410X(23)01280-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  609. JIANG X, Wang J, Li C, Yeoh EK, et al
    Impact of the surge of COVID-19 Omicron outbreak on the intention of seasonal influenza vaccination in Hong Kong: A cross-sectional study.
    Vaccine. 2023 Nov 11:S0264-410X(23)01304-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  610. HERZIG VAN WEES S, Stalgren M, Viberg N, Puranen B, et al
    "Who is Anders Tegnell?" Unanswered questions hamper COVID-19 vaccine uptake: A qualitative study among ethnic minorities in Sweden.
    Vaccine. 2023 Nov 10:S0264-410X(23)01328-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  611. LIU YY, Xu YQ, Zhong Y, Wei F, et al
    Pathogenicity of novel hantavirus isolate and antigenicity and immunogenicity of novel strain-based inactivated vaccine.
    Vaccine. 2023 Nov 10:S0264-410X(23)01329-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  612. GRABENSTEIN JD, Ferrara P, Mantovani LG, McGovern I, et al
    Evaluating risk of bias using ROBINS-I tool in nonrandomized studies of adjuvanted influenza vaccine.
    Vaccine. 2023 Nov 10:S0264-410X(23)01302-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  613. BRUXVOORT KJ, Sy LS, Hong V, Lewin B, et al
    Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US health care system.
    Vaccine. 2023 Nov 10:S0264-410X(23)01324-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  614. DUDLEY MZ, Schwartz B, Brewer J, Kan L, et al
    COVID-19 vaccination attitudes, values, intentions: US parents for their children, September 2021.
    Vaccine. 2023 Nov 9:S0264-410X(23)01295-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  615. ANDERSON EC, Blair PS, Finn A, Ingram J, et al
    Maternal vaccination provision in NHS maternity trusts across England.
    Vaccine. 2023 Nov 9:S0264-410X(23)01284-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  616. WIDDERSHOVEN V, Reijs RP, Eskes A, Verhaegh-Haasnoot A, et al
    Maternal pertussis vaccination behavior: Psychosocial, attitudinal and organizational factors.
    Vaccine. 2023 Nov 9:S0264-410X(23)01325-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  617. TECHAKRIENGKRAI N, Aryuman S, Vanlarat K, Karnchanapraphas C, et al
    Impacts of shelter management on canine rabies immune status.
    Vaccine. 2023 Nov 9:S0264-410X(23)01330-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  618. YANG C, Zheng Z, Zheng P, Chen J, et al
    Inactivated COVID-19 vaccines in peri-pregnancy period: Evaluation of safety for both pregnant women and neonates.
    Vaccine. 2023 Nov 8:S0264-410X(23)01322-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  619. TSAI SA, Lu CY, Chen TI, Huang SP, et al
    Adverse events from HPV vaccination in Taiwan.
    Vaccine. 2023 Nov 8:S0264-410X(23)01321-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  620. TAMIR TT, Kassie AT, Zegeye AF
    Prevalence and determinants of two or more doses of tetanus toxoid-containing vaccine immunization among pregnant women in sub-Saharan Africa: Evidence from recent demographic and health survey data.
    Vaccine. 2023 Nov 8:S0264-410X(23)01305-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  621. MVUNDURA M, Slavkovsky R, Debellut F, Naddumba T, et al
    Cost and operational context for national human papillomavirus (HPV) vaccine delivery in six low- and middle-income countries.
    Vaccine. 2023 Nov 8:S0264-410X(23)01306-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  622. GSELL PS, Giersing B, Gottlieb S, Wilder-Smith A, et al
    Key considerations for the development of novel mRNA candidate vaccines in LMICs: A WHO/MPP mRNA Technology Transfer Programme meeting report.
    Vaccine. 2023 Nov 8:S0264-410X(23)01210-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  623. COOPER LV, Stuart JM, Okot C, Asiedu-Bekoe F, et al
    Corrigendum to "Reactive vaccination as a control strategy for pneumococcal meningitis outbreaks in the African meningitis belt: Analysis of outbreak data from Ghana" [Vaccine 37(37) (2019) 5657-5663].
    Vaccine. 2023 Nov 7:S0264-410X(23)01293-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  624. INOUE Y, Li Y, Yamamoto S, Fukunaga A, et al
    The association between antipyretic analgesics use and SARS-CoV-2 antibody titers following the second dose of the BNT162b2 mRNA vaccine: An observational study.
    Vaccine. 2023 Nov 7:S0264-410X(23)01220-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  625. FLANDES X, Hansen CA, Palani S, Abbas K, et al
    Vaccine value profile for Chikungunya.
    Vaccine. 2023 Nov 7:S0264-410X(23)00915-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  626. HAEDER SF
    Assessing vaccine hesitancy and support for vaccination requirements for pets and potential Spillovers from humans.
    Vaccine. 2023 Nov 5:S0264-410X(23)01263-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  627. HANSEN LG, Larsen LE, Rasmussen TB, Miar Y, et al
    Investigation of the SARS-CoV-2 post-vaccination antibody response in Canadian farmed mink.
    Vaccine. 2023 Nov 4:S0264-410X(23)01288-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  628. JONES G, Perry M, Bailey R, Arumugam S, et al
    Dimensions of equality in uptake of COVID-19 vaccination in Wales, UK: A multivariable linked data population analysis.
    Vaccine. 2023 Nov 4:S0264-410X(23)01279-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  629. SPACKMAN E, Suarez DL, Lee CW, Pantin-Jackwood MJ, et al
    Efficacy of inactivated and RNA particle vaccines against a North American Clade 2.3.4.4b H5 highly pathogenic avian influenza virus in chickens.
    Vaccine. 2023 Nov 4:S0264-410X(23)01285-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  630. KHALIL I, Anderson JD, Bagamian KH, Baqar S, et al
    Vaccine value profile for enterotoxigenic Escherichia coli (ETEC).
    Vaccine. 2023;41 Suppl 2:S95-S113.
    PubMed     Abstract available


  631. TROTTER CL, Alderson M, Dangor Z, Ip M, et al
    Vaccine value profile for Group B streptococcus.
    Vaccine. 2023;41 Suppl 2:S41-S52.
    PubMed     Abstract available


  632. KAYE PM, Matlashewski G, Mohan S, Le Rutte E, et al
    Vaccine value profile for leishmaniasis.
    Vaccine. 2023;41 Suppl 2:S153-S175.
    PubMed     Abstract available


  633. ARMAH G, Lopman BA, Vinje J, O'Ryan M, et al
    Vaccine value profile for norovirus.
    Vaccine. 2023;41 Suppl 2:S134-S152.
    PubMed     Abstract available


  634. MARTIN LB, Khanam F, Qadri F, Khalil I, et al
    Vaccine value profile for Salmonella enterica serovar Paratyphi A.
    Vaccine. 2023;41 Suppl 2:S114-S133.
    PubMed     Abstract available


  635. HOTEZ PJ, Bottazzi ME, Kaye PM, Lee BY, et al
    Neglected tropical disease vaccines: hookworm, leishmaniasis, and schistosomiasis.
    Vaccine. 2023;41 Suppl 2.
    PubMed    


  636. HOLDER T, Coad M, Allan G, Hogarth PJ, et al
    Vaccination of calves with Bacillus Calmette-Guerin Danish strain 1331 results in a duration of immunity of at least 52 weeks.
    Vaccine. 2023 Nov 2:S0264-410X(23)01262-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  637. CHEN GL, Yu XY, Luo LP, Zhang F, et al
    Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults.
    Vaccine. 2023 Nov 2:S0264-410X(23)01278-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  638. AKHTAR Z, Gotberg M, Erlinge D, Christiansen EH, et al
    Optimal timing of influenza vaccination among patients with acute myocardial infarction - Findings from the IAMI trial.
    Vaccine. 2023 Nov 2:S0264-410X(23)01211-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  639. UGHASORO MD, Nnakenyi I, Echendu N, Akpeh JO, et al
    Neutralizing anti-polio antibody titre in newborn babies in post-polio eradication period in Nigeria.
    Vaccine. 2023;41:6820-6823.
    PubMed     Abstract available


  640. DO LAH, Le NTN, Mahmud S, Mulholland K, et al
    Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
    Vaccine. 2023;41:6782-6790.
    PubMed     Abstract available


  641. JAMES WG, Stanberry LR, LaRussa PS, Grodman MD, et al
    Vaccines and global health: COVID-19 vaccine development, strategy, and implementation symposium - Summary of the meeting at Vagelos College of Physicians and Surgeons (February 22-26, 2021, New York).
    Vaccine. 2023 Nov 1:S0264-410X(23)01254-9. doi: 10.1016/j.vaccine.2023.
    PubMed    


  642. GREYSON D, Goh G
    Education components of school vaccine mandates: An environmental scan.
    Vaccine. 2023 Nov 1:S0264-410X(23)01155-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  643. ALIZADEH M, Raj S, Shojadoost B, Matsuyama-Kato A, et al
    In ovo administration of retinoic acid enhances cell-mediated immune responses against an inactivated H9N2 avian influenza virus vaccine.
    Vaccine. 2023 Nov 1:S0264-410X(23)01261-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    October 2023
  644. SALLOUM M, Paviotti A, Bastiaens H, Van Geertruyden JP, et al
    The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023.
    Vaccine. 2023 Oct 28:S0264-410X(23)01259-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  645. RAMSAY JA, Jones M, Vande More AM, Hunt SL, et al
    A single blinded, phase IV, adaptive randomised control trial to evaluate the safety of coadministration of seasonal influenza and COVID-19 vaccines (The FluVID study).
    Vaccine. 2023 Oct 28:S0264-410X(23)01250-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  646. LIU Y, Sanchez-Ovando S, Carolan L, Dowson L, et al
    Superior immunogenicity of mRNA over adenoviral vectored COVID-19 vaccines reflects B cell dynamics independent of anti-vector immunity: Implications for future pandemic vaccines.
    Vaccine. 2023 Oct 28:S0264-410X(23)01217-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  647. TANI N, Ikematsu H, Goto T, Kondo S, et al
    Correlation between specific antibody response to wild-type BNT162b2 booster and the risk of breakthrough infection with omicron variants: Impact of household exposure in hospital healthcare workers.
    Vaccine. 2023;41:6672-6678.
    PubMed     Abstract available


  648. STEFANIZZI P, Di Lorenzo A, Martinelli A, Moscara L, et al
    Adverse events following immunization (AEFIs) with anti-meningococcus type B vaccine (4CMenB): Data of post-marketing active surveillance program. Apulia Region (Italy), 2019-2023.
    Vaccine. 2023 Oct 26:S0264-410X(23)01158-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  649. CENAT JM, Moshirian Farahi SMM, Broussard C, Dalexis RD, et al
    The state of COVID-19 vaccine confidence and need in Black individuals in Canada: Understanding the role of sociodemographic factors, health literacy, conspiracy theories, traumatic stressors and racial discrimination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01246-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  650. WALLIAR T, Khan B, Newstead S, Al-Assadi G, et al
    "Fighting the pandemic!" Western Australian pharmacists' perspectives on COVID-19 vaccines: A qualitative study.
    Vaccine. 2023 Oct 25:S0264-410X(23)01243-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  651. ANASTASSOPOULOU C, Boufidou F, Hatziantoniou S, Vasileiou K, et al
    Adverse events of acute nephrotoxicity reported to EudraVigilance and VAERS after COVID-19 vaccination.
    Vaccine. 2023 Oct 25:S0264-410X(23)01214-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  652. BURNETT E, Riaz A, Anwari P, Myat TW, et al
    Intussusception risk following oral monovalent rotavirus vaccination in 3 Asian countries: A self-control case series evaluation.
    Vaccine. 2023 Oct 24:S0264-410X(23)01225-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  653. TRICOU V, Winkle PJ, Tharenos LM, Rauscher M, et al
    Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults.
    Vaccine. 2023 Oct 24:S0264-410X(23)01132-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  654. FLOR N, Garcia MI, Molineri A, Bottasso O, et al
    Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection.
    Vaccine. 2023 Oct 24:S0264-410X(23)01221-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  655. KITIKOON P, Knetter SM, Mogler MA, Morgan CL, et al
    Quadrivalent neuraminidase RNA particle vaccine protects pigs against homologous and heterologous strains of swine influenza virus infection.
    Vaccine. 2023 Oct 24:S0264-410X(23)01175-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  656. SHARIF H, Ghani H, Ahmad L, Bagol S, et al
    Heterologous prime-boost with mRNA-1273 stimulates persistent neutralising antibodies in BBIBP-CorV-vaccinated individuals.
    Vaccine. 2023 Oct 23:S0264-410X(23)01227-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  657. DI GIUSEPPE G, Pelullo CP, Napoli A, Napolitano F, et al
    Willingness to receive Herpes Zoster vaccination among adults and older people: A cross sectional study in Italy.
    Vaccine. 2023 Oct 23:S0264-410X(23)01247-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  658. LOONEY MM, Hatherill M, Musvosvi M, Flynn J, et al
    Conference report: WHO meeting report on mRNA-based tuberculosis vaccine development.
    Vaccine. 2023 Oct 21:S0264-410X(23)01209-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  659. BRESEE J, Koh M, Chadwick C, Jit M, et al
    The need and ongoing efforts to understand the full value of improved influenza vaccines.
    Vaccine. 2023 Oct 21:S0264-410X(23)01245-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  660. TERADA M, Shimazu T, Saito J, Odawara M, et al
    Age, gender and socioeconomic disparities in human papillomavirus (HPV) awareness and knowledge among Japanese adults after a 7-year suspension of proactive recommendation for the HPV vaccine: A nationally representative cross-sectional survey.
    Vaccine. 2023 Oct 20:S0264-410X(23)01207-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  661. MORI Y, Uchida N, Wake A, Miyawaki K, et al
    Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
    Vaccine. 2023 Oct 20:S0264-410X(23)01022-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  662. WANGCHUK S, Prabhakaran AO, Dhakal GP, Zangmo C, et al
    Introducing seasonal influenza vaccine in Bhutan: Country experience and achievements.
    Vaccine. 2023 Oct 20:S0264-410X(23)01255-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  663. PUTRI WCWS, Sawitri AAS, Yuliyatni PCD, Ariawan IMD, et al
    Cost-effectiveness analysis of Japanese Encephalitis (JE) vaccination program in Bali Province, Indonesia.
    Vaccine. 2023 Oct 20:S0264-410X(23)01177-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  664. IRVING SA, Groom HC, Belongia EA, Crane B, et al
    Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons.
    Vaccine. 2023 Oct 20:S0264-410X(23)01206-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  665. VERMA N, Gupta P, Pandey AK, Awasthi S, et al
    Nasopharyngeal carriage of Streptococcus pneumoniae serotypes among sick and healthy children in northern India: A case-control study.
    Vaccine. 2023;41:6619-6624.
    PubMed     Abstract available


  666. HONGTU Q, BoLi L, Jianguo C, Shusheng P, et al
    Immunogenicity of rabies virus G mRNA formulated with lipid nanoparticles and nucleic acid immunostimulators in mice.
    Vaccine. 2023 Oct 20:S0264-410X(23)01191-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  667. MULLER T, Wallace RM, Freuling CM
    Rabies importation in dogs and reduction of waiting period - The fear for scientifically justified changes.
    Vaccine. 2023 Oct 20:S0264-410X(23)01043-5. doi: 10.1016/j.vaccine.2023.
    PubMed    


  668. HART R, Feygin Y, Kluthe T, Quinn KG, et al
    Emergency departments: An underutilized resource to address pediatric influenza vaccine coverage.
    Vaccine. 2023 Oct 19:S0264-410X(23)01222-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  669. MCCLYMONT E, Atkinson A, Albert A, Av-Gay G, et al
    Reactogenicity, pregnancy outcomes, and SARS-CoV-2 infection following COVID-19 vaccination during pregnancy in Canada: A national prospective cohort study.
    Vaccine. 2023 Oct 19:S0264-410X(23)01215-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  670. PUCHNER KP, Bottazzi ME, Periago V, Grobusch M, et al
    Vaccine value profile for Hookworm.
    Vaccine. 2023 Oct 18:S0264-410X(23)00540-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  671. KWAK HW, Park HJ, Jung SY, Oh EY, et al
    Corrigendum to "Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants" [Vaccine 41(11) (2023) 1892-1901].
    Vaccine. 2023 Oct 18:S0264-410X(23)01216-1. doi: 10.1016/j.vaccine.2023.
    PubMed    


  672. HONDA-OKUBO Y, Bowen R, Barker M, Bielefeldt-Ohmann H, et al
    Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants.
    Vaccine. 2023 Oct 18:S0264-410X(23)01190-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  673. RIEFOLO F, Castillo-Cano B, Martin-Perez M, Messina D, et al
    Effectiveness of homologous/heterologous booster COVID-19 vaccination schedules against severe illness in general population and clinical subgroups in three European countries.
    Vaccine. 2023 Oct 17:S0264-410X(23)01181-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  674. ANGULO FJ, Zhang P, Halsby K, Kelly P, et al
    A systematic literature review of the effectiveness of tick-borne encephalitis vaccines in Europe.
    Vaccine. 2023 Oct 17:S0264-410X(23)01184-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  675. CHOPRA A, Rodriguez A, Prakash A, Raskar R, et al
    Using neural networks to calibrate agent based models enables improved regional evidence for vaccine strategy and policy.
    Vaccine. 2023 Oct 17:S0264-410X(23)01016-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  676. HAEDER SF
    U.S. public support and opposition to vaccination mandates in K-12 education in light of the COVID-19 pandemic.
    Vaccine. 2023 Oct 17:S0264-410X(23)01188-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  677. YANG H, Wang Z, Zhang Y, Xu M, et al
    Effectiveness of inactivated COVID-19 vaccines against SARS-CoV-2 Omicron subvariant BF.7 among outpatients in Beijing, China.
    Vaccine. 2023 Oct 17:S0264-410X(23)01219-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  678. PLATENBURG PPLI, Deschamps F, Jung J, Leonard C, et al
    Carbohydrate fatty acid monosulphate ester is a potent adjuvant for low-dose seasonal influenza vaccines.
    Vaccine. 2023 Oct 16:S0264-410X(23)01189-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  679. WRIGHT J, Science M, Osman S, Arnold C, et al
    Uptake of pertussis immunization in pregnancy and determinants of vaccination in Toronto, Canada.
    Vaccine. 2023 Oct 14:S0264-410X(23)01192-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  680. MUKASA K, Sugawara T, Okutomi Y
    Susceptibility of nursery teachers to measles, rubella, varicella and mumps in Japan.
    Vaccine. 2023;41:6530-6534.
    PubMed     Abstract available


  681. ARASHIRO T, Arima Y, Kuramochi J, Muraoka H, et al
    Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan.
    Vaccine. 2023 Oct 13:S0264-410X(23)01194-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  682. MOSCA S, Lin Q, Stokes R, Bharucha T, et al
    Innovative method for rapid detection of falsified COVID-19 vaccines through unopened vials using handheld Spatially Offset Raman Spectroscopy (SORS).
    Vaccine. 2023 Oct 13:S0264-410X(23)01182-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  683. VAN EWIJK CE, Smit C, Bavalia R, Ainslie K, et al
    Acceptance and timeliness of post-exposure vaccination against mpox in high-risk contacts, Amsterdam, the Netherlands, May-July 2022.
    Vaccine. 2023 Oct 12:S0264-410X(23)01183-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  684. SUKWA N, Mubanga C, Hatyoka LM, Chilyabanyama ON, et al
    Safety, tolerability, and immunogenicity of an oral inactivated ETEC vaccine (ETVAX(R)) with dmLT adjuvant in healthy adults and children in Zambia: An age descending randomised, placebo-controlled trial.
    Vaccine. 2023 Oct 12:S0264-410X(23)01138-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  685. RODRIGUEZ VJ, Kozlova S, LaBarrie DL, Liu Q, et al
    Parental anxiety and pediatric vaccine refusal in a US national sample of parents.
    Vaccine. 2023 Oct 11:S0264-410X(23)01187-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  686. NAND KN, Jordan TB, Yuan X, Basore DA, et al
    Bacterial production of recombinant contraceptive vaccine antigen from CatSper displayed on a human papilloma virus-like particle.
    Vaccine. 2023 Oct 11:S0264-410X(23)01114-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  687. HAUSDORFF WP, Anderson JD 4th, Bagamian KH, Bourgeois AL, et al
    Vaccine value profile for Shigella.
    Vaccine. 2023 Oct 10:S0264-410X(22)01562-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  688. AYDIN I, May M, Pisano F, Mpofu-Maetzig N, et al
    Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study
    Vaccine. 2023 Oct 10:S0264-410X(23)01157-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  689. YAO X, Peng J, Ma Y, Fu M, et al
    Development of a vaccine hesitancy scale for childhood immunization in China.
    Vaccine. 2023 Oct 9:S0264-410X(23)01154-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  690. YU P, Liu Y, Tao X, He Y, et al
    Potential option for rabies post-exposure prophylaxis: New vaccine with PIKA adjuvant against diverse Chinese rabies strains.
    Vaccine. 2023 Oct 9:S0264-410X(23)01161-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  691. PARK H, Jang MS, Choi JA, Kim W, et al
    Nonclinical safety assessment and immunogenicity of rVSVInd(GML)-mspSGtc vaccine for SARS-CoV-2 in rabbits.
    Vaccine. 2023 Oct 9:S0264-410X(23)01178-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  692. CHECCHI M, Mesher D, Panwar K, Anderson A, et al
    The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
    Vaccine. 2023 Oct 9:S0264-410X(23)01162-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  693. MO C, Li X, Wu Q, Fan Y, et al
    SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses.
    Vaccine. 2023 Oct 9:S0264-410X(23)01156-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  694. SATHE N, Shaikh S, Bhavsar M, Parte L, et al
    Safety, immunogenicity and efficacy of Relcovax(R), a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
    Vaccine. 2023 Oct 8:S0264-410X(23)01176-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  695. FEBRIANI Y, Mansour T, Sadarangani M, Ulanova M, et al
    Tdap vaccine in pregnancy and immunogenicity of pertussis and pneumococcal vaccines in children: What is the impact of different immunization schedules?
    Vaccine. 2023 Oct 8:S0264-410X(23)01160-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  696. BOPPANA SB, van Boven M, Britt WJ, Gantt S, et al
    Vaccine value profile for cytomegalovirus.
    Vaccine. 2023 Oct 6:S0264-410X(23)00670-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  697. PROCTER TD, Ogasawara H, Spruin S, Wijayasri S, et al
    Thrombosis with thrombocytopenia syndrome (TTS) following adenovirus vector COVID-19 vaccination in Canada.
    Vaccine. 2023 Oct 6:S0264-410X(23)01159-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  698. LOPEZ-ZAMBRANO MA, Pita CC, Escribano MF, Galan Melendez IM, et al
    Factors associated to influenza vaccination among hospital's healthcare workers in the Autonomous Community of Madrid, Spain 2021-2022.
    Vaccine. 2023 Oct 6:S0264-410X(23)01117-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  699. PAPACHRISTIDOU S, Lapea V, Charisi M, Kourkouni E, et al
    A multicenter study on the epidemiology of complicated parapneumonic effusion in the era of currently available pneumococcal conjugate vaccines.
    Vaccine. 2023 Oct 5:S0264-410X(23)01164-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  700. CAVIT L, Charania NA
    Exploring factors that influence vaccination uptake for children with refugee backgrounds: An interpretive description study of primary healthcare providers' perspectives.
    Vaccine. 2023 Oct 4:S0264-410X(23)01141-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  701. OZAWA S, Schuh HB, Nakamura T, Yemeke TT, et al
    How to increase and maintain high immunization coverage: Vaccination Demand Resilience (VDR) framework.
    Vaccine. 2023 Oct 3:S0264-410X(23)01097-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  702. BEERENS D, Poland GA
    Latest developments in vaccine research: Selected papers from the 16th annual vaccine congress.
    Vaccine. 2023 Oct 3:S0264-410X(23)01153-2. doi: 10.1016/j.vaccine.2023.
    PubMed    


  703. KANEVSKY I, Surendran N, McElwee K, Lei L, et al
    Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age.
    Vaccine. 2023 Oct 3:S0264-410X(23)01113-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  704. ZACHRESON C, Tobin R, Szanyi J, Walker C, et al
    Individual variation in vaccine immune response can produce bimodal distributions of protection.
    Vaccine. 2023 Oct 2:S0264-410X(23)01095-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    September 2023
  705. OKOLI GN, Righolt CH, Zhang G, Alessi-Severini S, et al
    Impact of the universal seasonal influenza vaccination policy in the province of Manitoba, Canada: A population-based, province-wide record-linkage study.
    Vaccine. 2023 Sep 29:S0264-410X(23)01133-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  706. OVSYANNIKOVA IG, Haralambieva IH, Schaid DJ, Warner ND, et al
    Genome-wide determinants of cellular immune responses to mumps vaccine.
    Vaccine. 2023 Sep 29:S0264-410X(23)01055-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  707. MIAO X, Zhang L, Zhou P, Yu R, et al
    Adenovirus-vectored PDCoV vaccines induce potent humoral and cellular immune responses in mice.
    Vaccine. 2023 Sep 29:S0264-410X(23)01139-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  708. DE COUVREUR LA, Cobo MJ, Kennedy PJ, Ellis JT, et al
    Bibliometric analysis of parasite vaccine research from 1990 to 2019.
    Vaccine. 2023 Sep 28:S0264-410X(23)01105-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  709. KOCHHAR S, Okomo U, Nkereuwem O, Shaum A, et al
    Establishing vaccine pregnancy registries and active surveillance studies in low-and middle-income countries: Experience from an observational cohort surveillance project in The Gambia.
    Vaccine. 2023 Sep 28:S0264-410X(23)01111-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  710. DIONNE M, Sauvageau C, Kiely M, Rathwell M, et al
    "The problem is not lack of information": A qualitative study of parents and school nurses' perceptions of barriers and potential solutions for HPV vaccination in schools.
    Vaccine. 2023 Sep 28:S0264-410X(23)01140-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  711. TSIRIGOTAKI M, Galanakis E
    Impact of vaccines on Staphylococcus aureus colonization: A systematic review and meta-analysis.
    Vaccine. 2023 Sep 28:S0264-410X(23)01104-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  712. NUSSBAUM J, Cao X, Railkar RA, Sachs JR, et al
    Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults.
    Vaccine. 2023 Sep 28:S0264-410X(23)00623-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  713. HARBOE ZB, Hald A, Ekenberg C, Ete Wareham N, et al
    Implementation of a vaccination clinic for adult solid organ transplant candidates: A single-center experience.
    Vaccine. 2023 Sep 27:S0264-410X(23)01106-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  714. LAVELL AHA, Schramade AE, Sikkens JJ, van der Straten K, et al
    25-Hydroxyvitamin D concentrations do not affect the humoral or cellular immune response following SARS-CoV-2 mRNA vaccinations.
    Vaccine. 2023 Sep 27:S0264-410X(23)00957-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  715. SHEN X, Hao Y, Wang S, Li D, et al
    Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters.
    Vaccine. 2023 Sep 26:S0264-410X(23)01100-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  716. CASSARINO N, Ahnger-Pier KK, Wurcel A
    Trends in COVID-19 and influenza vaccine ordering and distribution in Massachusetts jails.
    Vaccine. 2023 Sep 25:S0264-410X(23)01115-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  717. SANA S, Merkelbach I, Magnee T, Kollmann J, et al
    Identifying barriers to vaccination intention at walk-in vaccination facilities in deprived neighbourhoods: A cross-sectional survey.
    Vaccine. 2023 Sep 25:S0264-410X(23)01038-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  718. GOLOVKINA MI, Ertz SC, Lechnir SS, Hayney MS, et al
    Providing influenza vaccines at endoscopy visits increases influenza vaccine uptake.
    Vaccine. 2023 Sep 23:S0264-410X(23)01108-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  719. SALO H, Perala J, Hannila-Handelberg T, Sarvikivi E, et al
    Decline in varicella cases contacting primary health care after introduction of varicella vaccination in Finland - A population-based register study.
    Vaccine. 2023 Sep 22:S0264-410X(23)01094-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  720. MATHUR I, Church R, Ruisch A, Noyes K, et al
    Insights to COVID-19 vaccine delivery: Results from a survey of 27 countries.
    Vaccine. 2023 Sep 22:S0264-410X(23)01053-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  721. NGAMCHALIEW P, Kaewkuea N, Nonthasorn N, Vonnasrichan T, et al
    Acceptance of COVID-19 vaccination and vaccine confidence levels in Thailand: A cross-sectional study.
    Vaccine. 2023 Sep 22:S0264-410X(23)01088-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  722. RAISER F, Davis M, Adelglass J, Cai MR, et al
    Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
    Vaccine. 2023;41:5965-5973.
    PubMed     Abstract available


  723. HOMAIRA N, He WQ, McRae J, Macartney K, et al
    Coverage and predictors of influenza and pertussis vaccination during pregnancy: a whole of population-based study.
    Vaccine. 2023 Sep 21:S0264-410X(23)01062-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  724. FU Y, Wu K, Wang Z, Yang H, et al
    Effectiveness of various COVID-19 vaccine regimens among 10.4 million patients from the National COVID Cohort Collaborative during Pre-Delta to Omicron periods - United States, 11 December 2020 to 30 June 2022.
    Vaccine. 2023 Sep 21:S0264-410X(23)01025-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  725. KIM DR, You YA, Ahn HS, Park EL, et al
    Statistical considerations on real time and extended controlled temperature conditions (ECTC) stability data analysis of vaccines.
    Vaccine. 2023 Sep 21:S0264-410X(23)00944-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  726. WILKINSON B, Patel KS, Smith K, Walker R, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 vir
    Vaccine. 2023 Sep 20:S0264-410X(23)00871-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  727. DEPEW CE, McSorley SJ
    The role of tissue resident memory CD4 T cells in Salmonella infection: Implications for future vaccines.
    Vaccine. 2023 Sep 20:S0264-410X(23)01066-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  728. ALHARBI HS
    Review: Factors influencing parents' decisions to vaccinate children against COVID-19.
    Vaccine. 2023 Sep 19:S0264-410X(23)01090-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  729. SCHMITZ KS, Comvalius AD, Nieuwkoop NJ, Geers D, et al
    A measles virus-based vaccine induces robust chikungunya virus-specific CD4(+) T-cell responses in a phase II clinical trial.
    Vaccine. 2023 Sep 17:S0264-410X(23)01092-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  730. HAN C, Zhao ZZ, Chan P, Li F, et al
    A large survey on COVID-19 vaccination in patients with Parkinson's disease and healthy population.
    Vaccine. 2023 Sep 17:S0264-410X(23)01056-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  731. LASSAUNIERE R, Polacek C, Linnea Tingstedt J, Fomsgaard A, et al
    Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine.
    Vaccine. 2023 Sep 17:S0264-410X(23)01091-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  732. WANG Y, Ji W, Li D, Sun T, et al
    Active inoculation with an inactivated Coxsackievirus A2 vaccine induces neutralizing antibodies and protects mice against lethal infection.
    Vaccine. 2023 Sep 15:S0264-410X(23)01049-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  733. SHAVER N, Katz M, Darko Asamoah G, Linkins LA, et al
    Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness.
    Vaccine. 2023 Sep 15:S0264-410X(23)01065-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  734. IRALA S, Hamid S, Penayo E, Michel F, et al
    COVID-19 vaccine effectiveness against hospitalizations in Paraguay, May 2021-April 2022: A test-negative design.
    Vaccine. 2023 Sep 14:S0264-410X(23)01069-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  735. SALAT J, Hunady M, Svoboda P, Strelcova L, et al
    Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs.
    Vaccine. 2023 Sep 14:S0264-410X(23)01089-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  736. LUGELO A, Hampson K, McElhinney LM, Lankester F, et al
    Evaluation of an iELISA for detection and quantification of rabies antibodies in domestic dog sera.
    Vaccine. 2023 Sep 14:S0264-410X(23)01058-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  737. REID MC, Mittler JE, Murphy JT, Stansfield SE, et al
    Evolution of HIV virulence in response to disease-modifying vaccines: A modeling study.
    Vaccine. 2023 Sep 13:S0264-410X(23)01027-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  738. JI WY, Liu DL, Yu R, Miao L, et al
    Vaccination coverage survey of children aged 1-3 years in Beijing, China, 2005-2021.
    Vaccine. 2023 Sep 12:S0264-410X(23)00946-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  739. MEERAUS W, Stuurman AL, Durukal I, Conde-Sousa E, et al
    COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron.
    Vaccine. 2023 Sep 11:S0264-410X(23)01051-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  740. REUSCHENBACH M, Doorbar J, Del Pino M, Joura EA, et al
    Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer.
    Vaccine. 2023 Sep 11:S0264-410X(23)00990-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  741. SU F, Xue Y, Ye S, Yu B, et al
    Integrative transcriptomic and metabolomic analysis in mice reveals the mechanism by which ginseng stem-leaf saponins enhance mucosal immunity induced by a porcine epidemic diarrhea virus vaccination.
    Vaccine. 2023 Sep 11:S0264-410X(23)01085-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  742. SURYAWANSHI YR
    An overview of protein-based SARS-CoV-2 vaccines.
    Vaccine. 2023 Sep 10:S0264-410X(23)01067-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  743. ROY VL, Majumder PP
    Genomic associations with antibody response to an oral cholera vaccine.
    Vaccine. 2023 Sep 10:S0264-410X(23)01084-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  744. FULLER HR, Huseth-Zosel A, Vleet BV, Hajdar M, et al
    Vaccine attitudes and acceptance among older adults in North Dakota: Understanding demographic characteristic variability.
    Vaccine. 2023 Sep 9:S0264-410X(23)01059-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  745. POTT H, Andrew MK, Shaffelburg Z, Nichols MK, et al
    Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canad
    Vaccine. 2023 Sep 9:S0264-410X(23)01026-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  746. MCCARTY JM, Bedell L, Mendy J, Coates EE, et al
    Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals.
    Vaccine. 2023 Sep 8:S0264-410X(23)01052-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  747. YU J, Sreenivasan C, Sheng Z, Zhai SL, et al
    A recombinant chimeric influenza virus vaccine expressing the consensus H3 hemagglutinin elicits broad hemagglutination inhibition antibodies against divergent swine H3N2 influenza viruses.
    Vaccine. 2023 Sep 7:S0264-410X(23)01060-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  748. PANDEY MK, Rajukumar K, Senthilkumar D, Kombiah S, et al
    Evaluation of dynamics of immune responses and protective efficacy in piglets immunized with an inactivated porcine reproductive and respiratory syndrome vaccine candidate.
    Vaccine. 2023 Sep 7:S0264-410X(23)01047-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  749. MONTEIRO HS, Lima Neto AS, Kahn R, Sousa GS, et al
    Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study.
    Vaccine. 2023;41:5742-5751.
    PubMed     Abstract available


  750. LI P, Jia WY, Zhang X, Wang DB, et al
    Effect of enterovirus 71 vaccine on epidemiological characteristics of hand, foot and mouth disease: An 8-year retrospective intermittent time series analysis.
    Vaccine. 2023 Sep 6:S0264-410X(23)01061-7. doi: 10.1016/j.vaccine.2023.
    PubMed    


  751. CHILDS K, Harvey Y, Waters R, Woma T, et al
    Development of a quadrivalent foot-and-mouth disease vaccine candidate for use in East Africa.
    Vaccine. 2023 Sep 5:S0264-410X(23)01054-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  752. PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al
    Comparative effectiveness and duration of protection of ChAdOx1, CoronaVac, BNT162b2, mRNA-1273, and Ad26.COV2.S COVID-19 vaccines for symptomatic and hospitalized Mu, Delta, and Omicron: A test-negative case-control study.
    Vaccine. 2023 Sep 5:S0264-410X(23)01028-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  753. YUE PHR, Lau HPB, Ng SM, Chan LWC, et al
    When to be vaccinated? What to consider? Modelling decision-making and time preference for COVID-19 vaccine through a conjoint experiment.
    Vaccine. 2023 Sep 5:S0264-410X(23)01024-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  754. TIEU HV, Karuna S, Huang Y, Sobieszczyk ME, et al
    Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.
    Vaccine. 2023 Sep 5:S0264-410X(23)00877-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  755. PHILLIPS A, Jiang Y, Walsh D, Andrews N, et al
    Background rates of adverse events of special interest for COVID-19 vaccines: A multinational Global Vaccine Data Network (GVDN) analysis.
    Vaccine. 2023 Sep 5:S0264-410X(23)01045-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  756. VAUX S, Gautier A, Nassany O, Bonmarin I, et al
    Vaccination acceptability in the French general population and related determinants, 2000-2021.
    Vaccine. 2023 Sep 4:S0264-410X(23)01018-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  757. YASUGI M, Nakagama Y, Kaku N, Nitahara Y, et al
    Characteristics of epitope dominance pattern and cross-variant neutralisation in 16 SARS-CoV-2 mRNA vaccine sera.
    Vaccine. 2023 Sep 4:S0264-410X(23)01040-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  758. ALSAIF F, Twigg M, Scott S, Blyth A, et al
    A systematic review of barriers and enablers associated with uptake of influenza vaccine among care home staff.
    Vaccine. 2023 Sep 4:S0264-410X(23)01048-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  759. CLAESSENS T, Krouwer S, Vandebosch H, Poels K, et al
    Pathways to informed choices: The impact of freedom of choice and two-sided messages on psychological reactance and vaccination intentions among individuals who express concerns.
    Vaccine. 2023 Sep 3:S0264-410X(23)00948-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  760. BIRNBAUM JA, Guttman D, Parulekar M, Omarufilo F, et al
    Eliminating hepatitis B vaccination disparities for West African immigrants.
    Vaccine. 2023 Sep 3:S0264-410X(23)01012-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  761. ZHOU G, Ma Q, Li Q, Wang S, et al
    The disruption of LPS in Salmonella Typhimurium provides partial protection against Salmonella Choleraesuis as a live attenuated vaccine.
    Vaccine. 2023 Sep 2:S0264-410X(23)01044-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  762. WILLIS DE, Moore R, Andersen JA, Li J, et al
    Correlates of COVID-19 vaccine coverage in Arkansas: Results from a weighted random sample survey.
    Vaccine. 2023 Sep 1:S0264-410X(23)01039-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  763. SUSARLA SK, Gupta M, Uttam KG, Palkar S, et al
    Immunogenicity and safety of Havisure(TM) vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study.
    Vaccine. 2023 Sep 1:S0264-410X(23)01050-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  764. DA PENHA GOMES GOUVEA M, Lira Machado KLL, de Oliveira YGP, Moulaz IR, et al
    Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose.
    Vaccine. 2023 Sep 1:S0264-410X(23)00954-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  765. SANCHEZ-GONZALEZ G, Luna-Casas G, Mascarenas C, Macina D, et al
    Pertussis in Mexico from 2000 to 2019: A real-world study of incidence, vaccination coverage, and vaccine effectiveness.
    Vaccine. 2023 Sep 1:S0264-410X(23)00989-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  766. PORRAS-RAMIREZ A, Sanchez-Paris R, Lopez-Devia W, Moreno-Perilla Z, et al
    Confirmed cases of COVID-19 after vaccination against COVID in health personnel in Bogota, Colombia.
    Vaccine. 2023 Sep 1:S0264-410X(23)00924-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  767. PALMER M, Katanoda K, Saito E, Acuti Martellucci C, et al
    Corrigendum to "Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis" [Vaccine 40(41) (2022) 5971-5996].
    Vaccine. 2023 Sep 1:S0264-410X(23)00787-9. doi: 10.1016/j.vaccine.2023.
    PubMed    


    August 2023
  768. FLOOD T, McLaughlin M, Hughes CM, Wilson IM, et al
    Applying the COM-B behaviour model to understand factors which impact school immunisation nurses' attitudes towards designing and delivering a HPV educational intervention in post-primary schools for 15-17 year old students in Northern Ireland, UK.
    Vaccine. 2023;41:5630-5639.
    PubMed     Abstract available


  769. GRILLS LA, Wagner AL
    The impact of the COVID-19 pandemic on parental vaccine hesitancy: A cross-sectional survey.
    Vaccine. 2023 Aug 31:S0264-410X(23)00977-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  770. SAKALA IG, Honda-Okubo Y, Petrovsky N
    Developmental and reproductive safety of Advax-CpG55.2 adjuvanted COVID-19 and influenza vaccines in mice.
    Vaccine. 2023 Aug 31:S0264-410X(23)01007-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  771. DUDLEY HM, O'Mara M, Auma A, Gong J, et al
    Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine.
    Vaccine. 2023 Aug 31:S0264-410X(23)00965-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  772. REGAN AK, Fell DB, Wise LA, Vazquez-Benitez G, et al
    Challenges & opportunities for the epidemiological evaluation of the effects of COVID-19 vaccination on reproduction and pregnancy.
    Vaccine. 2023 Aug 31:S0264-410X(23)00964-7. doi: 10.1016/j.vaccine.2023.
    PubMed    


  773. KRISHNA SUSARLA S, Jahagirdar R, Ghosh Uttam K, Srikanth Bhatt S, et al
    Immunogenicity and safety of Mebella vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study.
    Vaccine. 2023 Aug 31:S0264-410X(23)01021-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  774. SNIDER CJ, Zaman K, Wilkinson AL, Binte Aziz A, et al
    Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.
    Vaccine. 2023 Aug 29:S0264-410X(23)01009-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  775. PUNCHHI G, Negus R, Saif H, Pritchard S, et al
    Real-world challenges in eligibility for MMR vaccination two years after autologous and allogeneic HSCT.
    Vaccine. 2023 Aug 29:S0264-410X(23)00778-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  776. YESKENDIR A, Gusmanov A, Zhussupov B
    Parental attitudes, beliefs and behaviors toward childhood and COVID-19 vaccines: A countrywide survey conducted in Kazakhstan examining vaccine refusal and hesitancy.
    Vaccine. 2023 Aug 29:S0264-410X(23)01019-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  777. YI EJ, Kim YI, Song JH, Ko HJ, et al
    Potential of a bivalent vaccine for broad protection against enterovirus 71 and coxsackie virus 16 infections causing hand, foot, and mouth disease.
    Vaccine. 2023 Aug 28:S0264-410X(23)00961-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  778. HACKER E, Baker B, Lake T, Ross C, et al
    Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates.
    Vaccine. 2023 Aug 27:S0264-410X(23)00959-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  779. PHIRIYASART F, Aimyong N, Jirapongsuwan A, Roseh N, et al
    COVID-19 vaccine hesitancy among older adult Thai Muslim people: A case-control study.
    Vaccine. 2023 Aug 27:S0264-410X(23)00994-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  780. NYGARD S, Nygard M, Orumaa M, Hansen BT, et al
    Erratum to "Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals" [Vaccine 41(37) (2023) 5469-5476].
    Vaccine. 2023 Aug 26:S0264-410X(23)01010-1. doi: 10.1016/j.vaccine.2023.
    PubMed    


  781. UGAI S, Ugai T, Kanayama T, Kamiya H, et al
    Mumps vaccine hesitancy: Current evidence and an evidence-based campaign in Japan.
    Vaccine. 2023 Aug 26:S0264-410X(23)00976-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  782. YANG J, Li B, Yang D, Wu J, et al
    The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
    Vaccine. 2023 Aug 26:S0264-410X(23)01017-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  783. MOTTA M, Motta G, Stecula D
    Sick as a dog? The prevalence, politicization, and health policy consequences of canine vaccine hesitancy (CVH).
    Vaccine. 2023 Aug 26:S0264-410X(23)01015-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  784. JANSSEN ERC, van Montfoort AZ, Hollman F, Lambers Heerspink FO, et al
    The prevalence and clinical course of shoulder injury related to vaccine administration (SIRVA) after COVID-19 vaccines in Dutch hospital workers.
    Vaccine. 2023 Aug 25:S0264-410X(23)00975-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  785. CHIBA S, Halfmann PJ, Iida S, Hirata Y, et al
    Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.
    Vaccine. 2023 Aug 25:S0264-410X(23)01008-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  786. CHEUVART B, Callegaro A, Rosillon D, Meyer N, et al
    Effectiveness of maternal immunisation with a three-component acellular pertussis vaccine at preventing pertussis in infants in the United States: Post-hoc analysis of a case-control study using Bayesian dynamic borrowing.
    Vaccine. 2023 Aug 25:S0264-410X(23)00888-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  787. CHEN IR, Wang GJ, Hsueh PR, Chou CH, et al
    Immune responses and safety of COVID-19 vaccination in atypical hemolytic uremic syndrome patients in Taiwan.
    Vaccine. 2023 Aug 25:S0264-410X(23)00952-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  788. DENG L, Tapper K, Thosar D, Goeman E, et al
    Use of adrenaline to manage suspected anaphylaxis following COVID-19 vaccination: An Australian retrospective cohort study.
    Vaccine. 2023 Aug 24:S0264-410X(23)00956-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  789. GOULD S, Wrzesinski C, Stebbings R, Segal L, et al
    Report from an ICT 2022 workshop on toxicology for Covid19 vaccines: Industry, regulatory and CRO perspectives.
    Vaccine. 2023 Aug 24:S0264-410X(23)00972-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  790. MOHAMMED IS, Widome R, Searle KM
    COVID-19 vaccine decision-making among Black women: A qualitative study.
    Vaccine. 2023 Aug 24:S0264-410X(23)00920-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  791. WATERLOW NR, Procter SR, van Leeuwen E, Radhakrishnan S, et al
    The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis.
    Vaccine. 2023 Aug 24:S0264-410X(23)00963-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  792. STRUYF F, Hardt K, Van Rampelbergh R, Shukarev G, et al
    Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.S.
    Vaccine. 2023;41:5351-5359.
    PubMed     Abstract available


  793. TIAN J, Zheng B, Yang L, Guan Y, et al
    Effectiveness of 13-valent pneumococcal conjugate vaccine on all-cause pneumonia in children under 5 years in Shanghai, China: An observational study.
    Vaccine. 2023 Aug 23:S0264-410X(23)00973-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  794. HALDER P, Maiti S, Banerjee S, Das S, et al
    Bacterial ghost cell based bivalent candidate vaccine against Salmonella Typhi and Salmonella Paratyphi A: A prophylactic study in BALB/c mice.
    Vaccine. 2023 Aug 23:S0264-410X(23)00992-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  795. SHAPIRO JR, Andreani G, Dube C, Berube M, et al
    Development and characterization of a plant-derived norovirus-like particle vaccine.
    Vaccine. 2023 Aug 23:S0264-410X(23)00968-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  796. HOMAIRA N, Strachan R, Quinn H, Beggs S, et al
    Erratum to "Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study" [Vaccine 41(1) (2023) 85-91].
    Vaccine. 2023 Aug 23:S0264-410X(23)00870-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  797. KUMRU OS, Sanyal M, Friedland N, Hickey JM, et al
    Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines.
    Vaccine. 2023 Aug 22:S0264-410X(23)00969-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  798. MAKI Y, Edo N, Mizuguchi M, Ikeda M, et al
    Impact of frequency and duration of freeze-dried inactivated tissue culture hepatitis A vaccine (Aimmugen(R)) vaccination on antibody titers; a japanese cross-sectional study.
    Vaccine. 2023 Aug 22:S0264-410X(23)00962-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  799. YAO T, Guo Y, Xu X, Zhang X, et al
    Predictors of immune persistence induced by two-dose BBIBP-CorV vaccine in high-risk occupational population.
    Vaccine. 2023 Aug 19:S0264-410X(23)00974-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  800. SU Y, Guo Z, Gu X, Sun S, et al
    Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China.
    Vaccine. 2023 Aug 19:S0264-410X(23)00971-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  801. CHAIWONG W, Takheaw N, Pata S, Laopajon W, et al
    Neutralizing antibody and T-cell responses against SARS-CoV-2 variants by heterologous CoronaVac/ChAdOx-1 vaccination in elderly subjects with chronic obstructive pulmonary disease.
    Vaccine. 2023 Aug 18:S0264-410X(23)00966-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  802. ENUJIOKE SC, Shedd-Steele R, Daggy J, Burney HN, et al
    County-level correlates of completed HPV vaccination in Indiana.
    Vaccine. 2023 Aug 18:S0264-410X(23)00875-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  803. KENIGSBERG TA, Goddard K, Hanson KE, Lewis N, et al
    Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines.
    Vaccine. 2023 Aug 18:S0264-410X(23)00955-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  804. MORRISON K, Cullen L, James AB, Chua V, et al
    Predictors of incomplete COVID-19 vaccine schedule among adults in Scotland: Two retrospective cohort analyses of the primary schedule and third dose.
    Vaccine. 2023 Aug 17:S0264-410X(23)00916-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  805. PALACHE A, Billingsley JK, MacLaren K, Morgan L, et al
    Lessons learned from the COVID-19 pandemic for improved influenza control.
    Vaccine. 2023 Aug 17:S0264-410X(23)00960-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  806. DALE JB, Aranha MP, Penfound TA, Salehi S, et al
    Structure-guided design of a broadly cross-reactive multivalent group a streptococcal vaccine.
    Vaccine. 2023 Aug 16:S0264-410X(23)00958-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  807. ZUR M, Shelef L, Glassberg E, Fink N, et al
    Are intelligent people more likely to get vaccinated? The association between COVID-19 vaccine adherence and cognitive profiles.
    Vaccine. 2023 Aug 15:S0264-410X(23)00951-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  808. FILARDO TD, Prasad N, Waddell CJ, Persad N, et al
    Mpox vaccine acceptability among people experiencing homelessness in San Francisco - October-November 2022.
    Vaccine. 2023 Aug 15:S0264-410X(23)00914-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  809. REIFFERSCHEID L, Kiely MS, Lin MSN, Libon J, et al
    Effectiveness of hospital-based strategies for improving childhood immunization coverage: A systematic review.
    Vaccine. 2023;41:5233-5244.
    PubMed     Abstract available


  810. TOYAMA K, Eto T, Takazawa K, Shimizu S, et al
    DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
    Vaccine. 2023 Aug 14:S0264-410X(23)00824-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  811. WITTAWATMONGKOL O, Bunjoungmanee P, Kosalaraksa P, Laoprasopwattana K, et al
    Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
    Vaccine. 2023 Aug 14:S0264-410X(23)00953-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  812. FRANCONERI L, Antona D, Cauchemez S, Levy-Bruhl D, et al
    Two-dose measles vaccine effectiveness remains high over time: A French observational study, 2017-2019.
    Vaccine. 2023 Aug 14:S0264-410X(23)00950-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  813. YIN MZ, Gu YY, Shu JT, Zhang B, et al
    Cost-effectiveness of cytomegalovirus vaccination for females in China: A decision-analytical Markov study.
    Vaccine. 2023 Aug 12:S0264-410X(23)00943-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  814. BERTHELEMY C, Bouche P, Lamiral Z, Boivin JM, et al
    Parental acceptability of vaccinating young children against influenza and COVID-19.
    Vaccine. 2023 Aug 12:S0264-410X(23)00929-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  815. MALIRAT V, Caldevilla C, Cardillo S, Espinoza AM, et al
    Broad immunogenic spectrum of monovalent and trivalent foot-and-mouth disease virus vaccines containing O(1) campos, A24 cruzeiro and A Argentina 2001 strains against circulating viral lineages in cattle and pigs.
    Vaccine. 2023 Aug 11:S0264-410X(23)00939-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  816. SUFFEL AM, Walker JL, Williamson E, McDonald HI, et al
    Timeliness of childhood vaccination in England: A population-based cohort study.
    Vaccine. 2023 Aug 11:S0264-410X(23)00926-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  817. BUMATAY S, Dickinson C, Larsen R, Stock I, et al
    A comparison of electronic health records and the Oregon state immunization registry for human papilloma virus vaccine delivery (2005-2022).
    Vaccine. 2023 Aug 10:S0264-410X(23)00949-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  818. EIFFERT SR, Sturmer T, Thorpe CT, Traub R, et al
    Vaccine patterns among patients diagnosed with Guillain-Barre Syndrome and matched counterparts in a Medicare supplemental population, 2000-2020.
    Vaccine. 2023 Aug 10:S0264-410X(23)00947-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  819. CARDONA RSB, Weckx LY, de Moraes-Pinto MI, Ramos BCF, et al
    Pertussis antibodies and vaccination coverage among healthcare professionals in Brazil is inadequate: A cross-sectional serological study.
    Vaccine. 2023 Aug 10:S0264-410X(23)00940-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  820. HONDA-OKUBO Y, Bart Tarbet E, Hurst BL, Petrovsky N, et al
    An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection.
    Vaccine. 2023 Aug 9:S0264-410X(23)00941-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  821. BAGLIVO F, Magri M, De Angelis L, Aprile V, et al
    Performance comparison between heterologous and homologous COVID19 vaccine schedules on Omicron variant incidence: A real-world retrospective cohort study in Southern Italy.
    Vaccine. 2023 Aug 9:S0264-410X(23)00886-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  822. WARIRI O, Utazi CE, Okomo U, Metcalf CJE, et al
    Mapping the timeliness of routine childhood vaccination in The Gambia: A spatial modelling study.
    Vaccine. 2023 Aug 8:S0264-410X(23)00928-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  823. SHEARS MJ, Watson FN, Stone BC, Cruz Talavera I, et al
    Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates.
    Vaccine. 2023 Aug 8:S0264-410X(23)00913-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  824. KOCHHAR S, Izurieta HS, Chandler RE, Hacker A, et al
    Benefit-risk assessment of vaccines.
    Vaccine. 2023 Aug 8:S0264-410X(23)00872-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  825. PITTS PJ, Poland GA
    Trust and science: Public health's home field advantage in addressing vaccine hesitancy and improving immunization rates.
    Vaccine. 2023 Aug 6:S0264-410X(23)00927-1. doi: 10.1016/j.vaccine.2023.
    PubMed    


  826. VERJOVSKY M, Barreto MP, Carmo I, Coutinho B, et al
    Political quarrel overshadows vaccination advocacy: How the vaccine debate on Brazilian Twitter was framed by anti-vaxxers during Bolsonaro administration.
    Vaccine. 2023 Aug 5:S0264-410X(23)00921-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  827. CAMPBELL J, Kaur A, Gamino D, Benoit E, et al
    Individual and structural determinants of COVID-19 vaccine uptake in a marginalized community in the United States.
    Vaccine. 2023 Aug 5:S0264-410X(23)00923-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  828. SIMMS AJ, King KD, Tsui N, Edwards SA, et al
    COVID-19 vaccine behaviour among citizens of the Metis Nation of Ontario: A qualitative study.
    Vaccine. 2023 Aug 5:S0264-410X(23)00891-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  829. IZULLA P, Wagai JN, Akelo V, Ombeva A, et al
    Vaccine safety surveillance in Kenya using GAIA standards: A feasibility assessment of existing national and subnational research and program systems.
    Vaccine. 2023 Aug 5:S0264-410X(23)00906-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  830. CHICOYE A, Crepey P, Nguyen VH, Marquez-Pelaez S, et al
    Contributions of cost-effectiveness analyses (CEA) to influenza vaccination policy for older adults in Europe.
    Vaccine. 2023 Aug 5:S0264-410X(23)00919-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  831. MOSCARA L, Venerito V, Martinelli A, Di Lorenzo A, et al
    Safety profile and SARS-CoV-2 breakthrough infections among HCWs receiving anti-SARS-CoV-2 and influenza vaccines simultaneously: an Italian observational study.
    Vaccine. 2023 Aug 4:S0264-410X(23)00874-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  832. XU S, Yu H, Cheng X, Wu J, et al
    Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of Graves' disease: An observational cohort study.
    Vaccine. 2023 Aug 4:S0264-410X(23)00884-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  833. GRANT LR, Slack MPE, Theilacker C, Vojicic J, et al
    Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies.
    Vaccine. 2023 Aug 4:S0264-410X(23)00925-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  834. AUVIGNE V, Tamandjou Tchuem CR, Schaeffer J, Vaux S, et al
    Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech Original/BA.4-5 bivalent vaccine compared to the mRNA Original monovalent vaccines - A matched cohort study in France.
    Vaccine. 2023 Aug 2:S0264-410X(23)00917-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  835. SINGER D, Salem A, Stempniewicz N, Ma S, et al
    The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.
    Vaccine. 2023 Aug 2:S0264-410X(23)00837-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  836. CARTER A, Msemburi W, Sim SY, Gaythorpe KAM, et al
    Modeling the impact of vaccination for the immunization Agenda 2030: Deaths averted due to vaccination against 14 pathogens in 194 countries from 2021 to 2030.
    Vaccine. 2023 Aug 1:S0264-410X(23)00854-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  837. MO J, Spackman E, Swayne DE
    Prediction of highly pathogenic avian influenza vaccine efficacy in chickens by comparison of in vitro and in vivo data: A meta-analysis and systematic review.
    Vaccine. 2023 Aug 1:S0264-410X(23)00922-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    July 2023
  838. AMAI M, Nojima M, Yuki Y, Kiyono H, et al
    A review of criteria strictness in "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials".
    Vaccine. 2023 Jul 31:S0264-410X(23)00918-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  839. GUNALE B, Farinola N, Yeolekar L, Shrivastava S, et al
    A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults.
    Vaccine. 2023 Jul 31:S0264-410X(23)00876-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  840. HONDA-OKUBO Y, Sakala IG, Andre G, Tarbet EB, et al
    An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice.
    Vaccine. 2023 Jul 31:S0264-410X(23)00892-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  841. WALLACE M, Rosenblum HG, Moulia DL, Broder KR, et al
    A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States.
    Vaccine. 2023 Jul 30:S0264-410X(23)00868-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  842. VAN WALSTIJN C, Verweij S, Care R, Rigsby P, et al
    Variability of in vivo potency assays of whole-cell pertussis, inactivated polio, and meningococcal B vaccines.
    Vaccine. 2023 Jul 30:S0264-410X(23)00885-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  843. LIU B, Stepien S, Qian J, Gidding H, et al
    Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection.
    Vaccine. 2023 Jul 29:S0264-410X(23)00881-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  844. AMANI A, Njoh AA, Atuhebwe P, Ndoula S, et al
    Beyond the numbers: An in-depth look at Cameroon's fifth national COVID-19 vaccination campaign through geographical and gender lenses.
    Vaccine. 2023 Jul 29:S0264-410X(23)00905-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  845. DECEUNINCK G, Brousseau N, Lefebvre B, Quach C, et al
    Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada.
    Vaccine. 2023 Jul 29:S0264-410X(23)00880-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  846. GREEN-MCKENZIE J, Shofer FS, Kruse G, Momplaisir F, et al
    COVID-19 vaccine uptake before and after a vaccine mandate at a major academic hospital: Trends by race/ethnicity and level of patient contact.
    Vaccine. 2023 Jul 28:S0264-410X(23)00853-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  847. LENTSCH V, Aslani S, Echtermann T, Preet S, et al
    "EvoVax" - A rationally designed inactivated Salmonella Typhimurium vaccine induces strong and long-lasting immune responses in pigs.
    Vaccine. 2023 Jul 28:S0264-410X(23)00890-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  848. KIM SY, Lee KM, Kim KH
    Differences between DNA vaccine and single-cycle viral vaccine in the ability of cross-protection against viral hemorrhagic septicemia virus (VHSV) and infectious hematopoietic necrosis virus (IHNV).
    Vaccine. 2023 Jul 28:S0264-410X(23)00889-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  849. PADENIYA TN, Hui BB, Wood JG, Seib KL, et al
    The potential impact of a vaccine on Neisseria gonorrhoeae prevalence among heterosexuals living in a high prevalence setting.
    Vaccine. 2023 Jul 28:S0264-410X(23)00879-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  850. HAMAD SAIED M, van Straalen JW, de Roock S, de Joode-Smink GCJ, et al
    Long-term immunoprotection after live attenuated measles-mumps-rubella booster vaccination in children with juvenile idiopathic arthritis.
    Vaccine. 2023 Jul 27:S0264-410X(23)00883-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  851. LAVENDER B, Hooker C, Frampton C, Williams M, et al
    Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naive New Zealand cohort.
    Vaccine. 2023 Jul 27:S0264-410X(23)00882-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  852. JIANG XY, Gong MQ, Zhang HJ, Peng AQ, et al
    The safety and immunogenicity of a recombinant five-antigen Staphylococcus aureus vaccine among patients undergoing elective surgery for closed fractures: A randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial.
    Vaccine. 2023 Jul 27:S0264-410X(23)00878-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  853. NYGARD S, Nygard M, Orumaa M, Hansen BT, et al
    Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
    Vaccine. 2023 Jul 27:S0264-410X(23)00852-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  854. ROSA RG, Falavigna M, Manfio JL, de Araujo CLP, et al
    BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study.
    Vaccine. 2023 Jul 26:S0264-410X(23)00869-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  855. KABIR A, Randall D, Newall AT, Moore HC, et al
    Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study.
    Vaccine. 2023 Jul 26:S0264-410X(23)00873-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  856. KIM DH, Lee J, Youk S, Jeong JH, et al
    Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection.
    Vaccine. 2023;41:4787-4797.
    PubMed     Abstract available


  857. MARTINI M, Orsini D
    The ghost of polio haunts us once again. The appeal of the scientific community is clear: "Vaccinate your kids today!".
    Vaccine. 2023 Jul 24:S0264-410X(23)00850-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  858. TAMADA Y, Takeuchi K, Kusama T, Maeda M, et al
    Effectiveness of COVID-19 vaccines against infection in Japan: A test-negative study from the VENUS study.
    Vaccine. 2023 Jul 22:S0264-410X(23)00856-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  859. GHAZY RM, Ibrahim SA, Taha SHN, Elshabrawy A, et al
    Attitudes of parents towards influenza vaccine in the Eastern Mediterranean Region: A multilevel analysis.
    Vaccine. 2023 Jul 20:S0264-410X(23)00808-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  860. ARAUJO-CHAVERON L, Sicsic J, Moffroid H, Diaz Luevano C, et al
    Impact of a COVID-19 certificate requirement on vaccine uptake pattern and intention for future vaccination. A cross-sectional study among French adults.
    Vaccine. 2023 Jul 20:S0264-410X(23)00805-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  861. KIM YA, Mousavi K, Yazdi A, Zwierzyna M, et al
    Computational design of mRNA vaccines.
    Vaccine. 2023 Jul 20:S0264-410X(23)00836-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  862. ORAMI T, Aho C, Ford RL, Pomat WS, et al
    Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial.
    Vaccine. 2023 Jul 19:S0264-410X(23)00838-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  863. CANTARERO D, Ocana D, Onieva-Garcia MA, Rodriguez-Garcia J, et al
    Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain.
    Vaccine. 2023 Jul 19:S0264-410X(23)00828-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  864. JESUDASON T, Rodarte A, Tordrup D, Carias C, et al
    Systematic review of rotavirus vaccination cost-effectiveness in high income settings utilising dynamic transmission modelling techniques.
    Vaccine. 2023 Jul 19:S0264-410X(23)00749-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  865. CLIMACO MC, de Figueiredo LA, Lucas RC, Pinheiro GRG, et al
    Development of chimeric protein as a multivalent vaccine for human Kinetoplastid infections: Chagas disease and leishmaniasis.
    Vaccine. 2023 Jul 19:S0264-410X(23)00832-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  866. PISL V, Vevera J
    COVID-19 vaccine uptake in mental healthcare users: Czech nationwide register study.
    Vaccine. 2023 Jul 19:S0264-410X(23)00840-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  867. KATHERINE YIH W, Daley MF, Duffy J, Fireman B, et al
    Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink.
    Vaccine. 2023 Jul 19:S0264-410X(23)00823-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  868. VIETRI J, Sato R, Averin A, Weycker D, et al
    Pneumococcal vaccine uptake among Medicare Beneficiaries aged >/=65 years following the shared clinical decision-making recommendation for 13-valent pneumococcal conjugate vaccine in 2019.
    Vaccine. 2023 Jul 18:S0264-410X(23)00855-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  869. ZIMMERMAN RK, Patricia Nowalk M, Dauer K, Clarke L, et al
    Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design.
    Vaccine. 2023 Jul 18:S0264-410X(23)00741-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  870. DAS SK, Khan J
    Timeliness in the uptake of hepatitis B birth dose among Indian children under age five: A population-based study.
    Vaccine. 2023 Jul 17:S0264-410X(23)00827-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  871. BATOOL R, Yousafzai MT, Qureshi S, Muhammad S, et al
    Parental acceptance of typhoid conjugate vaccine for children aged 6 months to 15 years in an outbreak setting of Lyari Town Karachi, Pakistan.
    Vaccine. 2023 Jul 16:S0264-410X(23)00806-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  872. SABAT I, Neumann-Bohme S, Barros PP, Torbica A, et al
    Vaccine hesitancy comes in waves: Longitudinal evidence on willingness to vaccinate against COVID-19 from seven European countries.
    Vaccine. 2023 Jul 15:S0264-410X(23)00829-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  873. SCHAEFER GO, Emanuel EJ, Atuire CA, Leland RJ, et al
    Equitable global allocation of monkeypox vaccines.
    Vaccine. 2023 Jul 15:S0264-410X(23)00835-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  874. MOROS A, Prenafeta A, Barreiro A, Perozo E, et al
    Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate.
    Vaccine. 2023 Jul 15:S0264-410X(23)00820-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  875. CLOUSTON SAP, Hanes DW, Link BG
    Social inequalities and the early provision and dispersal of COVID-19 vaccinations in the United States: A population trends study.
    Vaccine. 2023 Jul 15:S0264-410X(23)00833-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  876. MYERS MG
    Beginning to address vaccine reluctance and refusal.
    Vaccine. 2023 Jul 14:S0264-410X(23)00851-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  877. GIERSING B, Karron R, Tufet-Bayona M, Trotter C, et al
    Vaccine Value profiles.
    Vaccine. 2023 Jul 14:S0264-410X(23)00786-7. doi: 10.1016/j.vaccine.2023.
    PubMed    


  878. TALOTTA R
    COVID-19 mRNA vaccines as hypothetical epigenetic players: Results from an in silico analysis, considerations and perspectives.
    Vaccine. 2023 Jul 13:S0264-410X(23)00819-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  879. GLESER D, Spinner K, Klement E
    Effectiveness of the strain 919 bovine ephemeral fever virus vaccine in the face of a real-world outbreak: A field study in Israeli dairy herds.
    Vaccine. 2023 Jul 12:S0264-410X(23)00747-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  880. ALABANZA C, Gavrilov V, Scott T, Yang RS, et al
    Quantitation of strain-specific hemagglutinin trimers in mosaic quadrivalent influenza nanoparticle vaccine by ELISA.
    Vaccine. 2023 Jul 12:S0264-410X(23)00821-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  881. AGRAWAL P, Damania D, Cseh A, Grab J, et al
    Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
    Vaccine. 2023 Jul 12:S0264-410X(23)00822-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  882. YAMAGUCHI K, Shimizu H, Takahashi K, Nagatomo T, et al
    Characterization of epitopes of human monoclonal antibodies against cytomegalovirus glycoprotein B for neutralization and antibody-dependent phagocytosis.
    Vaccine. 2023;41:4497-4507.
    PubMed     Abstract available


  883. MINCHIN J, Harris GH, Baumann S, Smith ER, et al
    Exclusion of pregnant people from emergency vaccine clinical trials: A systematic review of clinical trial protocols and reporting from 2009 to 2019.
    Vaccine. 2023 Jul 11:S0264-410X(23)00776-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  884. MIELLET WR, Pluister G, Sikking M, Tappel M, et al
    Surveillance of Neisseria meningitidis carriage four years after menACWY vaccine implementation in the Netherlands reveals decline in vaccine-type and rise in genogroup e circulation.
    Vaccine. 2023 Jul 7:S0264-410X(23)00781-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  885. WILLIS DE, Reece S, Gurel-Headley M, Selig JP, et al
    Social processes, practical issues, and COVID-19 vaccination among hesitant adults.
    Vaccine. 2023 Jul 7:S0264-410X(23)00809-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  886. FLEMING JA, Baral R, Higgins D, Khan S, et al
    Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.
    Vaccine. 2023 Jul 6:S0264-410X(22)01212-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  887. ZHANG X, Shen P, Liu J, Ji X, et al
    Evaluating the effectiveness and cost-effectiveness of free influenza vaccination policy for older adults in Yinzhou, China: Study protocol of a real-world analyses.
    Vaccine. 2023 Jul 5:S0264-410X(23)00790-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  888. WAGNER A, Juvalta S, Speranza C, Suggs LS, et al
    Let's talk about COVID-19 vaccination: Relevance of conversations about COVID-19 vaccination and information sources on vaccination intention in Switzerland.
    Vaccine. 2023 Jul 5:S0264-410X(23)00807-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  889. LE H, de Klerk N, Blyth CC, Gidding H, et al
    Non-specific benefit of seasonal influenza vaccine on respiratory syncytial virus-hospitalisations in children: An instrumental variable approach using population-based data.
    Vaccine. 2023 Jul 3:S0264-410X(23)00788-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  890. ROSHCHINA Y, Rozhkova K, Roshchin S
    Between nudges and mandates: The drivers of COVID-19 vaccination intentions and subsequent uptake in Russia.
    Vaccine. 2023 Jul 3:S0264-410X(23)00756-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  891. PATEL UC, Schultz T, Schmidt J
    Veteran influenza vaccination acceptance rates after completion of the COVID-19 vaccination series among historical influenza vaccine refusers.
    Vaccine. 2023 Jul 3:S0264-410X(23)00803-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  892. TUCKERMAN J, Kaufman J, Overmars I, Holland P, et al
    Barriers to COVID-19 vaccination of migrant populations: A qualitative interview study of immunisation providers in Victoria, Australia.
    Vaccine. 2023 Jul 3:S0264-410X(23)00804-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  893. TROGSTAD L, Laake I, Robertson AH, Mjaaland S, et al
    Heavy bleeding and other menstrual disturbances in young women after COVID-19 vaccination.
    Vaccine. 2023 Jul 3:S0264-410X(23)00801-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  894. GRUZDEV N, Pitcovski J, Katz C, Ruimi N, et al
    Development of toxin-antitoxin self-destructive bacteria, aimed for salmonella vaccination.
    Vaccine. 2023 Jul 1:S0264-410X(23)00777-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  895. IZUMI F, Miyamoto S, Masatani T, Sasaki M, et al
    Generation and characterization of a genetically modified live rabies vaccine strain with attenuating mutations in multiple viral proteins and evaluation of its potency in dogs.
    Vaccine. 2023 Jul 1:S0264-410X(23)00779-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  896. KELLY M, Mandlik A, Charles RC, Verma S, et al
    Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry.
    Vaccine. 2023 Jul 1:S0264-410X(23)00738-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    June 2023
  897. LIU Z, Pang C, Deng Y, Guo C, et al
    Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults.
    Vaccine. 2023 Jun 30:S0264-410X(23)00616-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  898. SHINJOH M, Furuichi M, Tsuzuki S, Iqbal A, et al
    Effectiveness of inactivated influenza and COVID-19 vaccines in hospitalized children in 2022/23 season in Japan - The first season of co-circulation of influenza and COVID-19.
    Vaccine. 2023 Jun 30:S0264-410X(23)00785-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  899. LIU Y, Zhang A, Wang Y, Yang J, et al
    Immunogenicity and protective effects of recombinant bivalent COVID-19 vaccine in mice and rhesus macaques.
    Vaccine. 2023 Jun 30:S0264-410X(23)00789-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  900. KU JH, Sy LS, Qian L, Ackerson BK, et al
    Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study.
    Vaccine. 2023;41:4212-4219.
    PubMed     Abstract available


  901. VAN DER BOOR SC, Schmitz-de Vries ETJ, Smits D, Scholl JHG, et al
    Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.
    Vaccine. 2023;41:4319-4326.
    PubMed     Abstract available


  902. ISHIKAWA K, Nascimento MC, Asano M, Hirata H, et al
    One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan.
    Vaccine. 2023;41:4199-4205.
    PubMed     Abstract available


  903. LEE KS, Rader NA, Miller-Stump OA, Cooper M, et al
    Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Vaccine. 2023 Jun 28:S0264-410X(23)00783-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  904. SHENG Y, Li Z, Lin X, Ma Y, et al
    The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
    Vaccine. 2023 Jun 28:S0264-410X(23)00759-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  905. CARRERA JM, Aktepe TE, Earnest L, Christiansen D, et al
    Adenovirus vector produced Zika virus-like particles induce a long-lived neutralising antibody response in mice.
    Vaccine. 2023 Jun 28:S0264-410X(23)00757-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  906. YUKI Y, Harada N, Sawada SI, Uchida Y, et al
    Biodistribution assessment of cationic pullulan nanogel, a nasal vaccine delivery system, in mice and non-human primates.
    Vaccine. 2023 Jun 27:S0264-410X(23)00754-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  907. DOMNICH A, Orsi A, Ogliastro M, Trombetta CS, et al
    Influenza vaccine effectiveness in preventing hospital encounters for laboratory-confirmed infection among Italian adults, 2022/23 season.
    Vaccine. 2023 Jun 27:S0264-410X(23)00775-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  908. KIM S, Ko M, Heo Y, Lee YK, et al
    Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
    Vaccine. 2023 Jun 27:S0264-410X(23)00780-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  909. GONZALES BE, Mercado EH, Castillo-Tokumori F, Montero AE, et al
    Pneumococcal serotypes and antibiotic resistance in healthy carriage children after introduction of PCV13 in Lima, Peru.
    Vaccine. 2023;41:4106-4113.
    PubMed     Abstract available


  910. CARNEIRO GB, Castro JT, Davi M, Miyaji EN, et al
    Immune responses and protection against Streptococcus pneumoniae elicited by recombinant Bordetella pertussis adenylate cyclase (CyaA) carrying fragments of pneumococcal surface protein A, PspA.
    Vaccine. 2023;41:4170-4182.
    PubMed     Abstract available


  911. BAUER BU, Schwecht KM, Jahnke R, Matthiesen S, et al
    Humoral and cellular immune responses in sheep following administration of different doses of an inactivated phase I vaccine against Coxiella burnetii.
    Vaccine. 2023 Jun 23:S0264-410X(23)00746-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  912. DU J, Wang T, Xu L, Wang C, et al
    Clostridium perfringens epsilon prototoxin mutant rpETX(Y30A/Y71A/H106P/Y196A) as a vaccine candidate against enterotoxemia.
    Vaccine. 2023 Jun 23:S0264-410X(23)00719-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  913. HOWARD MC
    Integrating the person-centered approach with the study of vaccine hesitancy: Applying latent profile analysis to identify vaccine hesitancy subpopulations and assess their relations with correlates and vaccination outcomes.
    Vaccine. 2023 Jun 23:S0264-410X(23)00742-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  914. BOLIO A, Goldstein I, Rauh L, Ratzan S, et al
    Statement: Multisectoral actions to build trust at the local and community level to promote vaccine acceptance.
    Vaccine. 2023 Jun 23:S0264-410X(23)00693-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  915. CHAUDHARY A, Madhavan R, Babji S, Raju R, et al
    Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India.
    Vaccine. 2023 Jun 23:S0264-410X(23)00744-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  916. HAIST V, Bellebeau-Barbier F, Montange C, Lemaitre L, et al
    Comparison of the local safety of two multi-component feline vaccines, adjuvanted (1 mL) versus non-adjuvanted at reduced volume (0.5 mL), using computed tomography imaging.
    Vaccine. 2023 Jun 23:S0264-410X(23)00720-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  917. TORP HANSEN K, Kusk Povlsen F, Hammer Bech B, Nygaard Hansen S, et al
    Immediate adverse reactions following COVID-19 vaccination among 16-65-year-old Danish citizens.
    Vaccine. 2023 Jun 23:S0264-410X(23)00758-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  918. TURLEY CB, Tables L, Fuller T, Sanders LJ, et al
    Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
    Vaccine. 2023 Jun 23:S0264-410X(23)00755-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  919. SALEH SN, McDonald SA, Basit MA, Kumar S, et al
    Public perception of COVID-19 vaccines through analysis of Twitter content and users.
    Vaccine. 2023 Jun 23:S0264-410X(23)00743-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  920. DE MELO ARAUJO AC, da Silva Aragao J, de Souza WV, Rodrigues LC, et al
    The impact of implementing the 10-valent pneumococcal conjugate vaccine on hospitalizations for pneumonia among children.
    Vaccine. 2023 Jun 21:S0264-410X(23)00724-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  921. FUKUSHIMA S, Kiyohara T, Nakano T, Tada Y, et al
    Delaying the third dose of Japanese aluminum-free hepatitis A vaccine Aimmugen elicits effective immune responses against hepatitis A in adults.
    Vaccine. 2023 Jun 21:S0264-410X(23)00723-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  922. JIANG B, Luo Y, Yan N, Shen Z, et al
    An X-ray inactivated vaccine against Pseudomonas aeruginosa Keratitis in mice.
    Vaccine. 2023 Jun 21:S0264-410X(23)00627-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  923. KIM J, Han K, Chung SJ, Kim C, et al
    Psychometric validation of the Korean versions of the Vaccine Hesitancy Scale and Vaccination Attitudes Examination Scale.
    Vaccine. 2023 Jun 21:S0264-410X(23)00721-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  924. PERRILLO R, Garrido LF, Ma TW, Rahimi R, et al
    Vaccination with HepB-CpG vaccine in individuals undergoing immune suppressive drug therapy.
    Vaccine. 2023 Jun 21:S0264-410X(23)00716-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  925. AUGUSTYNIAK A, Szymanski T, Porzucek F, Mieloch AA, et al
    A cohort study reveals different dynamics of SARS-CoV-2-specific antibody formation after Comirnaty and Vaxzevria vaccination.
    Vaccine. 2023 Jun 21:S0264-410X(23)00665-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  926. LUANGASANATIP N, Painter C, Pan-Ngum W, Saralamba S, et al
    How to model the impact of vaccines for policymaking when the characteristics are uncertain: A case study in Thailand prior to the vaccine rollout during the COVID-19 pandemic.
    Vaccine. 2023 Jun 20:S0264-410X(23)00740-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  927. CHEN X, Lin Y, Yue S, Yang Y, et al
    PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness.
    Vaccine. 2023 Jun 20:S0264-410X(23)00737-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  928. KREMER P, Haruna F, Tuffour Sarpong R, Agamah D, et al
    An impact assessment of the use of aerial logistics to improve access to vaccines in the Western-North Region of Ghana.
    Vaccine. 2023 Jun 19:S0264-410X(23)00701-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  929. SUZUKI H, Fujita H, Iwai K, Kuroki H, et al
    Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033).
    Vaccine. 2023 Jun 19:S0264-410X(23)00625-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  930. EKIMOV A, Arunachalam AB, Blake T, Bodle J, et al
    Assessing the stability-indicating properties of alternative potency assays for inactivated influenza vaccine.
    Vaccine. 2023 Jun 19:S0264-410X(23)00726-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  931. AILLOUD J, Branchereau M, Fall E, Juneau C, et al
    How can we improve the acceptability of vaccination against Human Papillomavirus (HPV) in France? An original qualitative study with focus groups comprising parents and school staff, interviewed separately.
    Vaccine. 2023 Jun 19:S0264-410X(23)00656-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  932. TATON M, Willems F, Widomski C, Martin C, et al
    Impact of pregnancy on polyfunctional IgG and memory B cell responses to Tdap immunization.
    Vaccine. 2023;41:4009-4018.
    PubMed     Abstract available


  933. TAFURI S, Cuscianna E, Bianchi FP
    Prevalence of poliovirus neutralizing antibodies in Italian population: A systematic review and meta-analysis.
    Vaccine. 2023;41:4057-4063.
    PubMed     Abstract available


  934. HONDA-OKUBO Y, Li L, Andre G, Leong KH, et al
    An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge.
    Vaccine. 2023 Jun 19:S0264-410X(23)00748-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  935. UDA K, Okubo Y, Tsuge M, Tsukahara H, et al
    Impacts of routine varicella vaccination program and COVID-19 pandemic on varicella and herpes zoster incidence and health resource use among children in Japan.
    Vaccine. 2023 Jun 19:S0264-410X(23)00739-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  936. TZENG R, Huang FY, Lee J
    Compliance, procrastination and refusal: American COVID-19 vaccination trust and value orientation.
    Vaccine. 2023 Jun 19:S0264-410X(23)00745-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  937. ORANGZEB S, Watle SV, Caugant DA
    Adherence to vaccination guidelines of patients with complete splenectomy in Norway, 2008-2020.
    Vaccine. 2023 Jun 17:S0264-410X(23)00699-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  938. HAMEL BL, Patel J, Still J, Joshi A, et al
    A diagnostic quandary: Rotavirus vaccine associated diarrhea.
    Vaccine. 2023 Jun 17:S0264-410X(23)00715-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  939. MASOUD D, Pierz A, Rauh L, Cruz AK, et al
    Vaccine Trust Gauge: Mixed methods research to measure and understand vaccine trust.
    Vaccine. 2023 Jun 17:S0264-410X(23)00690-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  940. DOYON-PLOURDE P, Przepiorkowski J, Young K, Zhao L, et al
    Intraseasonal waning immunity of seasonal influenza vaccine - A systematic review and meta-analysis.
    Vaccine. 2023 Jun 16:S0264-410X(23)00713-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  941. SINGH A, Boggiano C, Eller MA, Maciel M Jr, et al
    Optimizing the Immunogenicity of HIV Vaccines by Adjuvants - NIAID Workshop Report.
    Vaccine. 2023 Jun 16:S0264-410X(23)00694-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  942. DUNN DT, Gilson R, McCormack S, McCoy LE, et al
    Licenced doses of approved COVID-19 vaccines may not be optimal: A review of the early-phase, dose-finding trials.
    Vaccine. 2023 Jun 16:S0264-410X(23)00712-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  943. BISWAS RK, Afiaz A, Huq S, Farzana M, et al
    Public opinion on COVID-19 vaccine prioritization in Bangladesh: Who gets the vaccine and whom do you leave out?
    Vaccine. 2023 Jun 16:S0264-410X(23)00725-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  944. PIGNATTI P, Ramirez GA, Russo M, Marraccini P, et al
    Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients.
    Vaccine. 2023 Jun 15:S0264-410X(23)00714-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  945. MUANGNOICHAROEN S, Wiangcharoen R, Nanthapisal S, Kamolratakul S, et al
    Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
    Vaccine. 2023 Jun 15:S0264-410X(23)00718-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  946. KENIGSBERG TA, Hanson KE, Klein NP, Zerbo O, et al
    Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink.
    Vaccine. 2023 Jun 15:S0264-410X(23)00717-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  947. PUTHANAKIT T, Chokephaibulkit K, Chaithongwongwatthana S, Bhat N, et al
    A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women.
    Vaccine. 2023 Jun 15:S0264-410X(23)00657-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  948. NISHIYAMA A, Adachi Y, Tonouchi K, Moriyama S, et al
    Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses.
    Vaccine. 2023 Jun 15:S0264-410X(23)00685-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  949. SHOAIBI A, Lloyd PC, Wong HL, Clarke TC, et al
    Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S.
    Vaccine. 2023 Jun 14:S0264-410X(23)00682-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  950. CIEMINS EL, Gillen A, Tallam M
    RSV: A vaccine is coming, time to educate providers.
    Vaccine. 2023 Jun 14:S0264-410X(23)00695-3. doi: 10.1016/j.vaccine.2023.
    PubMed    


  951. MUWONGE R, Basu P
    Re: Using observational data to explore the hypothesis that a single dose of current HPV vaccines can provide durable protection: Reply to the commentary written by Christine Velicer, Alain Luxembourg, Ya-Ting Chen, Melvin Kohn, and Alfred Saah, Merck
    Vaccine. 2023 Jun 14:S0264-410X(23)00696-5. doi: 10.1016/j.vaccine.2023.
    PubMed    


  952. WOO EJ, Gee J, Marquez P, Baggs J, et al
    Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
    Vaccine. 2023 Jun 13:S0264-410X(23)00687-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  953. YOUNG S, Goldin S, Dumolard L, Shendale S, et al
    National vaccination policies for health workers - A cross-sectional global overview.
    Vaccine. 2023 Jun 13:S0264-410X(23)00518-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  954. CINCONZE E, Rosillon D, Rappuoli R, Vadivelu K, et al
    Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review.
    Vaccine. 2023 Jun 13:S0264-410X(23)00552-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  955. SAADATIAN-ELAHI M, Henaff L, Elias C, Nunes MC, et al
    Patient influenza vaccination reduces the risk of hospital-acquired influenza: An incident test negative-case control study in Lyon university hospital, France (2004-2020).
    Vaccine. 2023 Jun 13:S0264-410X(23)00621-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  956. SMITH WJ, Thompson R, Egan PM, Zhang Y, et al
    Impact of aluminum adjuvants on the stability of pneumococcal polysaccharide-protein conjugate vaccines.
    Vaccine. 2023 Jun 13:S0264-410X(23)00620-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  957. ACEVES-SANCHEZ MJ, Barrios-Payan JA, Segura-Cerda CA, Flores-Valdez MA, et al
    BCG∆BCG1419c and BCG differ in induction of autophagy, c-di-GMP content, proteome, and progression of lung pathology in Mycobacterium tuberculosis HN878-infected male BALB/c mice.
    Vaccine. 2023;41:3824-3835.
    PubMed     Abstract available


  958. MUNOZ FM, Posavad CM, Richardson BA, Badell ML, et al
    COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
    Vaccine. 2023 Jun 13:S0264-410X(23)00698-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  959. WATESKA AR, Nowalk MP, Lin CJ, Harrison LH, et al
    Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults.
    Vaccine. 2023 Jun 12:S0264-410X(23)00669-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  960. SATO R
    Revisiting the measurement of vaccine hesitancy: Comparison between routine immunization and supplementary immunization activity in Nigeria.
    Vaccine. 2023 Jun 12:S0264-410X(23)00691-6. doi: 10.1016/j.vaccine.2023.
    PubMed    


  961. AL-RASHEED M, Ball C, Parthiban S, Ganapathy K, et al
    Evaluation of protection and immunity induced by infectious bronchitis vaccines administered by oculonasal, spray or gel routes in commercial broiler chicks.
    Vaccine. 2023 Jun 12:S0264-410X(23)00642-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  962. TINGGAARD M, Slotved HC, Jorgensen CS, Kronborg G, et al
    Predictors of serological non-response to the 13-valent pneumococcal conjugate vaccine followed by the 23-valent polysaccharide vaccine among adults living with HIV.
    Vaccine. 2023 Jun 12:S0264-410X(23)00686-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  963. MA D, Tian S, Qin Q, Yu Y, et al
    Construction of an inhalable recombinant M2e-FP-expressing Bacillus subtilis spores-based vaccine and evaluation of its protection efficacy against influenza in a mouse model.
    Vaccine. 2023 Jun 10:S0264-410X(23)00655-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  964. ACKERSON B, Sy LS, Slezak J, Qian L, et al
    Post-licensure safety study of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in adult recipients of HepB-CpG vaccine versus HepB-alum vaccine.
    Vaccine. 2023 Jun 10:S0264-410X(23)00661-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  965. NAKAO R, Hirayama S, Yamaguchi T, Senpuku H, et al
    A bivalent outer membrane vesicle-based intranasal vaccine to prevent infection of periodontopathic bacteria.
    Vaccine. 2023 Jun 9:S0264-410X(23)00619-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  966. MADRAN B, Kayi I, Beser A, Ergonul O, et al
    Uptake of COVID-19 vaccines among healthcare workers and the effect of nudging interventions: A mixed methods study.
    Vaccine. 2023 Jun 9:S0264-410X(23)00688-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  967. UI M, Hirama T, Akiba M, Honda M, et al
    Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
    Vaccine. 2023 Jun 9:S0264-410X(23)00663-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  968. MARTINEZ MR, Gao J, Wan H, Kang H, et al
    Inactivated influenza virions are a flexible vaccine platform for eliciting protective antibody responses against neuraminidase.
    Vaccine. 2023 Jun 8:S0264-410X(23)00629-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  969. DE GIER B, van Asten L, Boere TM, van Roon A, et al
    Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022.
    Vaccine. 2023 Jun 8:S0264-410X(23)00660-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  970. NOGAREDA F, Gharpure R, Contreras M, Velandia M, et al
    Seasonal influenza vaccination in the Americas: Progress and challenges during the COVID-19 pandemic.
    Vaccine. 2023 Jun 8:S0264-410X(23)00689-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  971. KALKOWSKA DA, Badizadegan K, Thompson KM
    Outbreak management strategies for cocirculation of multiple poliovirus types.
    Vaccine. 2023;41:3718-3727.
    PubMed     Abstract available


  972. MWENDA V, Jalang'o R, Miano C, Bor JP, et al
    Impact, cost-effectiveness, and budget implications of HPV vaccination in Kenya: A modelling study.
    Vaccine. 2023 Jun 7:S0264-410X(23)00546-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  973. SHAW RJ, Doyle AJ, Millen EA, Stowe J, et al
    Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria.
    Vaccine. 2023 Jun 7:S0264-410X(23)00662-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  974. KATO H, Hozawa T, Fukushima W, Nobusawa E, et al
    Influenza vaccine viruses and the development of seasonal vaccines: A Japanese perspective.
    Vaccine. 2023 Jun 6:S0264-410X(23)00640-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  975. MITCHELL SL, Schulkin J, Power ML
    Vaccine hesitancy in pregnant Women: A narrative review.
    Vaccine. 2023 Jun 6:S0264-410X(23)00608-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  976. KIM DELUCA E, Gebremariam A, Rose A, Biggerstaff M, et al
    Cost-effectiveness of routine annual influenza vaccination by age and risk status.
    Vaccine. 2023 Jun 6:S0264-410X(23)00495-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  977. PELLETIER C, Labbe F, Bettinger JA, Curran J, et al
    From high hopes to disenchantment: A qualitative analysis of editorial cartoons on COVID-19 vaccines in Canadian newspapers.
    Vaccine. 2023 Jun 6:S0264-410X(23)00658-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  978. KIM WJ, Roberts CC, Song JY, Yoon JG, et al
    Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.
    Vaccine. 2023 Jun 6:S0264-410X(23)00683-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  979. ELDER E, Bangalore Revanna C, Johansson C, Wallin RPA, et al
    Protective immunity induced by an inhaled SARS-CoV-2 subunit vaccine.
    Vaccine. 2023 Jun 6:S0264-410X(23)00684-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  980. YANAI T, Yoshida S, Takeuchi M, Kawakami K, et al
    Pneumonia hospitalization after introduction of pneumococcal conjugate vaccine in Japan: Descriptive study using a nationwide claims database.
    Vaccine. 2023 Jun 5:S0264-410X(23)00626-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  981. MAKANUT S, Wangteeraprasert A, Jitpewngam W, Ngoenkam J, et al
    Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
    Vaccine. 2023 Jun 5:S0264-410X(23)00666-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  982. WESSELINK AK, Lovett SM, Weinberg J, Geller RJ, et al
    COVID-19 vaccination and menstrual cycle characteristics: A prospective cohort study.
    Vaccine. 2023 Jun 5:S0264-410X(23)00681-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  983. KOZMA GT, Meszaros T, Berenyi P, Facsko R, et al
    Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG.
    Vaccine. 2023 Jun 5:S0264-410X(23)00667-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  984. VOHRA P, Bremner A, Nicholls B, Chintoan-Uta C, et al
    Evaluation of N-glycan-decorated live attenuated Escherichia coli and outer membrane vesicles as vaccines against Campylobacter jejuni colonisation in chickens.
    Vaccine. 2023 Jun 3:S0264-410X(23)00595-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  985. ERGUN T, Hosgoren Tekin S, Apti Sengun O, Akin Cakici O, et al
    Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study.
    Vaccine. 2023 Jun 3:S0264-410X(23)00615-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  986. FEDDEMA JJ, Fernald KDS, Schikan HGCP, van de Burgwal LHM, et al
    Upscaling vaccine manufacturing capacity - Kkey bottlenecks and lessons learned.
    Vaccine. 2023 Jun 3:S0264-410X(23)00554-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  987. RAINA MACINTYRE C, Lim S, Gurdasani D, Miranda M, et al
    Early detection of emerging infectious diseases - implications for vaccine development.
    Vaccine. 2023 Jun 2:S0264-410X(23)00630-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  988. MVUNDURA M, Ng J, Reynolds K, Theng Ng Y, et al
    Vaccine wastage in Ghana, Mozambique, and Pakistan: An assessment of wastage rates for four vaccines and the context, causes, drivers, and knowledge, attitudes and practices for vaccine wastage.
    Vaccine. 2023 Jun 1:S0264-410X(23)00582-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  989. SANDERS C, Matthews RL, Esfahani SHZ, Khan N, et al
    Cross-neutralizing protection of vaginal and oral mucosa from HPV challenge by vaccination in a mouse model.
    Vaccine. 2023 Jun 1:S0264-410X(23)00618-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    May 2023
  990. CHORIN O, Markovich MP, Avramovich E, Rahmani S, et al
    Oral and fecal polio vaccine excretion following bOPV vaccination among Israeli infants.
    Vaccine. 2023 May 31:S0264-410X(23)00585-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  991. OLIVERA MESA D, Winskill P, Ghani AC, Hauck K, et al
    The societal cost of vaccine refusal: A modelling study using measles vaccination as a case study.
    Vaccine. 2023 May 30:S0264-410X(23)00589-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  992. SCHLEY K, Borchert K, Seidel K, Jacob C, et al
    Did the change of the vaccination schedule effect pneumococcal conjugate vaccination compliance and adherence of premature and mature born infants in Germany? Answers from a claims database analysis.
    Vaccine. 2023 May 30:S0264-410X(23)00594-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  993. WANG LJ, Tsai CS, Chou WJ, Li CJ, et al
    Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study.
    Vaccine. 2023 May 29:S0264-410X(23)00628-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  994. ARROSPIDE A, Sagardui MG, Larizgoitia I, Iturralde A, et al
    Effectiveness of the booster dose of COVID-19 vaccine in the Basque Country during the sixth wave: A nationwide cohort study.
    Vaccine. 2023 May 29:S0264-410X(23)00622-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  995. HU S, Xiong C, Zhao Y, Yuan X, et al
    Vaccination, human mobility, and COVID-19 health outcomes: Empirical comparison before and during the outbreak of SARS-Cov-2 B.1.1.529 (Omicron) variant.
    Vaccine. 2023 May 29:S0264-410X(23)00617-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  996. PAYNTER J, Howe AS, Best E, Petousis-Harris H, et al
    A retrospective cohort study investigating the comparative effectiveness of pneumococcal vaccines against hospitalisation with otitis media and pneumonia in New Zealand.
    Vaccine. 2023 May 25:S0264-410X(23)00591-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  997. MILLER ER, Moro PL, Shimabukuro TT, Carlock G, et al
    COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office.
    Vaccine. 2023 May 24:S0264-410X(23)00613-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  998. HORI D, Keneda Y, Ozaki A, Tabuchi T, et al
    Sexual orientation was associated with intention to be vaccinated with a smallpox vaccine against mpox: A cross-sectional preliminary survey in Japan.
    Vaccine. 2023 May 24:S0264-410X(23)00611-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  999. CURTIS MG, Davoudpour S, Rodriguez-Ortiz AE, Felt D, et al
    Predictors of Mpox vaccine uptake among sexual and gender minority young adults living in Illinois: Unvaccinated vs. double vs. single dose vaccine recipients.
    Vaccine. 2023 May 24:S0264-410X(23)00593-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1000. RAO S, Abeyratne E, Freitas JR, Yang C, et al
    A booster regime of liposome-delivered live-attenuated CHIKV vaccine RNA genome protects against chikungunya virus disease in mice.
    Vaccine. 2023 May 23:S0264-410X(23)00571-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1001. MOHAMMED AM, Musa A, Etapelong SG, Bolori MT, et al
    Expanding polio surveillance reach beyond vaccination reach in Borno State, Nigeria: The contribution of community informants from insecure areas engaged to conduct polio surveillance in security compromised areas, 2018-2019.
    Vaccine. 2023 May 23:S0264-410X(23)00547-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1002. CHOUDHARY P, Boamah B, Hon Ng S, White A, et al
    Solidified saturated fats coating subunit vaccines greatly extended vaccine booster release and contributed to a Th1/Th2 mixed immune response in mice.
    Vaccine. 2023 May 23:S0264-410X(23)00550-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1003. NUGENT C, Abul Y, White EM, Shehadeh F, et al
    Second monovalent SARS-CoV-2 mRNA booster restores Omicron-specific neutralizing activity in both nursing home residents and health care workers.
    Vaccine. 2023;41:3403-3409.
    PubMed     Abstract available


  1004. WANG R, Fan X, Jiang Y, Li G, et al
    Immunogenicity and efficacy analyses of EPC002, ECA006, and EPCP009 protein subunit combinations as tuberculosis vaccine candidates.
    Vaccine. 2023 May 22:S0264-410X(23)00385-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1005. EGER J, Kaplan LC, Sternberg H
    How to reduce vaccination hesitancy? The relevance of evidence and its communicator.
    Vaccine. 2023 May 22:S0264-410X(23)00298-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1006. ALICANDRO G, Orena BS, Rosazza C, Cariani L, et al
    Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis.
    Vaccine. 2023 May 22:S0264-410X(23)00590-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1007. GHAZNAVI C, Eguchi A, Suu Lwin K, Yoneoka D, et al
    Estimating global changes in routine childhood vaccination coverage during the COVID-19 pandemic, 2020-2021.
    Vaccine. 2023 May 22:S0264-410X(23)00583-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1008. GUO BQ, Li HB, Yang LQ
    Incidence of myopericarditis after mRNA COVID-19 vaccination: A meta-analysis with focus on adolescents aged 12-17 years.
    Vaccine. 2023 May 22:S0264-410X(23)00610-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1009. BOLSEWICZ KT, Steffens MS, King C, Abdi I, et al
    A qualitative study on COVID-19 pandemic impacts on parental attitudes and intentions for routine adolescent vaccinations: The role of trust.
    Vaccine. 2023 May 22:S0264-410X(23)00586-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1010. JOUDEH AI, Lutf AQ, Mahdi S, Tran G, et al
    Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.
    Vaccine. 2023 May 22:S0264-410X(23)00609-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1011. EMBI PJ, Levy ME, Patel P, DeSilva MB, et al
    Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021.
    Vaccine. 2023 May 22:S0264-410X(23)00588-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1012. MALO B, Labbe F, Meyer SB, Filice E, et al
    "I Want People to Be Able to Make an Informed Choice": How Quebec naturopaths discuss vaccination in their practice.
    Vaccine. 2023 May 18:S0264-410X(23)00553-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1013. SHAW CA, August A, Bart S, Booth PJ, et al
    A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults.
    Vaccine. 2023 May 18:S0264-410X(23)00488-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1014. BOING AF, Boing AC, Barberia L, Borges ME, et al
    Uncovering inequities in Covid-19 vaccine coverage for adults and elderly in Brazil: A multilevel study of 2021-2022 data.
    Vaccine. 2023 May 17:S0264-410X(23)00569-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1015. MARTINON-TORRES F, Wysocki J, Szenborn L, Carmona-Martinez A, et al
    A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
    Vaccine. 2023;41:3387-3398.
    PubMed     Abstract available


  1016. WANLAPAKORN N, Pruetarat N, Sarawanangkoor N, Phanphanit K, et al
    Immunogenicity of the pentavalent DTwP-HB-Hib vaccine (Shan-5) used in the Thai Expanded Program on Immunization compared to the hexavalent DTaP-HB-Hib-IPV and DTwP-HB-Hib (Quinvaxem) vaccines administered to infants at 2, 4, 6 months of age.
    Vaccine. 2023 May 16:S0264-410X(23)00541-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1017. ZHOU ZH, Cortese MM, Fang JL, Wood R, et al
    Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.
    Vaccine. 2023 May 16:S0264-410X(23)00568-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1018. LIMAYE RJ, Singh P, Paul A, Fesshaye B, et al
    COVID-19 vaccine decision-making among pregnant and lactating women in Bangladesh.
    Vaccine. 2023 May 15:S0264-410X(23)00551-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1019. SUN W
    Monkeypox, smallpox, FDA, and accelerated approval of vaccines - A regulatory perspective.
    Vaccine. 2023 May 15:S0264-410X(23)00526-1. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1020. SHATO T, Humble S, Anandarajah A, Barnette A, et al
    Influences of sociodemographic characteristics and parental HPV vaccination hesitancy on HPV vaccination coverage in five US states.
    Vaccine. 2023 May 15:S0264-410X(23)00517-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1021. BLACK SB, Chandler RE, Edwards KM, Sturkenboom MCJM, et al
    Assessing vaccine safety during a pandemic: Recent experience and lessons learned for the future.
    Vaccine. 2023 May 15:S0264-410X(23)00468-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1022. OHM M, van Straalen JW, Zijlstra M, de Joode-Smink G, et al
    Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: A prospective observational cohort study.
    Vaccine. 2023 May 15:S0264-410X(23)00480-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1023. GARCIA-FOGEDA I, Besbassi H, Lariviere Y, Ogunjimi B, et al
    Within-host modeling to measure dynamics of antibody responses after natural infection or vaccination: A systematic review.
    Vaccine. 2023 May 15:S0264-410X(23)00422-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1024. SURIE D, Bonnell LN, DeCuir J, Gaglani M, et al
    Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022.
    Vaccine. 2023 May 15:S0264-410X(23)00567-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1025. MARRON L, Ferenczi A, O'Brien KM, Cotter S, et al
    A national survey of parents' views on childhood vaccinations in Ireland.
    Vaccine. 2023 May 13:S0264-410X(23)00522-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1026. GEORGE TK, Nair NP, Singh AK, Dilesh Kumar A, et al
    Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach.
    Vaccine. 2023 May 12:S0264-410X(23)00486-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1027. VESIKARI T, Langley JM, Spaans JN, Petrov I, et al
    The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine.
    Vaccine. 2023 May 11:S0264-410X(23)00528-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1028. CHOI Y, Lee GS, Li S, Lee JW, et al
    Hepatitis B vaccine delivered by microneedle patch: Immunogenicity in mice and rhesus macaques.
    Vaccine. 2023 May 11:S0264-410X(23)00524-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1029. PIERRE E, Pladys A, Bayat-Makoei S, Tattevin P, et al
    Pneumococcal vaccination coverage at the initiation of chronic dialysis, and its association with mortality during the first year.
    Vaccine. 2023 May 11:S0264-410X(23)00521-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1030. KEHAGIA E, Papakyriakopoulou P, Valsami G
    Advances in intranasal vaccine delivery: A promising non-invasive route of immunization.
    Vaccine. 2023 May 11:S0264-410X(23)00529-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1031. MIDDLETON BF, Danchin M, Cunliffe NA, Jones MA, et al
    Histo-blood group antigen profile of Australian Aboriginal children and seropositivity following oral rotavirus vaccination.
    Vaccine. 2023 May 11:S0264-410X(23)00525-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1032. ROBERTS-MCCARTHY E, Buck PO, Smith-Ray RL, Van de Velde N, et al
    Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic.
    Vaccine. 2023 May 11:S0264-410X(23)00383-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1033. VAN IERSEL SCJL, McDonald SA, de Gier B, Knol MJ, et al
    Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022.
    Vaccine. 2023 May 10:S0264-410X(23)00545-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1034. GOVINDAN V, Ganaie FA, Ramakrishnan SM, Ravindran S, et al
    Estimation of baseline IgG antibody levels to 23 pneumococcal vaccine-type capsular polysaccharides in healthy vaccine naive Indian adults.
    Vaccine. 2023 May 10:S0264-410X(23)00497-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1035. RUBIN THOMPSON LJ, Grubo M, Veller M, Badenhorst RH, et al
    Building global vaccine manufacturing capacity: Spotlight on Africa.
    Vaccine. 2023 May 10:S0264-410X(23)00527-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1036. WILSON RJ, Leigh L, Bah H, Larson HJ, et al
    HPV vaccination acceptance and perceptions related to fertility and population control in the Gambia: An anthropological analysis.
    Vaccine. 2023 May 10:S0264-410X(23)00508-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1037. LANGLETE P, Tesli M, Veneti L, Starrfelt J, et al
    Estimated vaccine effectiveness against SARS-CoV-2 Delta and Omicron infections among health care workers and the general adult population in Norway, August 2021 - January 2022.
    Vaccine. 2023 May 10:S0264-410X(23)00549-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1038. SMITH K, Hegazy K, Cai MR, McKnight I, et al
    Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials.
    Vaccine. 2023 May 10:S0264-410X(23)00543-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1039. BERRY A, Kapelus D, Singh P, Groome M, et al
    ABO blood types, but not Secretor or Lewis blood types, influence strength of antibody response to Hepatitis B vaccine in Black South African children.
    Vaccine. 2023 May 9:S0264-410X(23)00465-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1040. HIEBERT J, Saboui M, Frost JR, Zubach V, et al
    Mumps resurgence in a highly vaccinated population: Insights gained from surveillance in Canada, 2002-2020.
    Vaccine. 2023 May 9:S0264-410X(23)00513-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1041. CHIAVENNA C, Leone LP, Melegaro A, Rotesi T, et al
    Personal risk or societal benefit? Investigating adults' support for COVID-19 childhood vaccination.
    Vaccine. 2023 May 9:S0264-410X(23)00544-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1042. OLUSANYA OA, Tomar A, Thomas J, Alonge K, et al
    Application of the theoretical domains framework to identify factors influencing catch-up HPV vaccinations among male college students in the United States: A review of evidence and recommendations.
    Vaccine. 2023 May 8:S0264-410X(23)00509-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1043. SUTTON WJH, Branham PJ, Williamson YM, Cooper HC, et al
    Quantification of SARS-CoV-2 spike protein expression from mRNA vaccines using isotope dilution mass spectrometry.
    Vaccine. 2023 May 8:S0264-410X(23)00458-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1044. BORDALO FERREIRA F, Rafael MA, Coimbra L, Boavida N, et al
    Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.
    Vaccine. 2023 May 8:S0264-410X(23)00530-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1045. KURIYAMA K, Murakami K, Masuda T, Sugiura K, et al
    Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
    Vaccine. 2023 May 8:S0264-410X(23)00519-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1046. FITZ-PATRICK D, Young M, Yacisin K, McElwee K, et al
    Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults >/=65 years old.
    Vaccine. 2023 May 8:S0264-410X(23)00520-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1047. GOLDBLATT D, Andrews NJ, Sheppard CL, Rose S, et al
    Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants.
    Vaccine. 2023;41:3019-3023.
    PubMed     Abstract available


  1048. KPOZEHOUEN EB, Heywood AE, Menzies R, Seale H, et al
    Informing the design of a whole of life immunisation register for Australia.
    Vaccine. 2023;41:3011-3018.
    PubMed     Abstract available


  1049. LEWIS CY, Mishra K, Sun Y, Sechrist SJ, et al
    Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data.
    Vaccine. 2023 May 5:S0264-410X(23)00491-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1050. CZIBENER C, Rey Serantes DA, Romani AM, Bruno L, et al
    Bm Delta-pgm, a vaccine for the control of Brucella melitensis with cross-species protective properties.
    Vaccine. 2023 May 5:S0264-410X(23)00511-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1051. RODRIGUEZ DM, Major CG, Sanchez-Gonzalez L, Jones E, et al
    Dengue vaccine acceptability before and after the availability of COVID-19 vaccines in Puerto Rico.
    Vaccine. 2023 May 5:S0264-410X(23)00516-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1052. KINGSLEY T, Phelan D, Poland GA
    Corrigendum to "A review of 2023 adult immunization schedule updates" [Vaccine 41(16) (2023) 2631-2633].
    Vaccine. 2023 May 3:S0264-410X(23)00462-0. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1053. TALBIRD SE, Anderson SA, Nossov M, Beattie N, et al
    Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis B in adults in the United States.
    Vaccine. 2023 May 3:S0264-410X(23)00414-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1054. KU JH, Sy LS, Qian L, Ackerson BK, et al
    Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study.
    Vaccine. 2023 May 3:S0264-410X(23)00498-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1055. BERAN J, Lattanzi M, Costantini M, Pammolli A, et al
    Sustained antibody persistence for at least 15 years after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules: Third 5-year follow-up.
    Vaccine. 2023 May 2:S0264-410X(23)00485-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1056. VOSS SS, Norgaard SK, Valentiner-Branth P
    Identification of subgroups in the Danish population for targeted human papillomavirus vaccination efforts.
    Vaccine. 2023 May 2:S0264-410X(23)00484-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1057. FUKUNAGA R, Kaplan ZE, Rodriguez T, Hagan L, et al
    Attitudes towards COVID-19 vaccination among incarcerated persons in the Federal Bureau of Prisons, June-July 2021.
    Vaccine. 2023 May 2:S0264-410X(23)00512-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1058. SIDDIQUE M, Iftikhar S, Dharma VK, Shah MT, et al
    Using geographic information system to track children and optimize immunization coverage and equity in Karachi, Pakistan.
    Vaccine. 2023;41:2922-2931.
    PubMed     Abstract available


  1059. VEREEN RJ, Aden JK, Drumm CM
    Newborn medication adherence and childhood under-immunization in military beneficiaries.
    Vaccine. 2023;41:2887-2892.
    PubMed     Abstract available


  1060. LEFFERTS B, Bruden D, Plumb ID, Hodges E, et al
    Effectiveness of the COVID-19 vaccines on preventing symptomatic SARS-CoV-2 infections and hospitalizations in Southwestern Alaska, January-December 2021.
    Vaccine. 2023 May 1:S0264-410X(23)00496-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1061. MESINA FZ, Sapinoso FAD, De Castro JAV, Vaswani PPM, et al
    Hematologic adverse events reported after COVID-19 vaccination in the Philippines: A national database study.
    Vaccine. 2023 May 1:S0264-410X(23)00490-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1062. KUHLBRANDT C, McGowan CR, Stuart R, Grenfell P, et al
    COVID-19 vaccination decisions among Gypsy, Roma, and Traveller communities: A qualitative study moving beyond "vaccine hesitancy".
    Vaccine. 2023 May 1:S0264-410X(23)00515-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1063. HUSSAINI L, Labberton AS, Winje BA, Kraft KB, et al
    COVID-19 vaccination rates among adolescents (12-17 years) by immigrant background and sociodemographic factors: A nationwide registry study in Norway.
    Vaccine. 2023 May 1:S0264-410X(23)00514-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    April 2023
  1064. CHU K, Li Y, Yu D, Song Y, et al
    Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study.
    Vaccine. 2023 Apr 29:S0264-410X(23)00259-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1065. MARCHESE AM, Zhou X, Kinol J, Underwood E, et al
    NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.
    Vaccine. 2023 Apr 29:S0264-410X(23)00467-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1066. HALSEY N, Evans S, Santosham M, Hacker A, et al
    Considerations for unblinding individual study participants during vaccine trials.
    Vaccine. 2023 Apr 28:S0264-410X(23)00425-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1067. COSTA JP, Jesus S, Colaco M, Duarte A, et al
    Endotoxin contamination of nanoparticle formulations: A concern in vaccine adjuvant mechanistic studies.
    Vaccine. 2023 Apr 28:S0264-410X(23)00487-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1068. IMMINK MM, van der Maas NAT, de Melker HE, Ferreira JA, et al
    Socio-psychological determinants of second trimester maternal pertussis vaccination acceptance in the Netherlands.
    Vaccine. 2023 Apr 28:S0264-410X(23)00482-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1069. BLACK S, Evans S
    Serious adverse events following mRNA vaccination in randomized trials in adults.
    Vaccine. 2023 Apr 28:S0264-410X(23)00432-2. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1070. VANNI T, da Graca Salomao M, Viscondi JYK, Braga PE, et al
    A randomized, double-blind, non-inferiority trial comparing the immunogenicity and safety of two seasonal inactivated influenza vaccines in adults.
    Vaccine. 2023 Apr 28:S0264-410X(23)00464-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1071. DE LA TORRE ARRIETA J, Briceno D, de Castro IG, Roser B, et al
    A thermostable tetanus/diphtheria (Td) vaccine in the StablevaX pre-filled delivery system.
    Vaccine. 2023 Apr 28:S0264-410X(23)00431-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1072. KOEN AL, Izu A, Baillie V, Kwatra G, et al
    Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
    Vaccine. 2023 Apr 27:S0264-410X(23)00483-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1073. KIM C, Aminawung JA, Brinkley-Rubinstein L, Wang EA, et al
    COVID-19 vaccine deliberation in individuals directly impacted by incarceration.
    Vaccine. 2023 Apr 26:S0264-410X(23)00492-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1074. GREENBERG V, Vazquez-Benitez G, Kharbanda EO, Daley MF, et al
    Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes.
    Vaccine. 2023 Apr 26:S0264-410X(23)00457-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1075. SHARFF KA, Tandy TK, Lewis PF, Johnson ES, et al
    Cardiac events following JYNNEOS vaccination for prevention of Mpox.
    Vaccine. 2023 Apr 26:S0264-410X(23)00466-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1076. ALSUHEBANY N, Alowais SA, Aldairem A, Almohareb SN, et al
    Identifying gaps in vaccination perception after mandating the COVID-19 vaccine in Saudi Arabia.
    Vaccine. 2023 Apr 26:S0264-410X(23)00481-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1077. LU X, Masuda S, Horlad H, Katoh T, et al
    Safety and adverse effects of the coronavirus disease 2019 vaccine among the general Japanese adult population.
    Vaccine. 2023 Apr 26:S0264-410X(23)00469-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1078. SMITH MJ, Emanuel EJ
    Learning from five bad arguments against mandatory vaccination.
    Vaccine. 2023 Apr 25:S0264-410X(23)00461-9. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1079. KIM SJ, Kwon SL, Lee JY, Oh J, et al
    Why school is crucial to increase vaccination coverage for children: Evaluation of school vaccination check program in South Korea 2021-2022.
    Vaccine. 2023 Apr 25:S0264-410X(23)00430-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1080. JIANG M, Vaisanen E, Kolehmainen P, Huttunen M, et al
    COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs.
    Vaccine. 2023 Apr 25:S0264-410X(23)00463-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1081. CAI B, Peyrani P, Beeslaar J, Burman C, et al
    Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp.
    Vaccine. 2023;41:2729-2733.
    PubMed     Abstract available


  1082. WALTER D, Ophir Y, Ye H
    Conspiracies, misinformation and resistance to public health measures during COVID-19 in white nationalist online communication.
    Vaccine. 2023;41:2868-2877.
    PubMed     Abstract available


  1083. CHARLTON CL, Bailey AM, Thompson LA, Kanji JN, et al
    What's in a number? The value of titers as routine proof of immunity for medical students.
    Vaccine. 2023;41:2734-2738.
    PubMed     Abstract available


  1084. KLOSE SM, De Souza DP, Disint JF, Andrews DM, et al
    Reversion of mutations in a live mycoplasma vaccine alters its metabolism.
    Vaccine. 2023 Apr 24:S0264-410X(23)00459-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1085. ROPER RL, Garzino-Demo A, Del Rio C, Brechot C, et al
    Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategies.
    Vaccine. 2023 Apr 21:S0264-410X(23)00393-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1086. MA L, Brecher M, Soufal A, Gaiotto T, et al
    Structural interrogation of a trimeric prefusion RSV fusion protein vaccine candidate by a camelid nanobody.
    Vaccine. 2023 Apr 19:S0264-410X(23)00413-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1087. CLARKE L, Brighton T, Chunilal SD, Lee CSM, et al
    Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem.
    Vaccine. 2023 Apr 19:S0264-410X(23)00379-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1088. TERRINONI M, Nordqvist SL, Lofstrand M, Nilsson F, et al
    A thermostable, dry formulation inactivated Hikojima whole cell/cholera toxin B subunit oral cholera vaccine.
    Vaccine. 2023 Apr 19:S0264-410X(23)00387-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1089. GIRNDT M, Houser P, Manllo-Karim R, Ervin JE, et al
    Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease.
    Vaccine. 2023 Apr 19:S0264-410X(23)00420-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1090. BAO Y, He L, Miao B, Zhong Z, et al
    BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai.
    Vaccine. 2023 Apr 19:S0264-410X(23)00377-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1091. TOPAZIAN HM, Schmit N, Gerard-Ursin I, Charles GD, et al
    Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis.
    Vaccine. 2023 Apr 18:S0264-410X(23)00394-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1092. PILLSBURY A, Phillips A, Deng L, Quinn H, et al
    Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines.
    Vaccine. 2023 Apr 18:S0264-410X(23)00441-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1093. MIDDELDORP M, Steens A, Lagerweij G, van Sorge NM, et al
    The burden of invasive meningococcal disease in the Netherlands, 2011-2020.
    Vaccine. 2023;41:2664-2670.
    PubMed     Abstract available


  1094. HOUTSMA C, Raines AM, Reggio A, Rushing LK, et al
    COVID-19 vaccine distribution: A high reliability organization approach.
    Vaccine. 2023 Apr 17:S0264-410X(23)00423-1. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1095. GORDON SF, Lam J, Vasquez JT, Cercone R, et al
    A tailored COVID-19 vaccination pathway for children 5-11 years in Victoria, Australia.
    Vaccine. 2023 Apr 17:S0264-410X(23)00424-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1096. TCHOUALEU DD, Fleming M, Traicoff DA
    A systematic review of pre-service training on vaccination and immunization.
    Vaccine. 2023 Apr 15:S0264-410X(23)00369-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1097. KANG B, Goldlust S, Lee EC, Hughes J, et al
    Spatial distribution and determinants of childhood vaccination refusal in the United States.
    Vaccine. 2023 Apr 15:S0264-410X(23)00402-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1098. LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Biela M, et al
    COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS).
    Vaccine. 2023 Apr 14:S0264-410X(23)00427-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1099. FREITAG TL, Fagerlund R, Karam NL, Leppanen VM, et al
    Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Vaccine. 2023 Apr 14:S0264-410X(23)00403-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1100. KUAN-MAHECHA MA, Rahman S, Martinez-Rivera P, Lamb MM, et al
    Differences in parental vaccine confidence and attitudes by health system in Guatemala and their impact on immunization timeliness.
    Vaccine. 2023 Apr 13:S0264-410X(23)00371-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1101. ANDRAUD M, Herve S, Gorin S, Barbier N, et al
    Evaluation of early single dose vaccination on swine influenza A virus transmission in piglets: From experimental data to mechanistic modelling.
    Vaccine. 2023 Apr 13:S0264-410X(23)00401-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1102. KATTSTROM M, Uggla B, Tina E, Kimby E, et al
    Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia.
    Vaccine. 2023 Apr 13:S0264-410X(23)00399-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1103. FORTUNA LBDP, Miranda FM, Antunes IMF, Silva AB, et al
    Prevalence, capsular types, antimicrobial resistance and risk factors associated with pneumococcal carriage among children after long-term 10-valent pneumococcal conjugate vaccine use in Brazil.
    Vaccine. 2023 Apr 13:S0264-410X(23)00415-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1104. LI J, Shi LW, Yu BW, Huang LR, et al
    Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial.
    Vaccine. 2023 Apr 13:S0264-410X(23)00392-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1105. KHANAM F, Babu G, Rahman N, Liu X, et al
    Immune responses in children after vaccination with a typhoid Vi-tetanus toxoid conjugate vaccine in Bangladesh.
    Vaccine. 2023 Apr 13:S0264-410X(23)00397-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1106. ESTEPHAN L, Lin YC, Lin YT, Chen YH, et al
    Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.
    Vaccine. 2023 Apr 12:S0264-410X(23)00421-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1107. YOUNG G, Zahralban-Steele M, Dean HJ
    Impact of prior flavivirus vaccination on immunogenicity and efficacy of an inactivated Zika vaccine in Indian rhesus macaques.
    Vaccine. 2023 Apr 11:S0264-410X(23)00398-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1108. KIM GL, Pyo SW, Yi H, Kim SH, et al
    Immunogenicity and Protective Efficacy of Recombinant Protective Antigen Anthrax Vaccine (GC1109) in A/J Mice Model.
    Vaccine. 2023 Apr 11:S0264-410X(23)00386-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1109. UEMURA K, Ono S, Michihata N, Yamana H, et al
    Duration of influenza vaccine effectiveness in the elderly in Japan: A retrospective cohort study using large-scale population-based registry data.
    Vaccine. 2023 Apr 10:S0264-410X(23)00373-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1110. RATHORE APS, St John AL
    Promises and challenges of mucosal COVID-19 vaccines.
    Vaccine. 2023 Apr 10:S0264-410X(23)00396-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1111. KAWADE A, Dayma G, Apte A, Telang N, et al
    Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (Synflorix(TM) and Prevenar13(TM))) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-lab
    Vaccine. 2023 Apr 10:S0264-410X(23)00388-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1112. PERKINS-OINES S, Dias N, Krafsur G, Abdelsalam K, et al
    The effect of neonatal vaccination for bovine respiratory disease in the face of a dual challenge with bovine viral diarrhea virus and Mannheimia hemolytica.
    Vaccine. 2023 Apr 10:S0264-410X(23)00391-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1113. CHANG CC, Algaissi A, Lai CC, Chang CK, et al
    Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus.
    Vaccine. 2023 Apr 10:S0264-410X(23)00390-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1114. DOLD C, Zhu H, Silva-Reyes L, Blackwell L, et al
    Immunisation with purified Coxiella burnetii phase I lipopolysaccharide confers partial protection in mice independently of co-administered adenovirus vectored vaccines.
    Vaccine. 2023 Apr 8:S0264-410X(23)00395-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1115. HARRIS C, Cottrell S, Perry M, Meaden R, et al
    A pilot intervention to improve uptake and equality of childhood influenza vaccination in an area of Wales, through the introduction of a mixed delivery model including nursery school immunisation sessions.
    Vaccine. 2023 Apr 8:S0264-410X(23)00382-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1116. HARRIS JN, Mauro CM, Morgan TL, de Roche A, et al
    Factors impacting parental uptake of COVID-19 vaccination for U.S. Children ages 5-17.
    Vaccine. 2023 Apr 7:S0264-410X(23)00384-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1117. HAMAD SAIED M, van Straalen JW, de Roock S, de Joode-Smink GCJ, et al
    Safety of Measles-Mumps-Rubella booster vaccination in patients with juvenile idiopathic arthritis: A long-term follow-up study.
    Vaccine. 2023 Apr 7:S0264-410X(23)00381-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1118. JAGNE I, von Mollendorf C, Wee-Hee A, Ortika B, et al
    A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age.
    Vaccine. 2023 Apr 7:S0264-410X(23)00370-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1119. VARGAS-ZAMBRANO JC, Clark LR, Johnson DR, Monfredo C, et al
    Prenatal tetanus-diphtheria-acellular pertussis vaccine effectiveness at preventing infant pertussis.
    Vaccine. 2023 Apr 7:S0264-410X(23)00342-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1120. LIU J, Guo S, Jin Z, Zhao K, et al
    Adjuvanted quaternized chitosan composite aluminum nanoparticles-based vaccine formulation promotes immune responses in chickens.
    Vaccine. 2023 Apr 7:S0264-410X(23)00374-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1121. LEIGH HOBBS J, Paul LA, Buchan SA, Harris T, et al
    Methodological changes implemented over time to support accurate and timely COVID-19 vaccine coverage estimates: Ontario, Canada.
    Vaccine. 2023 Apr 7:S0264-410X(23)00389-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1122. SMITS PD, Gratzl S, Simonov M, Nachimuthu SK, et al
    Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities.
    Vaccine. 2023;41:2447-2455.
    PubMed     Abstract available


  1123. HEMPEL K, McDonald W, Osgood ND, Fisman D, et al
    Evaluation of the effectiveness of maternal immunization against pertussis in Alberta using agent-based modeling: A Canadian immunization research network study.
    Vaccine. 2023;41:2430-2438.
    PubMed     Abstract available


  1124. AFSAR A, Mallya A, Mohammed AAG, Anand S, et al
    Monovalent type 2 OPV (mOPV2) management in the field: Interventions and lessons learned.
    Vaccine. 2023;41 Suppl 1:A79-A84.
    PubMed     Abstract available


  1125. GOLD MS, Amarasinghe A, Greenhawt M, Kelso JM, et al
    Anaphylaxis: Revision of the Brighton collaboration case definition.
    Vaccine. 2023;41:2605-2614.
    PubMed     Abstract available


  1126. BURKHOLDER B, Wadood Z, Kassem AM, Ehrhardt D, et al
    The immediate impact of the COVID-19 pandemic on polio immunization and surveillance activities.
    Vaccine. 2023;41 Suppl 1:A2-A11.
    PubMed     Abstract available


  1127. VOORMAN A, O'Reilly K, Lyons H, Goel AK, et al
    Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies.
    Vaccine. 2023;41 Suppl 1:A105-A112.
    PubMed     Abstract available


  1128. KALKOWSKA DA, Pallansch MA, Wassilak SGF, Cochi SL, et al
    Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
    Vaccine. 2023;41 Suppl 1:A136-A141.
    PubMed     Abstract available


  1129. KALKOWSKA DA, Voorman A, Pallansch MA, Wassilak SGF, et al
    The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.
    Vaccine. 2023;41 Suppl 1:A12-A18.
    PubMed     Abstract available


  1130. PAYNE JR, Bose S, Kubiak RW, Nolen LD, et al
    Evaluation of mortality risk after COVID-19 vaccination, Utah 2021.
    Vaccine. 2023 Apr 5:S0264-410X(23)00380-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1131. WANG SM, Keegan EA, Bryan KM, Kazma J, et al
    Human papillomavirus vaccination receipt and provider counseling rates among high-risk patients.
    Vaccine. 2023 Apr 5:S0264-410X(23)00378-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1132. BRAEYE T, Catteau L, Brondeel R, van Loenhout JAF, et al
    Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022.
    Vaccine. 2023 Apr 5:S0264-410X(23)00376-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1133. MACHIDA M, Inoue S
    Patterns of HPV vaccine hesitancy among catch-up generations in Japan: A descriptive study.
    Vaccine. 2023 Apr 4:S0264-410X(23)00355-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1134. KIM H, Cho HK, Kang YM, Sagong M, et al
    Protective efficacy of a bivalent H5 influenza vaccine candidate against both clades 2.3.2.1 and 2.3.4.4 high pathogenic avian influenza viruses in SPF chickens.
    Vaccine. 2023 Apr 4:S0264-410X(23)00311-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1135. PRADA E, Langbecker A, Catalan-Matamoros D
    Public discourse and debate about vaccines in the midst of the covid-19 pandemic: A qualitative content analysis of Twitter.
    Vaccine. 2023 Apr 4:S0264-410X(23)00375-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1136. FRODLUND M, Nived P, Chatzidionysiou A, Sodergren A, et al
    The impact of immunomodulating treatment on the immunogenicity of COVID-19 vaccines in patients with immune-mediated inflammatory rheumatic diseases compared to healthy controls. A Swedish nationwide study (COVID19-REUMA).
    Vaccine. 2023 Apr 4:S0264-410X(23)00372-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1137. TOSHKOV D
    What accounts for the variation in COVID-19 vaccine hesitancy in Eastern, Southern and Western Europe?
    Vaccine. 2023 Apr 4:S0264-410X(23)00314-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1138. URQUIDI C, Santelices E, Lagomarcino AJ, Teresa Valenzuela M, et al
    The added effect of non-pharmaceutical interventions and lifestyle behaviors on vaccine effectiveness against severe COVID-19 in Chile: A matched case-double control study.
    Vaccine. 2023 Apr 3:S0264-410X(23)00354-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1139. MAQUILING A, Jeevakanthan A, Ho Mi Fane B
    The effect of vaccine mandate announcements on vaccine uptake in Canada: An interrupted time series analysis.
    Vaccine. 2023 Apr 3:S0264-410X(23)00334-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1140. ALI Y, Piche-Renaud PP, Karimi-Shahrbabak E, Farrar DS, et al
    Pediatricians' perceptions, practices, and barriers regarding COVID-19 vaccine for children: A cross-sectional survey in Ontario, Canada.
    Vaccine. 2023 Apr 3:S0264-410X(23)00335-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1141. PRASAD N, Stoecker C, Xing W, Cho BH, et al
    Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States.
    Vaccine. 2023 Apr 1:S0264-410X(23)00338-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1142. CRIADO MF, Kassa A, Bertran K, Kwon JH, et al
    Efficacy of multivalent recombinant herpesvirus of turkey vaccines against high pathogenicity avian influenza, infectious bursal disease, and Newcastle disease viruses.
    Vaccine. 2023 Apr 1:S0264-410X(23)00349-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1143. LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
    Lack of association between vaccination rates and excess mortality in Cyprus during the COVID-19 pandemic.
    Vaccine. 2023 Apr 1:S0264-410X(23)00316-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    March 2023
  1144. XU S, Zhang B, Yao J, Ruan W, et al
    A new H9 influenza virus mRNA vaccine elicits robust protective immunity against infection.
    Vaccine. 2023 Mar 31:S0264-410X(23)00343-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1145. DATAR RS, Fette LM, Hinkelman AN, Hammershaimb EA, et al
    Factors associated with COVID-19 vaccination during June-October 2021: A multi-site prospective study.
    Vaccine. 2023 Mar 31:S0264-410X(23)00352-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1146. HU Y, Wang Y, Shao T, Tang W, et al
    Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.
    Vaccine. 2023 Mar 30:S0264-410X(23)00350-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1147. STEIN-ZAMIR C, Shoob H, Abramson D
    Measles clinical presentation, hospitalization and vaccination status among children in a community-wide outbreak.
    Vaccine. 2023 Mar 29:S0264-410X(23)00337-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1148. FUKUDA H, Maeda M, Murata F
    Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study.
    Vaccine. 2023 Mar 29:S0264-410X(23)00353-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1149. SANTI LAURINI G, Montanaro N, Broccoli M, Bonaldo G, et al
    Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database.
    Vaccine. 2023 Mar 28:S0264-410X(23)00348-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1150. SU WJ, Arnold Chan K, Chuang JH, Wang TA, et al
    Acute reactions after a homologous primary COVID-19 vaccination series: Analysis of Taiwan V-Watch data.
    Vaccine. 2023 Mar 28:S0264-410X(23)00336-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1151. DUGOVICH AM, Cox TH, Weeda ER, Garner SS, et al
    First hepatitis B vaccine uptake in neonates prior to and during the COVID-19 pandemic.
    Vaccine. 2023 Mar 27:S0264-410X(23)00333-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1152. PANNUS P, Depickere S, Kemlin D, Georges D, et al
    Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naive nursing home residents and healthy adults.
    Vaccine. 2023 Mar 27:S0264-410X(23)00340-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1153. GIDENGIL CA, Parker AM, Markowitz LE, Gedlinske AM, et al
    Health care provider knowledge around shared clinical decision-making regarding HPV vaccination of adults aged 27-45 years in the United States.
    Vaccine. 2023 Mar 27:S0264-410X(23)00186-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1154. CIAPPONI A, Berrueta M, P K Parker E, Bardach A, et al
    Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis.
    Vaccine. 2023 Mar 27:S0264-410X(23)00332-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1155. HU B, Yang W, Bouanchaud P, Chongo Y, et al
    Determinants of COVID-19 vaccine acceptance in Mozambique: The role of institutional trust.
    Vaccine. 2023 Mar 27:S0264-410X(23)00347-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1156. KANG SW, Park H, Yeun Kim J, Bae JY, et al
    Comparison of culture-competent virus shedding duration of SARS-CoV-2 Omicron variant in regard to vaccination status: A prospective cohort study.
    Vaccine. 2023 Mar 27:S0264-410X(23)00339-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1157. CESUR F, Atasever Z, Ozoran Y
    Impact of vitamin D3 supplementation on COVID-19 vaccine response and immunoglobulin G antibodies in deficient women: A randomized controlled trial.
    Vaccine. 2023 Mar 27:S0264-410X(23)00341-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1158. DE SANTIS R, Faggioni G, Amoroso A, Ciammaruconi A, et al
    Durability of neutralizing antibodies against yellow fever virus after vaccination in healthy adults.
    Vaccine. 2023 Mar 24:S0264-410X(23)00284-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1159. THWAITES CL, Thanh TT, Ny NTH, Nguyet LA, et al
    Seroprotection against tetanus in southern Vietnam.
    Vaccine. 2023;41:2208-2213.
    PubMed     Abstract available


  1160. FREEMAN RE, Leary CS, Graham JM, Albers AN, et al
    Geographic proximity to immunization providers and vaccine series completion among children ages 0-24 months.
    Vaccine. 2023 Mar 22:S0264-410X(23)00297-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1161. VAN KESSEL R, Forman R, Milstein R, Mastylak A, et al
    Divergent COVID-19 vaccine policies: Policy mapping of ten European countries.
    Vaccine. 2023 Mar 22:S0264-410X(23)00320-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1162. PHOOLCHAROEN W, Shanmugaraj B, Khorattanakulchai N, Sunyakumthorn P, et al
    Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
    Vaccine. 2023 Mar 21:S0264-410X(23)00312-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1163. SATO R
    Vaccine hesitancy against COVID-19 vaccine over time in Nigeria.
    Vaccine. 2023 Mar 21:S0264-410X(23)00313-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1164. MCCARTY JM, Cassie D, Bedell L
    Immunogenicity of partial doses of live oral cholera vaccine CVD 103-HgR in children in the United States.
    Vaccine. 2023 Mar 21:S0264-410X(23)00260-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1165. XU S, Duan H, An Y, Jin X, et al
    Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE.
    Vaccine. 2023 Mar 21:S0264-410X(23)00319-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1166. YANG J, Huo X, Jiang Q, Liao Y, et al
    Preclinical safety evaluation of intradermal SARS-CoV-2 inactivated vaccine (Vero cells) administration in macaques.
    Vaccine. 2023 Mar 21:S0264-410X(23)00317-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1167. MURPHY A, Kirby A, De Blasio F
    The economic impact of the introduction of universal rotavirus vaccination on rotavirus gastroenteritis related hospitalisations in children in Ireland.
    Vaccine. 2023 Mar 20:S0264-410X(23)00257-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1168. ATMAR RL, Bernstein DI, Winokur P, Frey SE, et al
    Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial.
    Vaccine. 2023 Mar 18:S0264-410X(23)00285-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1169. WILSON GJ, Rodriguez B, Li SS, Allen M, et al
    Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.
    Vaccine. 2023 Mar 17:S0264-410X(23)00262-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1170. SHAHID S, Ahmed S, Qazi MF, Ali R, et al
    Differential coverage for vaccines in the expanded program on immunization (EPI) among children in rural Pakistan.
    Vaccine. 2023 Mar 16:S0264-410X(23)00254-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1171. NAKANO T
    Changes in vaccination administration in Japan.
    Vaccine. 2023 Mar 16:S0264-410X(23)00282-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1172. PEREZ MA, Hsiao HM, Chen X, Kunkel A, et al
    Serologic responses to COVID-19 vaccination in children with history of multisystem inflammatory syndrome (MIS-C).
    Vaccine. 2023 Mar 15:S0264-410X(23)00283-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1173. RIDDLE MS, Louis Bourgeois A, Clifford A, Jeon S, et al
    Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert convening.
    Vaccine. 2023 Mar 15:S0264-410X(23)00250-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1174. LIN JH, Huang YT, Yu JC, Chan KA, et al
    Mediation and instrumental variable analyses for vaccine-induced antibody titer against influenza B.
    Vaccine. 2023 Mar 14:S0264-410X(23)00261-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1175. LAMUDA PA, Azar A, Taylor BG, Balawajder EF, et al
    Latent class analysis of medical mistrust and COVID-19 vaccine hesitancy among adults in the United States just prior to FDA emergency use authorization.
    Vaccine. 2023 Mar 13:S0264-410X(23)00263-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1176. KELLY D, O'Donnell K, Marron L, Dwyer R, et al
    Immunocompromise among vaccinated versus unvaccinated COVID-19 cases admitted to critical care in Ireland, July to October 2021.
    Vaccine. 2023 Mar 13:S0264-410X(23)00258-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1177. WONODI C, Moss W
    Editorial from guest editors for vaccine supplement: Vaccine-derived poliovirus type 2 outbreaks after the cessation of use of oral poliovirus vaccine type 2_ 2016-2021 journal supplement.
    Vaccine. 2023 Mar 11:S0264-410X(23)00244-X. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1178. KWAK HW, Park HJ, Jung SY, Oh EY, et al
    Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants.
    Vaccine. 2023;41:1892-1901.
    PubMed     Abstract available


  1179. KIM E, He J, Kaufhold RM, McGuinness D, et al
    Evaluation of cross-protection between S. Pneumoniae serotypes 35B and 29 in a mouse model.
    Vaccine. 2023;41:1774-1777.
    PubMed     Abstract available


  1180. LIU YC, Munoz FM, Izurieta HS, Tamborska AA, et al
    Anosmia: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
    Vaccine. 2023;41:1902-1910.
    PubMed     Abstract available


  1181. SRIVASTAV A, Lu PJ, Amaya A, Dever JA, et al
    Prevalence of influenza-specific vaccination hesitancy among adults in the United States, 2018.
    Vaccine. 2023 Mar 10:S0264-410X(23)00255-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1182. ALLEMAN MM, Jorba J, Riziki Y, Henderson E, et al
    Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021.
    Vaccine. 2023 Mar 10:S0264-410X(23)00177-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1183. CLAY PA, Thompson TD, Markowitz LE, Ekwueme DU, et al
    Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States.
    Vaccine. 2023 Mar 10:S0264-410X(23)00184-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1184. SEAL AJ, Mohamed HA, Stokes-Walter R, Mohamed S, et al
    Use of an adapted participatory learning and action cycle to increase knowledge and uptake of child vaccination in internally displaced persons camps (IVACS): A cluster-randomised controlled trial.
    Vaccine. 2023 Mar 9:S0264-410X(23)00142-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1185. SYLVIE YANG R, Yang Y, Gowetski DB, Tsybovsky Y, et al
    Characterization of Flu MOSAIC nanoparticle vaccine candidate using high performance size-exclusion chromatography to support vaccine process development.
    Vaccine. 2023 Mar 9:S0264-410X(23)00248-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1186. RIVAS DRZ, Ticona JPA, Doss-Gollin S
    Lessons from the Bolivian vaccine mandate.
    Vaccine. 2023 Mar 9:S0264-410X(23)00251-7. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1187. SANCHEZ L, Nakama T, Nagai H, Matsuoka O, et al
    Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults >/= 60 years of age: Results from a phase III, randomized clinical trial.
    Vaccine. 2023 Mar 9:S0264-410X(23)00225-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1188. PLUMB ID, Fette LM, Tjaden AH, Feldstein L, et al
    Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March-October, 2021.
    Vaccine. 2023 Mar 9:S0264-410X(23)00253-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1189. IKEWAKI N, Kurosawa G, Levy GA, Preethy S, et al
    Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and beta glucans as a safer strategy in management.
    Vaccine. 2023 Mar 8:S0264-410X(23)00252-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1190. CHOWDHURY F, Aziz AB, Ahmmed F, Ahmed T, et al
    The interplay between WASH practices and vaccination with oral cholera vaccines in protecting against cholera in urban Bangladesh: Reanalysis of a cluster-randomized trial.
    Vaccine. 2023 Mar 8:S0264-410X(23)00197-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1191. MANANDHAR P, Wannemuehler K, Danovaro-Holliday MC, Nic Lochlainn L, et al
    Corrigendum to "Use of catch-up vaccinations in the second year of life (2YL) platform to close immunity gaps: A secondary DHS analysis in Pakistan, Philippines, and South Africa" [Vaccine 41(1) (2023) 61-67].
    Vaccine. 2023 Mar 8:S0264-410X(23)00168-8. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1192. GILBERT M, Ablona A, Chang HJ, Grennan T, et al
    Uptake of Mpox vaccination among transgender people and gay, bisexual and other men who have sex with men among sexually-transmitted infection clinic clients in Vancouver, British Columbia.
    Vaccine. 2023 Mar 7:S0264-410X(23)00229-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1193. BACON A, Teixeira M, Costa V, Bone P, et al
    Generation of a thermostable, oral Zika vaccine that protects against virus challenge in non-human primates.
    Vaccine. 2023 Mar 7:S0264-410X(23)00198-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1194. BOONE AC, Kulkarni RR, Cortes AL, Villalobos T, et al
    In ovo HVT vaccination enhances cellular responses at hatch and addition of poly I:C offers minimal adjuvant effects.
    Vaccine. 2023 Mar 7:S0264-410X(23)00238-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1195. YELVERTON V, Hair NL, Ghosh SH, Mfinanga SG, et al
    Corrigendum to "Beyond coverage: Rural-urban disparities in the timeliness of childhood vaccinations in Tanzania" [Vaccine 40(37) (2022) 5483-5493].
    Vaccine. 2023 Mar 6:S0264-410X(23)00218-9. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1196. HART RJ, Baumer-Mouradian S, Bone JN, Olson P, et al
    Factors associated with US caregivers' uptake of pediatric COVID-19 vaccine by race and ethnicity.
    Vaccine. 2023 Mar 6:S0264-410X(23)00242-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1197. PRYSLIAK T, Menghwar H, Perez-Casal J
    Complement-mediated killing of Mycoplasma bovis does not play a role in the protection of animals against an experimental challenge.
    Vaccine. 2023;41:1743-1752.
    PubMed     Abstract available


  1198. GELORMINI M, Gripenberg M, Marke D, Murray M, et al
    Coverage survey and lessons learned from a pre-emptive cholera vaccination campaign in urban and rural communities affected by landslides and floods in Freetown Sierra Leone.
    Vaccine. 2023 Mar 3:S0264-410X(23)00037-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1199. WU L, Yang S, Huang Z, Liu J, et al
    Safety of concomitant administration of inactivated hepatitis A vaccine with other vaccines in children under 16 years old in post-marketing surveillance.
    Vaccine. 2023 Mar 3:S0264-410X(23)00226-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1200. BAEK YJ, Kim WJ, Ko JH, Lee YJ, et al
    A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.
    Vaccine. 2023;41:1694-1702.
    PubMed     Abstract available


  1201. GRIGNOLIO CORSINI A, Zagarella RM, Adamo M, Caporale C, et al
    From COVID-19 vaccine candidates to compulsory vaccination: The attitudes of Italian citizens in the key 7-month of vaccination campaign.
    Vaccine. 2023 Mar 3:S0264-410X(23)00243-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1202. ESTEPHAN L, Liu LT, Lien CE, Smith ER, et al
    A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.
    Vaccine. 2023 Mar 3:S0264-410X(23)00245-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1203. GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al
    Willingness to vaccinate children against COVID-19 declined during the pandemic.
    Vaccine. 2023 Mar 2:S0264-410X(23)00223-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1204. XIE S, Monteiro K, Gjelsvik A
    The association between maternal influenza vaccination during pregnancy and adverse birth outcomes in the United States: Pregnancy risk Assessment Monitoring System (PRAMS).
    Vaccine. 2023 Mar 2:S0264-410X(23)00228-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1205. NEWALL AT, Beutels P, Kis Z, Towse A, et al
    Placing a value on increased flexible vaccine manufacturing capacity for future pandemics.
    Vaccine. 2023 Mar 2:S0264-410X(23)00219-0. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1206. NARII N, Kitamura T, Komukai S, Zha L, et al
    Association of pneumococcal vaccination with cardiovascular diseases in older adults: The vaccine effectiveness, networking, and universal safety (VENUS) study.
    Vaccine. 2023 Mar 2:S0264-410X(23)00240-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1207. LUDWIKOWSKA KM, Popiel A, Matkowska-Kocjan A, Olbromski MJ, et al
    COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study.
    Vaccine. 2023 Mar 2:S0264-410X(23)00227-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1208. BEAUJEAN M, Uijen RF, Langereis JD, Boccara D, et al
    The immunological effects of intradermal particle-based vaccine delivery using a novel microinjection needle studied in a human skin explant model.
    Vaccine. 2023 Mar 2:S0264-410X(23)00175-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1209. HURSTAK EE, Paasche-Orlow MK, Hahn EA, Henault LE, et al
    The mediating effect of health literacy on COVID-19 vaccine confidence among a diverse sample of urban adults in Boston and Chicago.
    Vaccine. 2023 Mar 2:S0264-410X(23)00202-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1210. NA L, Banks S, Wang PP
    Racial and ethnic disparities in COVID-19 vaccine uptake: A mediation framework.
    Vaccine. 2023 Mar 1:S0264-410X(23)00241-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    February 2023
  1211. DARWAR R, Biya O, Greene SA, Jorba J, et al
    Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020.
    Vaccine. 2023 Feb 28:S0264-410X(23)00214-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1212. AL ALAWI S, Al Zaabi O, Heffernan ME, Arulappan J, et al
    Knowledge, attitudes and acceptance toward Human papillomavirus (HPV) vaccination: Perspectives of Muslim women and men.
    Vaccine. 2023 Feb 27:S0264-410X(23)00217-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1213. ITAMOCHI M, Yazawa S, Inasaki N, Saga Y, et al
    Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
    Vaccine. 2023 Feb 27:S0264-410X(23)00222-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1214. MALTEZOU HC, Hatziantoniou S, Theodoridou K, Vasileiou K, et al
    Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.
    Vaccine. 2023 Feb 27:S0264-410X(23)00221-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1215. TAMANDJOU TCHUEM CR, Auvigne V, Vaux S, Montagnat C, et al
    Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Vaccine. 2023 Feb 27:S0264-410X(23)00216-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1216. O'KENNEDY MM, Abolnik C, Smith T, Motlou T, et al
    Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits.
    Vaccine. 2023 Feb 27:S0264-410X(23)00185-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1217. GUERIN RJ, Naeim A, Baxter-King R, Okun AH, et al
    Erratum to "Parental intentions to vaccinate children against COVID-19: Findings from a U.S. National Survey" [Vaccine 41(1) (2023) 101-108.
    Vaccine. 2023 Feb 25:S0264-410X(23)00107-X. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1218. CHANG AM, Chen CC, Lee JW, Hou DL, et al
    Effects of a novel recombinant Gonadotropin-Releasing Hormone-1 vaccine on the reproductive function of mixed-breed dogs (Canis familiaris) in Taiwan.
    Vaccine. 2023 Feb 25:S0264-410X(23)00215-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1219. BAKHSHIZADEH GASHTI A, Chahal PS, Gaillet B, Garnier A, et al
    Purification of recombinant vesicular stomatitis virus-based HIV vaccine candidate.
    Vaccine. 2023 Feb 24:S0264-410X(23)00201-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1220. ZHANG Y, Na D, Zhang W, Liu X, et al
    Development of stable HEK293T cell pools expressing CSFV E2 protein: A potential antigen expression platform.
    Vaccine. 2023;41:1573-1583.
    PubMed     Abstract available


  1221. FEITSMA EA, Janssen YF, Boersma HH, van Sleen Y, et al
    A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
    Vaccine. 2023 Feb 23:S0264-410X(23)00200-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1222. FANTINATO FFST, Wachira VK, Porto VBG, Peixoto HM, et al
    Factors associated with yellow fever vaccine failure: A systematic literature review.
    Vaccine. 2023 Feb 23:S0264-410X(23)00133-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1223. HOSSEINNEZHAD-LAZARJANI E, Doosti A, Sharifzadeh A
    Novel csuC-DNA nanovaccine based on chitosan candidate vaccine against infection with Acinetobacter baumannii.
    Vaccine. 2023 Feb 23:S0264-410X(23)00181-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1224. BENFIELD T, Ramet M, Valentini P, Seppa I, et al
    Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2).
    Vaccine. 2023 Feb 23:S0264-410X(23)00176-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1225. KABIR SULAIMAN S, Sale Musa M, Isma'il Tsiga-Ahmed F, Muhammad Dayyab F, et al
    COVID-19 vaccine hesitancy among people living with HIV in a low-resource setting: A multi-center study of prevalence, correlates and reasons.
    Vaccine. 2023 Feb 23:S0264-410X(23)00199-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1226. CANNON K, Cardona JF, Yacisin K, Thompson A, et al
    Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial.
    Vaccine. 2023 Feb 22:S0264-410X(22)01459-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1227. KASSTAN B, Chantler T, Marcus B, Mounier-Jack S, et al
    Linked poliovirus incidents in the UK, USA and Israel: Silent transmission or missed warnings of vaccine inequity?
    Vaccine. 2023 Feb 22:S0264-410X(23)00178-0. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1228. KOUIAVSKAIA D, Mirochnitchenko O, Troy S, Chumakov K, et al
    Antigenic diversity of type 1 polioviruses and its implications for the efficacy of polio vaccines.
    Vaccine. 2023 Feb 22:S0264-410X(23)00052-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1229. ZHANG H, Chen L, Huang Z, Li D, et al
    The effects of parent's health literacy and health beliefs on vaccine hesitancy.
    Vaccine. 2023 Feb 21:S0264-410X(23)00161-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1230. SABATO B, Augusto PSA, Lima Goncalves Pereira R, Coutinho Batista Esteves F, et al
    Safety and immunogenicity of the anti-cocaine vaccine UFMG-VAC-V4N2 in a non-human primate model.
    Vaccine. 2023 Feb 21:S0264-410X(23)00166-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1231. HAMBURG M, Poland GA
    The time is now for committed and comprehensive action to attain more broadly protective coronavirus vaccines: The coronavirus vaccines R&D roadmap.
    Vaccine. 2023 Feb 21:S0264-410X(23)00196-2. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1232. MOORE KA, Leighton T, Ostrowsky JT, Anderson CJ, et al
    A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy.
    Vaccine. 2023 Feb 21:S0264-410X(23)00167-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1233. MOTTA M, Callaghan T, Lunz-Trujillo K, Lockman A, et al
    Erroneous Consonance. How inaccurate beliefs about physician opinion influence COVID-19 vaccine hesitancy.
    Vaccine. 2023 Feb 20:S0264-410X(23)00195-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1234. LU L, Ma W, Johnson CH, Khan SA, et al
    In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer.
    Vaccine. 2023 Feb 20:S0264-410X(23)00183-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1235. DUDLEY MZ, Gerber JE, Budigan Ni H, Blunt M, et al
    Vaccinomics: A scoping review.
    Vaccine. 2023 Feb 18:S0264-410X(23)00135-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1236. USTYUGOVA IV, Pougatcheva S, Farrell T, Strugnell T, et al
    AF03 adjuvant improves anti-hemagglutinin and anti-neuraminidase immune responses induced by licensed seasonal quadrivalent influenza vaccines in mice.
    Vaccine. 2023 Feb 18:S0264-410X(23)00169-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1237. GEOGHEGAN S, Acosta F, Stephens LC, Gillan H, et al
    Maternity care provider acceptance of a future Group B Streptococcus vaccine - A qualitative study in three countries.
    Vaccine. 2023 Feb 18:S0264-410X(23)00172-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1238. YI W, Wang H, Qin H, Wang Q, et al
    Construction and efficacy of a new live chimeric C-strain vaccine with DIVA characteristics against classical swine fever.
    Vaccine. 2023 Feb 18:S0264-410X(23)00179-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1239. FORD A, Hwang A, Mo AX, Baqar S, et al
    Meeting Summary: Global Vaccine and Immunization Research Forum, 2021.
    Vaccine. 2023 Feb 18:S0264-410X(23)00163-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1240. SHERMAN SM, Lingley-Heath N, Lai J, Sim J, et al
    Parental acceptance of and preferences for administration of routine varicella vaccination in the UK: A study to inform policy.
    Vaccine. 2023;41:1438-1446.
    PubMed     Abstract available


  1241. RANADE D, Jena R, Patil K, Dogar V, et al
    A novel high throughput plate-based method for 2-PE quantification in novel multidose vaccines (R21 malaria, Covishield and Covovax) and combination vaccines (Hexavalent).
    Vaccine. 2023 Feb 17:S0264-410X(23)00174-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1242. PARODI A, Martini M
    History of vaccine and immunization: Vaccine-hesitancy discussion in Germany in XIX century.
    Vaccine. 2023 Feb 17:S0264-410X(23)00164-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1243. MORAIS A, Morais J, Felix M, Neto Z, et al
    Genetic and epidemiological description of an outbreak of circulating vaccine-derived polio-virus type 2 (cVDPV2) in Angola, 2019-2020.
    Vaccine. 2023 Feb 17:S0264-410X(23)00170-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1244. DA SILVA AB, Cardoso-Marques NT, Dolores IM, Teixeira LM, et al
    Carriage prevalence, serotype distribution, antimicrobial resistance, pspA typing and pilus islets of Streptococcus pneumoniae isolated from adults living in a Brazilian urban slum.
    Vaccine. 2023;41:1431-1437.
    PubMed     Abstract available


  1245. MEYER C, Goffe L, Antonopoulou V, Graham F, et al
    Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England.
    Vaccine. 2023 Feb 17:S0264-410X(23)00182-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1246. ZIMMERMANN BM, Paul KT, Araujo ER, Buyx A, et al
    The social and socio-political embeddedness of COVID-19 vaccination decision-making: A five-country qualitative interview study from Europe.
    Vaccine. 2023 Feb 16:S0264-410X(23)00139-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1247. PILIC A, Reda S, Jo CL, Burchett H, et al
    Use of existing systematic reviews for the development of evidence-based vaccination recommendations: Guidance from the SYSVAC expert panel.
    Vaccine. 2023 Feb 16:S0264-410X(23)00162-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1248. BENEDICT KPOZEHOUEN E, Arrudsivah B, Raina Macintyre C
    Knowledge, attitudes and practices of health care workers in a cardiology department on influenza vaccination.
    Vaccine. 2023 Feb 15:S0264-410X(23)00112-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1249. KLOUWENS MJ, Trentelman JJA, Barriales D, Ersoz JI, et al
    The Ixodes ricinus salivary gland proteome during feeding and B. Afzelii infection: New avenues for an anti-tick vaccine.
    Vaccine. 2023 Feb 14:S0264-410X(23)00129-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1250. WAHAB MT, Tan RKJ, Cook AR, Prem K, et al
    Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis.
    Vaccine. 2023 Feb 14:S0264-410X(23)00160-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1251. VOJICIC J, Grajales AG, Cane A
    Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
    Vaccine. 2023 Feb 14:S0264-410X(23)00130-5. doi: 10.1016/j.vaccine.2023.
    PubMed    


  1252. SAELEE R, Chandra Murthy N, Patel Murthy B, Zell E, et al
    Minority Health Social Vulnerability Index and COVID-19 vaccination coverage - The United States, December 14, 2020-January 31, 2022.
    Vaccine. 2023 Feb 13:S0264-410X(23)00157-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1253. WANKHEDE D, Grover S, Hofman P
    Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis.
    Vaccine. 2023 Feb 13:S0264-410X(23)00115-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1254. AFREH OK, Angwaawie P, Attivor E, Boateng LA, et al
    Examining confidence and hesitancy towards COVID-19 vaccines: A cross-sectional survey using in-person data collection in rural Ghana.
    Vaccine. 2023 Feb 13:S0264-410X(23)00159-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1255. CAMPMAN SL, van Rossem G, Boyd A, Coyer L, et al
    Intent to vaccinate against SARS-CoV-2 and its determinants across six ethnic groups living in Amsterdam, the Netherlands: A cross-sectional analysis of the HELIUS study.
    Vaccine. 2023 Feb 13:S0264-410X(23)00165-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1256. BARNES K, Faasse K, Colagiuri B
    The impact of side effect framing on COVID-19 booster vaccine intentions in an Australian sample.
    Vaccine. 2023 Feb 13:S0264-410X(23)00158-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1257. GETCHELL M, Mantaring EJ, Yee K, Pronyk P, et al
    Cost-effectiveness of sub-national geographically targeted vaccination programs: A systematic review.
    Vaccine. 2023 Feb 11:S0264-410X(23)00132-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1258. O'LEARY ST, Spina CI, Spielvogle H, Robinson JD, et al
    Development of PIVOT with MI: A motivational Interviewing-Based vaccine communication training for pediatric clinicians.
    Vaccine. 2023 Feb 10:S0264-410X(23)00136-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1259. FACCHIN G, Bella A, Del Manso M, Rota MC, et al
    Decline in reported measles cases in Italy in the COVID-19 era, January 2020 - July 2022: The need to prevent a resurgence upon lifting non-pharmaceutical pandemic measures.
    Vaccine. 2023;41:1286-1289.
    PubMed     Abstract available


  1260. SELL H, Raj Paudel Y, Voaklander D, MacDonald SE, et al
    School immunization coverage in adolescents during the COVID-19 pandemic: A retrospective cohort study.
    Vaccine. 2023;41:1333-1341.
    PubMed     Abstract available


  1261. DE VRIES M, Claassen L, Lambooij MS, Timen A, et al
    Did the temporary suspension of Vaxzveria vaccinations influence COVID-19 vaccination intentions, vaccination perceptions and trust in the vaccination campaign? A repeated survey study in the Netherlands.
    Vaccine. 2023 Feb 10:S0264-410X(23)00138-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1262. HOSAIN R, Aquino P, Baccarini C, Smolenov I, et al
    Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study.
    Vaccine. 2023 Feb 10:S0264-410X(23)00144-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1263. FEIKIN DR, Higdon MM, Andrews N, Collie S, et al
    Assessing COVID-19 vaccine effectiveness against Omicron subvariants: Report from a meeting of the World Health Organization.
    Vaccine. 2023 Feb 9:S0264-410X(23)00146-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1264. SILVA VASCONCELOS G, da Conceicao Rodrigues Fernandes M, Cardoso Matsui T, Claudia Dos Santos Luciano M, et al
    Persistent SARS-COV-2 infection in vaccinated individual with three doses of COVID-19 vaccine.
    Vaccine. 2023 Feb 9:S0264-410X(23)00145-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1265. BUNTINX E, Brochado L, Borja-Tabora C, Yu CY, et al
    Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naive and exposed individuals in a phase 2/3, double-blind, randomized study.
    Vaccine. 2023 Feb 9:S0264-410X(23)00143-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1266. OK BAIK Y, Lee Y, Lee C, Kyung Kim S, et al
    A Phase II/III, Multicenter, Observer-blinded, Randomized, Non-inferiority and Safety, study of typhoid conjugate vaccine (EuTCV) compared to Typbar-TCV(R) in healthy 6 Months-45 years aged participants.
    Vaccine. 2023 Feb 9:S0264-410X(22)01524-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1267. SHEN AK, Browne S, Srivastava T, Kornides ML, et al
    Persuading the "Movable Middle": Characteristics of effective messages to promote routine and COVID-19 vaccinations for adults and children - The impact of COVID-19 on beliefs and attitudes.
    Vaccine. 2023 Feb 9:S0264-410X(23)00141-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1268. WATANABE A, Iwagami M, Yasuhara J, Takagi H, et al
    Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis.
    Vaccine. 2023 Feb 8:S0264-410X(23)00134-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1269. PERETTI A, Scorpio DG, Kong WP, Pang YS, et al
    A multivalent polyomavirus vaccine elicits durable neutralizing antibody responses in macaques.
    Vaccine. 2023 Feb 8:S0264-410X(23)00128-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1270. BUGHIN J, Cincera M, Peters K, Reykowska D, et al
    Make it or break it: On-time vaccination intent at the time of Covid-19.
    Vaccine. 2023 Feb 8:S0264-410X(23)00140-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1271. DENG HM, Romero N, Allard N, Rowe S, et al
    Uptake of perinatal immunoprophylaxis for infants born to women with a record of hepatitis B in Victoria (2009-2017).
    Vaccine. 2023 Feb 7:S0264-410X(23)00076-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1272. ERDEM R, De Coster I, Withanage K, Mercer LD, et al
    Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study.
    Vaccine. 2023 Feb 4:S0264-410X(23)00078-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1273. FELL DB, Torok E, Sprague AE, Regan AK, et al
    Temporal trends and determinants of COVID-19 vaccine coverage and series initiation during pregnancy in Ontario, Canada, December 2020 to December 2021: A population-based retrospective cohort study.
    Vaccine. 2023 Feb 3:S0264-410X(23)00114-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1274. HASSAN RAZA S, Yousaf M, Zaman U, Waheed Khan S, et al
    Unlocking infodemics and mysteries in COVID-19 vaccine hesitancy: Nexus of conspiracy beliefs, digital informational support, psychological Well-being, and religious fatalism.
    Vaccine. 2023 Feb 3:S0264-410X(23)00079-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1275. SEESEN M, Jearanaiwitayakul T, Limthongkul J, Midoeng P, et al
    A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells.
    Vaccine. 2023 Feb 3:S0264-410X(23)00096-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1276. PARK I, Unger ER, Kemp TJ, Pinto LA, et al
    The second HPV serology meeting: Progress and challenges in standardization of human papillomavirus serology assays.
    Vaccine. 2023;41:1177-1181.
    PubMed     Abstract available


  1277. LI R, Liu H, Fairley CK, Ong JJ, et al
    mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia.
    Vaccine. 2023 Feb 3:S0264-410X(23)00126-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1278. MALTEZOU HC, Basoulis D, Bonelis K, Gamaletsou MN, et al
    Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece.
    Vaccine. 2023 Feb 2:S0264-410X(23)00109-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1279. ANDREJKO KL, Myers JF, Fukui N, Nelson L, et al
    Real-world uptake of COVID-19 vaccination among individuals expressing vaccine hesitancy: A registry-linkage study.
    Vaccine. 2023 Feb 1:S0264-410X(23)00108-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1280. HAMADA H, Futamura M, Ito H, Yamamoto R, et al
    Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study.
    Vaccine. 2023 Feb 1:S0264-410X(23)00082-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1281. JOHNSON R, Djaafara B, Haw D, Doohan P, et al
    The societal value of SARS-CoV-2 booster vaccination in Indonesia.
    Vaccine. 2023 Feb 1:S0264-410X(23)00110-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    January 2023
  1282. UWAMINO Y, Yokoyama T, Sato Y, Shibata A, et al
    Humoral and cellular immune response dynamics in Japanese healthcare workers up to six months after receiving a third dose of BNT162b2 monovalent vaccine.
    Vaccine. 2023 Jan 31:S0264-410X(23)00081-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1283. PATRICIA WODI A, Marquez P, Mba-Jonas A, Barash F, et al
    Spontaneous reports of primary ovarian insufficiency after vaccination: A review of the vaccine adverse event reporting system (VAERS).
    Vaccine. 2023 Jan 31:S0264-410X(22)01563-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1284. STONE AE, Rambaran S, Trinh IV, Estrada M, et al
    Route and antigen shape immunity to dmLT-adjuvanted vaccines to a greater extent than biochemical stress or formulation excipients.
    Vaccine. 2023 Jan 31:S0264-410X(23)00055-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1285. HUANG CY, Chi H, Chang L, Chiu NC, et al
    Typical time courses and appearance of skin reactions at the site of Bacillus Calmette-Guerin vaccination for infants inoculated at 5-8 months of age.
    Vaccine. 2023 Jan 30:S0264-410X(23)00083-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1286. KABIR SULAIMAN S, Isma'il Tsiga-Ahmed F, Sale Musa M, Kabir Sulaiman A, et al
    Prevalence, determinants, and reasons for malaria vaccine hesitancy among caregivers of under-five children in Nigeria: Results from a nationwide cross-sectional survey.
    Vaccine. 2023 Jan 30:S0264-410X(23)00089-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1287. RAABE V, Lai L, Morales J, Xu Y, et al
    Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVDeltaG-ZEBOV-GP).
    Vaccine. 2023 Jan 30:S0264-410X(23)00090-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1288. SESHADRI S, Martin SW, Hills SL, Collins LC Jr, et al
    Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011-August 2019.
    Vaccine. 2023 Jan 30:S0264-410X(23)00093-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1289. GRESSENS SB, Wiedemann A, Dechenaud M, Dupuis J, et al
    Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies.
    Vaccine. 2023 Jan 30:S0264-410X(23)00095-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1290. HARBIN A, Laventhal N, Navin M
    Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19.
    Vaccine. 2023 Jan 27:S0264-410X(23)00087-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1291. PARODI JB, Indavere A, Bobadilla Jacob P, Toledo GC, et al
    Impact of COVID-19 vaccination in post-COVID cardiac complications.
    Vaccine. 2023 Jan 27:S0264-410X(23)00084-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1292. MATTA MG, Pulido L, Herrera-Paz JJ, Picco JM, et al
    Influenza and pneumococcal vaccine prescription for adults during COVID-19 first wave in three regions of Argentina.
    Vaccine. 2023 Jan 27:S0264-410X(23)00088-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1293. BARAL R, Levin A, Odero C, Pecenka C, et al
    Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program.
    Vaccine. 2023 Jan 27:S0264-410X(23)00064-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1294. PIRAS-DOUCE F, Broudic K, Chautard E, Raynal F, et al
    Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
    Vaccine. 2023 Jan 24:S0264-410X(22)01464-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1295. SUZUKI F, Maeyama JI, Kubota A, Nishimune A, et al
    Effect of cigarette smoke on mucosal vaccine response with activation of plasmacytoid dendritic cells: The outcomes of in vivo and in vitro experiments.
    Vaccine. 2023 Jan 24:S0264-410X(23)00030-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1296. TENG Y, Hanibuchi T, Machida M, Nakaya T, et al
    Psychological determinants of COVID-19 vaccine acceptance: A comparison between immigrants and the host population in Japan.
    Vaccine. 2023 Jan 23:S0264-410X(23)00056-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1297. ZOLOTAROVA T, Dussault C, Park H, Varsaneux O, et al
    Education increases COVID-19 vaccine uptake among people in Canadian federal prisons in a prospective randomized controlled trial: The EDUCATE study.
    Vaccine. 2023 Jan 23:S0264-410X(23)00061-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1298. MYERS TR, Marquez PL, Gee JM, Hause AM, et al
    The v-safe after vaccination health checker: Active vaccine safety monitoring during CDC's COVID-19 pandemic response.
    Vaccine. 2023 Jan 23:S0264-410X(22)01545-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1299. JOSHI K, Rumpler E, Kennedy-Shaffer L, Bosan R, et al
    Comparative performance of between-population vaccine allocation strategies with applications for emerging pandemics.
    Vaccine. 2023 Jan 23:S0264-410X(22)01579-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1300. STRATHDEE SA, Abramovitz D, Vera CF, Artamonova I, et al
    Predictors of COVID-19 vaccine uptake among people who inject drugs.
    Vaccine. 2023 Jan 23:S0264-410X(23)00063-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1301. KRAUSE NM, Beets B, Howell EL, Tosteson H, et al
    Collateral damage from debunking mRNA vaccine misinformation.
    Vaccine. 2023;41:922-929.
    PubMed     Abstract available


  1302. RENNERT W, Hindiyeh M, Allahham M, Mercer LD, et al
    Introducing ROTAVAC(R) to the occupied Palestinian Territories: Impact on diarrhea incidence, rotavirus prevalence and genotype composition.
    Vaccine. 2023;41:945-954.
    PubMed     Abstract available


  1303. KUZEL TG, Fu J, Anderson M, Stec M, et al
    Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naive and previously-infected individuals.
    Vaccine. 2023;41:879-882.
    PubMed     Abstract available


  1304. FAIZULOEV E, Gracheva A, Korchevaya E, Smirnova D, et al
    Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity.
    Vaccine. 2023;41:892-902.
    PubMed     Abstract available


  1305. GROSSMAN-GIRON A, Tzur Bitan D, Shemesh S, Mayer Y, et al
    COVID-19 vaccine hesitancy scale and its association with actual COVID-19 vaccine uptake in Israel.
    Vaccine. 2023 Jan 23:S0264-410X(23)00065-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1306. MALLAH SI, Alawadhi A, Jawad J, Wasif P, et al
    Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.
    Vaccine. 2023 Jan 23:S0264-410X(23)00053-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1307. VATCHARAVONGVAN P, Boonyanitchayakul N, Khampachuea P, Sinturong I, et al
    Health Belief Model and parents' acceptance of the Pfizer-BioNTech and Sinopharm COVID-19 vaccine for children aged 5-18 years Old: A national survey.
    Vaccine. 2023 Jan 23:S0264-410X(23)00050-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1308. GRASSLY NC, Andrews N, Cooper G, Stephens L, et al
    Effect of maternal immunisation with multivalent vaccines containing inactivated poliovirus vaccine (IPV) on infant IPV immune response: A phase 4, multi-centre randomised trial.
    Vaccine. 2023 Jan 21:S0264-410X(23)00057-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1309. KRAMER C, Song M, Sufrin CB, Eber GB, et al
    COVID-19 vaccination hesitancy and uptake: Perspectives from people released from the Federal Bureau of Prisons.
    Vaccine. 2023 Jan 21:S0264-410X(23)00060-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1310. DARBY B, Alexander V, Murphy J
    SARS-CoV-2 vaccine breakthrough infections in Virginia, January 17, 2021 - June 30, 2021.
    Vaccine. 2023 Jan 20:S0264-410X(23)00062-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1311. BIANCHI FP, Stefanizzi P, Martinelli A, Brescia N, et al
    COVID-19 vaccination hesitancy in people affected by diabetes and strategies to increase vaccine compliance: A systematic narrative review and meta-analysis.
    Vaccine. 2023 Jan 20:S0264-410X(23)00058-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1312. DUDLEY MZ, Schuh HB, Shaw J, Rimal RN, et al
    COVID-19 vaccination among different types of US Healthcare Personnel.
    Vaccine. 2023 Jan 20:S0264-410X(23)00051-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1313. TRICOU V, Eyre S, Ramjee M, Collini P, et al
    A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.
    Vaccine. 2023 Jan 19:S0264-410X(23)00007-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1314. MARSHALL S, Fleming A, Sahm LJ, Moore AC, et al
    Identifying intervention strategies to improve HPV vaccine decision-making using behaviour change theory.
    Vaccine. 2023 Jan 18:S0264-410X(23)00036-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1315. GHORBANI A, Ngunjiri JM, Edward C Abundo M, Pantin-Jackwood M, et al
    Development of in Ovo-Compatible NS1-truncated live attenuated influenza vaccines by modulation of hemagglutinin cleavage and polymerase Acidic X Frameshifting sites.
    Vaccine. 2023 Jan 18:S0264-410X(23)00029-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1316. ZABALZA-BARANGUA A, Poveda-Urkixo I, Mena-Bueno S, Ramirez GA, et al
    Vaccine properties of Brucella melitensis 16MDeltawzm and reactivation of placental infection in pregnant sheep.
    Vaccine. 2023 Jan 16:S0264-410X(23)00028-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1317. MOINI A, Rabiei M, Pirjani R, Abiri A, et al
    COVID‑19 vaccine hesitancy among pregnant women and their reported reasons for vaccine refusal - A prospective study in Tehran, Iran.
    Vaccine. 2023 Jan 16:S0264-410X(23)00032-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1318. YANG H, Li Z, Zhang R, Guo S, et al
    Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVac(R)) among population aged 3 years and older in a large-scale use: A multi-center open-label study in China.
    Vaccine. 2023 Jan 13:S0264-410X(23)00031-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1319. KALRA S, Kalra D, Grafova I, Rubin JS, et al
    Association of death or illness from COVID-19 among family and friends on vaccine uptake within four months of the Emergency Use Authorization. Findings from a national survey in the United States.
    Vaccine. 2023 Jan 13:S0264-410X(23)00035-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1320. BEDSTON S, Lowthian E, Jarvis CI, Akbari A, et al
    COVID-19 booster vaccination uptake and infection breakthrough amongst health care workers in Wales: A national prospective cohort study.
    Vaccine. 2023 Jan 13:S0264-410X(23)00034-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1321. KLUWER B, Margrethe Rydland K, Nybru Gleditsch R, Mamelund SE, et al
    Social and demographic patterns of influenza vaccination coverage in Norway, influenza seasons 2014/15 to 2020/21.
    Vaccine. 2023 Jan 11:S0264-410X(23)00013-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1322. DU J, Liu B, Wang T, Zhu Z, et al
    A non-toxic recombinant bivalent chimeric protein rETX(m3)CSA(m4/TMD) as a potential vaccine candidate against enterotoxemia and braxy.
    Vaccine. 2023 Jan 10:S0264-410X(22)01419-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1323. ELLISON TJ, Talbott GC, Henderson DR
    Intradermal delivery of a quadrivalent cell-based seasonal influenza vaccine using an adjuvanted skin patch vaccination platform.
    Vaccine. 2023;41:304-314.
    PubMed     Abstract available


  1324. MOELLER-ARENDT M, van de Witte S, Nauta J, de Voogd H, et al
    Enhanced passive safety surveillance of Influvac(R) and Influvac(R) Tetra: Results from seven consecutive seasons.
    Vaccine. 2023;41:606-613.
    PubMed     Abstract available


  1325. TAKAHASHI H, Morita M, Kamiya H, Fukusumi M, et al
    Genomic characterization of Japanese meningococcal strains isolated over a 17-year period between 2003 and 2020 in Japan.
    Vaccine. 2023;41:416-426.
    PubMed     Abstract available


  1326. DESCHANVRES C, Levieux K, Launay E, Huby AC, et al
    Non-immunization associated with increased risk of sudden unexpected death in infancy: A national case-control study.
    Vaccine. 2023;41:391-396.
    PubMed     Abstract available


  1327. WAGNER AL, Moniz MH, Stout MJ, Townsel C, et al
    Experiences, risk perceptions, and COVID-19 vaccination outcomes among hospital workers.
    Vaccine. 2023 Jan 9:S0264-410X(23)00012-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1328. NAVIN MC, Scherer AM, Bradley E, Attwell K, et al
    School staff as vaccine advocates: Perspectives on vaccine mandates and the student registration process.
    Vaccine. 2023 Jan 9:S0264-410X(23)00014-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1329. MENON I, Kang SM, Braz Gomes K, Uddin MN, et al
    Laser-assisted intradermal delivery of a microparticle vaccine for respiratory syncytial virus induces a robust immune response.
    Vaccine. 2023 Jan 9:S0264-410X(23)00002-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1330. KEVIN YIN J, Harris RC, Loiacono MM, Chit A, et al
    Letter to editor regarding a review of MF59-adjuvanted influenza vaccine by Gartner et al.
    Vaccine. 2023 Jan 9:S0264-410X(22)01559-6. doi: 10.1016/j.vaccine.2022.
    PubMed    


  1331. CHAWANPAIBOON S, Anuwutnawin S, Kanjanapongporn A, Pooliam J, et al
    Breastfeeding women's attitudes towards and acceptance and rejection of COVID-19 vaccination: Implementation research.
    Vaccine. 2023 Jan 9:S0264-410X(23)00015-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1332. OZAKI T, Nishimura N, Gotoh K, Takemoto K, et al
    Anti-varicella-zoster virus antibody titers and seroprotection status from before the first dose of varicella vaccination to before entering elementary school in one region in Japan.
    Vaccine. 2023 Jan 9:S0264-410X(23)00010-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1333. WHITEHEAD HS, French CE, Caldwell DM, Letley L, et al
    A systematic review of communication interventions for countering vaccine misinformation.
    Vaccine. 2023 Jan 9:S0264-410X(22)01593-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1334. TULLOCH JSP, Lawrenson K, Gordon AL, Ghebrehewet S, et al
    COVID-19 vaccine hesitancy in care home staff: A survey of Liverpool care homes.
    Vaccine. 2023 Jan 9:S0264-410X(23)00009-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1335. MORO PL, Zhang B, Ennulat C, Harris M, et al
    Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Vaccine. 2023 Jan 9:S0264-410X(23)00016-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1336. EBRAHIMI N, Mazdak M, Shaygannejad V, Mirmosayyeb O, et al
    CNS demyelinating disease following inactivated or viral vector SARS-CoV-2 vaccines: A case series.
    Vaccine. 2023 Jan 6:S0264-410X(23)00004-X. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1337. JANG Y, Cho H, Chun J, Park K, et al
    Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice.
    Vaccine. 2023 Jan 6:S0264-410X(22)01602-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1338. LUPINACCI R, Rupp R, Wittawatmongkol O, Jones J, et al
    A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
    Vaccine. 2023 Jan 6:S0264-410X(22)01575-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1339. LONG Z, He J, Shuai Q, Zhang K, et al
    Influenza vaccination-induced H3 stalk-reactive memory B-cell clone expansion.
    Vaccine. 2023 Jan 6:S0264-410X(22)01603-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1340. CUTLAND CL, Peyrani P, Webber C, Newton R, et al
    A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children.
    Vaccine. 2023 Jan 6:S0264-410X(22)01461-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1341. XIE L, Ren J, Min S, Zhu X, et al
    Knowledge, attitude, and perception regarding HPV-related diseases and vaccination among the general public in Guizhou Province of China.
    Vaccine. 2023 Jan 5:S0264-410X(22)01538-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1342. TSUCHIYA Y, Tamura H, Fujii K, Numaguchi H, et al
    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan.
    Vaccine. 2023 Jan 5:S0264-410X(23)00006-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1343. TORALES J, Cuenca-Torres O, Barrios L, Armoa-Garcia L, et al
    An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
    Vaccine. 2023;41:109-118.
    PubMed     Abstract available


  1344. HOMAIRA N, Strachan R, Quinn H, Beggs S, et al
    Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study.
    Vaccine. 2023;41:85-91.
    PubMed     Abstract available


  1345. MAERTZDORF KM, Rietman ML, Lambooij MS, Verschuren WMM, et al
    Willingness to get vaccinated against influenza, pneumococcal disease, pertussis, and herpes zoster - A pre-COVID-19 exploration among the older adult population.
    Vaccine. 2023 Jan 4:S0264-410X(23)00001-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  1346. VALENCIA-HERNANDEZ AM, Zillinger T, Ge Z, Tan PS, et al
    Complexing CpG adjuvants with cationic liposomes enhances vaccine-induced formation of liver T(RM) cells.
    Vaccine. 2023 Jan 4:S0264-410X(22)01572-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1347. IMMINK MM, Kemmeren JM, Broeders L, Bekker MN, et al
    Reactogenicity and safety of second trimester maternal tetanus, diphtheria and acellular pertussis vaccination in the Netherlands.
    Vaccine. 2023 Jan 3:S0264-410X(22)01596-1. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1348. BAGGA S, Krishnan A, Dar L
    Revisiting live attenuated influenza vaccine efficacy among children in developing countries.
    Vaccine. 2023 Jan 3:S0264-410X(22)01594-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1349. REGO RT, Kenney B, Ngugi AK, Espira L, et al
    COVID-19 vaccination refusal trends in Kenya over 2021.
    Vaccine. 2023 Jan 3:S0264-410X(22)01601-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1350. OVERBO J, Aziz A, Zaman K, Clemens J, et al
    Immunogenicity and safety of a two-dose regimen with hepatitis E virus vaccine in healthy adults in rural Bangladesh: A randomized, double-blind, controlled, phase 2/pilot trial.
    Vaccine. 2023 Jan 2:S0264-410X(22)01599-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1351. SONGOL A, Amiri-Farahani L, Haghani S, Pezaro S, et al
    Comparing the effect of parental education via both lecture and film upon vaccination uptake for children under one year of age: A cluster randomized clinical trial.
    Vaccine. 2023 Jan 2:S0264-410X(22)01522-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1352. SHOOK NJ, Oosterhoff B, Sevi B
    A longitudinal assessment of variability in COVID-19 vaccine hesitancy and psychosocial correlates in a national United States sample.
    Vaccine. 2023 Jan 2:S0264-410X(22)01600-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1353. FORD JS, Rouleau SG, Wagner JL, Adams CB, et al
    Assessment of a COVID-19 vaccination protocol for unhoused patients in the emergency department.
    Vaccine. 2023 Jan 2:S0264-410X(22)01598-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


    December 2022
  1354. MOETLHOA B, Tjale M, Pretorius A, Hayeshi R, et al
    Rift Valley Fever vaccine strategies: Enhanced stability of RVF Clone 13.
    Vaccine. 2022 Dec 31:S0264-410X(22)01591-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1355. AZUMA M, Oishi K, Akeda Y, Morino S, et al
    Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naive adults aged >/= 65 years: Comparison of booster effects based on intervals of 0.5 and 1.0 year.
    Vaccine. 2022 Dec 31:S0264-410X(22)01595-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1356. KIM TV, Pham TND, Le DH, Dao DVB, et al
    Significant gaps in hepatitis B vaccination in adults in Viet Nam: Important targets toward hepatitis B elimination by 2030.
    Vaccine. 2022 Dec 30:S0264-410X(22)01577-8. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1357. BURROWS H, Antillon M, Gauld JS, Kim JH, et al
    Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness.
    Vaccine. 2022 Dec 29:S0264-410X(22)01557-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1358. ZUBKOVA I, Zhao Y, Cui Q, Kachko A, et al
    Assessing the impact of hepatitis B immune globulin (HBIG) on responses to hepatitis B vaccine during co-administration.
    Vaccine. 2022 Dec 29:S0264-410X(22)01590-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1359. WANG H, Cao L, Logue CM, Barbieri NL, et al
    Evaluation of immunogenicity and efficacy of the enterobactin conjugate vaccine in protecting chickens from colibacillosis.
    Vaccine. 2022 Dec 28:S0264-410X(22)01592-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1360. TOTTEY S, Shoji Y, Mark Jones R, Musiychuk K, et al
    Engineering of a plant-produced virus-like particle to improve the display of the Plasmodium falciparum Pfs25 antigen and transmission-blocking activity of the vaccine candidate.
    Vaccine. 2022 Dec 28:S0264-410X(22)01573-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1361. GAMBLE A, Hastings TJ, Westrick SC, Smith M, et al
    COVID-19 booster vaccination in rural community pharmacies.
    Vaccine. 2022 Dec 26:S0264-410X(22)01576-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1362. XIE Z, Hamadi HY, Mainous AG, Hong YR, et al
    Association of dual COVID-19 and seasonal influenza vaccination with COVID-19 infection and disease severity.
    Vaccine. 2022 Dec 23:S0264-410X(22)01568-7. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1363. ANDREJKO KL, Myers JF, Openshaw J, Fukui N, et al
    Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022 influenza season.
    Vaccine. 2022 Dec 23:S0264-410X(22)01578-X. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1364. CURRY S, Kaufhold RM, Monslow MA, Zhang Y, et al
    Preclinical evaluation of an investigational 21-valent pneumococcal conjugate vaccine, V116, in adult-rhesus monkey, rabbit, and mouse models.
    Vaccine. 2022 Dec 22:S0264-410X(22)01531-6. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1365. SAIAG E, Alcalay Y, Marudi O, Orr-Urtreger A, et al
    Cellular and humoral immune response to the fourth Pfizer-BioNTech COVID-19 vaccine dose in individuals aged 60 years and older.
    Vaccine. 2022 Dec 21:S0264-410X(22)01560-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1366. WAND O, Breslavsky A, Bar-Shai A, Levy C, et al
    One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine.
    Vaccine. 2022 Dec 21:S0264-410X(22)01567-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1367. TYAGI P, Ganguly M, Manney S, Wadkar K, et al
    Neurovirulence, viscerotropism and immunogenicity of live attenuated yellow fever 17D vaccine virus in non-human primates.
    Vaccine. 2022 Dec 21:S0264-410X(22)01543-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1368. SIENA E, Schiavetti F, Borgogni E, Taccone M, et al
    Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response.
    Vaccine. 2022 Dec 21:S0264-410X(22)01519-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1369. XU S, Huang R, Sy LS, Hong V, et al
    A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination.
    Vaccine. 2022 Dec 20:S0264-410X(22)01561-4. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available


  1370. RANE MS, Robertson MM, Kulkarni SG, Frogel D, et al
    Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting.
    Vaccine. 2022 Dec 20:S0264-410X(22)01564-X. doi: 10.1016/j.vaccine.2022.